0001583771-23-000010.txt : 20230814 0001583771-23-000010.hdr.sgml : 20230814 20230814161226 ACCESSION NUMBER: 0001583771-23-000010 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hepion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001583771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462783806 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36856 FILM NUMBER: 231170244 BUSINESS ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 BUSINESS PHONE: 732-902-4000 MAIL ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 FORMER COMPANY: FORMER CONFORMED NAME: ContraVir Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130806 10-Q 1 hepa-20230630.htm 10-Q hepa-20230630
000158377112/312023Q2false0.0500015837712023-01-012023-06-3000015837712023-08-07xbrli:shares00015837712023-06-30iso4217:USD00015837712022-12-310001583771us-gaap:SeriesAPreferredStockMember2023-06-30iso4217:USDxbrli:shares0001583771us-gaap:SeriesAPreferredStockMember2022-12-310001583771us-gaap:SeriesCPreferredStockMember2023-06-300001583771us-gaap:SeriesCPreferredStockMember2022-12-3100015837712023-04-012023-06-3000015837712022-04-012022-06-3000015837712022-01-012022-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-12-310001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2022-12-310001583771us-gaap:CommonStockMember2022-12-310001583771us-gaap:AdditionalPaidInCapitalMember2022-12-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001583771us-gaap:RetainedEarningsMember2022-12-310001583771us-gaap:RetainedEarningsMember2023-01-012023-03-3100015837712023-01-012023-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001583771us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-310001583771us-gaap:CommonStockMember2023-01-012023-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2023-03-310001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2023-03-310001583771us-gaap:CommonStockMember2023-03-310001583771us-gaap:AdditionalPaidInCapitalMember2023-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001583771us-gaap:RetainedEarningsMember2023-03-3100015837712023-03-310001583771us-gaap:RetainedEarningsMember2023-04-012023-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001583771us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001583771us-gaap:CommonStockMember2023-04-012023-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2023-06-300001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2023-06-300001583771us-gaap:CommonStockMember2023-06-300001583771us-gaap:AdditionalPaidInCapitalMember2023-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001583771us-gaap:RetainedEarningsMember2023-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-12-310001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2021-12-310001583771us-gaap:CommonStockMember2021-12-310001583771us-gaap:AdditionalPaidInCapitalMember2021-12-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001583771us-gaap:RetainedEarningsMember2021-12-3100015837712021-12-310001583771us-gaap:RetainedEarningsMember2022-01-012022-03-3100015837712022-01-012022-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001583771us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2022-01-012022-03-310001583771us-gaap:CommonStockMember2022-01-012022-03-310001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-03-310001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2022-03-310001583771us-gaap:CommonStockMember2022-03-310001583771us-gaap:AdditionalPaidInCapitalMember2022-03-310001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001583771us-gaap:RetainedEarningsMember2022-03-3100015837712022-03-310001583771us-gaap:RetainedEarningsMember2022-04-012022-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001583771us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001583771us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-06-300001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2022-06-300001583771us-gaap:CommonStockMember2022-06-300001583771us-gaap:AdditionalPaidInCapitalMember2022-06-300001583771us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001583771us-gaap:RetainedEarningsMember2022-06-3000015837712022-06-3000015837712023-05-032023-05-03xbrli:pure00015837712022-01-012022-12-31hepa:segment0001583771us-gaap:SeriesAPreferredStockMember2014-10-140001583771us-gaap:SeriesAPreferredStockMember2022-06-300001583771us-gaap:SeriesCPreferredStockMemberus-gaap:PreferredStockMember2018-07-030001583771us-gaap:SeriesCPreferredStockMember2018-07-032018-07-030001583771us-gaap:SeriesCPreferredStockMember2018-07-030001583771us-gaap:WarrantMember2018-07-032018-07-030001583771us-gaap:SeriesCPreferredStockMember2022-06-300001583771us-gaap:FairValueMeasurementsRecurringMember2023-06-300001583771us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001583771us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001583771us-gaap:FairValueMeasurementsRecurringMember2022-12-310001583771us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001583771us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001583771us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001583771us-gaap:MeasurementInputDiscountRateMember2023-06-300001583771us-gaap:MeasurementInputDiscountRateMember2022-12-310001583771srt:MinimumMember2023-01-012023-06-300001583771srt:MaximumMember2023-01-012023-06-300001583771srt:MinimumMember2022-01-012022-12-310001583771srt:MaximumMember2022-01-012022-12-310001583771hepa:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001583771hepa:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-06-300001583771hepa:ContingentConsiderationMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001583771us-gaap:EquipmentMember2023-06-300001583771us-gaap:EquipmentMember2022-12-310001583771us-gaap:FurnitureAndFixturesMember2023-06-300001583771us-gaap:FurnitureAndFixturesMember2022-12-3100015837712013-06-032013-06-030001583771us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001583771us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001583771us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001583771us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001583771us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001583771us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001583771us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001583771us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001583771us-gaap:EmployeeStockOptionMember2022-12-310001583771hepa:ExercisePriceRangeOneMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001583771us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeTwoMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeThreeMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeFourMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeFiveMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeSixMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771us-gaap:EmployeeStockOptionMember2023-06-300001583771hepa:ExercisePriceRangeSevenMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeEightMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771hepa:ExercisePriceRangeNineMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771us-gaap:EmployeeStockOptionMember2022-06-300001583771us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001583771us-gaap:SeriesAPreferredStockMember2023-01-012023-06-300001583771us-gaap:SeriesAPreferredStockMember2022-01-012022-06-300001583771us-gaap:SeriesCPreferredStockMember2023-01-012023-06-300001583771us-gaap:SeriesCPreferredStockMember2022-01-012022-06-300001583771us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001583771us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001583771us-gaap:WarrantMember2023-01-012023-06-300001583771us-gaap:WarrantMember2022-01-012022-06-300001583771hepa:OfficeSpaceMember2018-12-310001583771hepa:OfficeAndResearchLaboratoryMember2019-10-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________
FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 30, 2023
Or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                           to                           
Commission File Number 001-36856
a2.jpg
HEPION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
46-2783806
(I.R.S. Employer
Identification Number)
399 Thornall Street, First Floor
Edison, New Jersey 08837
(Address of Principal Executive Offices)
(732902-4000
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per shareHEPA
The Nasdaq Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:
Large accelerated filer
Accelerated filer
Non-accelerated filer 
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 
The number of shares of the registrant’s Common Stock outstanding as of August 7, 2023 was 3,838,289.



HEPION PHARMACEUTICALS, INC.
FORM 10-Q
TABLE OF CONTENTS



NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q for Hepion Pharmaceuticals, Inc. may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, those discussed under Item 1A. Risk Factors and elsewhere in the audited consolidated financial statements as of and for the year ended December 31, 2022 contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 10, 2023. These factors include the uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate safety and efficacy in larger-scale clinical trials, the risk that we will not obtain approval to market our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change and thus you should not unduly rely on these statements. Cautionary Note Regarding Forward-Looking Statements.
1

PART I—FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
June 30,
2023
December 31,
2022
Assets
Current assets:
Cash$30,521,733 $51,189,088 
Prepaid expenses2,240,723 5,306,985 
Total current assets32,762,456 56,496,073 
Property and equipment, net60,770 81,620 
Right-of-use assets 50,585 
In-process research and development3,190,000 3,190,000 
Other assets488,884 426,174 
Total assets$36,502,110 $60,244,452 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$4,191,225 $2,665,896 
Accrued expenses3,108,794 4,799,983 
Operating lease liabilities, current 53,614 
Short-term portion of contingent consideration373,710 366,229 
Total current liabilities7,673,729 7,885,722 
Contingent consideration2,046,290 2,093,771 
Deferred tax liability409,022 409,022 
Total liabilities10,129,041 10,388,515 
Commitments and contingencies (see Note 11)
Stockholders' equity:
Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
855,808 855,808 
Series C convertible preferred stock, stated value $1,000 per share, 1,800 and 1,801 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
839,320 840,320 
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 3,838,289 and 3,811,481 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
384 381 
Additional paid-in capital227,806,020 223,950,940 
Accumulated other comprehensive loss(87,651)(90,168)
Accumulated deficit(203,040,812)(175,701,344)
Total stockholders' equity26,373,069 49,855,937 
Total liabilities and stockholders' equity$36,502,110 $60,244,452 
The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
2

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)

Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Revenues$ $ $ $ 
Cost and expenses:
Research and development11,880,669 15,701,955 21,678,328 20,013,089 
General and administrative2,284,961 2,425,242 5,696,467 5,366,576 
Goodwill impairment loss 1,870,924  1,870,924 
Total operating expenses14,165,630 19,998,121 27,374,795 27,250,589 
Loss from operations(14,165,630)(19,998,121)(27,374,795)(27,250,589)
Other income (expense):
Interest expense(2,351)(3,178)(4,673)(5,387)
Change in fair value of contingent consideration88,434 90,000 40,000 414,992 
Loss before income taxes(14,079,547)(19,911,299)(27,339,468)(26,840,984)
Income tax benefit (expense)     
Net loss$(14,079,547)$(19,911,299)$(27,339,468)$(26,840,984)
Weighted-average common shares outstanding:
Basic and diluted3,826,505 3,811,481 3,819,035 3,811,463 
Net loss per common share: (see Note 10)
Basic and diluted$(3.68)$(5.22)$(7.16)$(7.04)









The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).


3

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)

Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Net loss$(14,079,547)$(19,911,299)$(27,339,468)$(26,840,984)
Other comprehensive income (loss):
Foreign currency translation(16,836)(39,113)2,517 (29,967)
Total other comprehensive income (loss)(16,836)(39,113)2,517 (29,967)
Comprehensive loss$(14,096,383)$(19,950,412)$(27,336,951)$(26,870,951)

































The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
4

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)

Preferred StockPreferred StockAdditional Paid in CapitalAccumulated other Comprehensive Income (Loss)Accumulated DeficitTotal Stockholders' Equity
Series ASeries CCommon Stock
SharesAmountSharesAmountSharesAmount
Balance at December 31, 202285,581 $855,808 1,801 $840,320 3,811,481 $381 $223,950,940 $(90,168)$(175,701,344)$49,855,937 
Net loss— — — — — — — — (13,259,921)(13,259,921)
Other comprehensive income (loss)— — — — — — — 19,353 — 19,353 
Stock-based compensation expense— — — — — — 537,123 — — 537,123 
Conversion of Series C to common— — (1)(1,000)1 — 1,000 — —  
Balance at March 31, 202385,581 855,808 1,800 839,320 3,811,482 381 224,489,063 (70,815)(188,961,265)37,152,492 
Net loss— — — — — — — — (14,079,547)(14,079,547)
Other comprehensive income (loss)— — — — — — — (16,836)— (16,836)
Stock-based compensation expense— — — — — — 333,954 — — 333,954 
Stock-based liability awards converted to equity— — — — — — 2,983,006 — — 2,983,006 
Issuance of common stock in connection with stock split— — — — 26,807 3 (3)— —  
Balance at June 30, 202385,581 $855,808 1,800 $839,320 3,838,289 $384 $227,806,020 $(87,651)$(203,040,812)$26,373,069 







The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
5

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(Unaudited)

Preferred StockPreferred StockAdditional Paid in CapitalAccumulated other Comprehensive Income (Loss)Accumulated DeficitTotal Stockholders’ Equity 
Series ASeries CCommon Stock
SharesAmountSharesAmountSharesAmount
Balance at December 31, 202185,581 $855,808 1,806 $845,320 3,811,263 $381 $224,794,789 $ $(133,501,295)$92,995,003 
Net loss— — — — — — — — (6,929,685)(6,929,685)
Other comprehensive income (loss)— — — — — — — 9,146 — 9,146 
Stock-based compensation expense— — — — — — 556,610 — — 556,610 
Conversion of Series C to common— — (5)(5,000)2 — 5,000 — —  
Issuance of common stock, net— — — — 216 — 5,008 — — 5,008 
Balance at March 31, 202285,581 855,808 1,801 840,320 3,811,481 381 225,361,407 9,146 (140,430,980)86,636,082 
Net loss— — — — — — — — (19,911,299)(19,911,299)
Other comprehensive income (loss)— — — — — — — (39,113)— (39,113)
Stock-based compensation expense— — — — — — 634,651 — — 634,651 
Balance at June 30, 202285,581 $855,808 1,801 $840,320 3,811,481 $381 $225,996,058 $(29,967)$(160,342,279)$67,320,321 









The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
6

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)

Six Months Ended
June 30,
20232022
Cash flows from operating activities:
Net loss$(27,339,468)$(26,840,984)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation871,077 1,703,958 
Depreciation36,366 41,257 
Change in fair value of contingent consideration(40,000)(414,992)
Impairment of goodwill 1,870,924 
Changes in operating assets and liabilities:
Accounts payable and accrued expenses2,815,672 7,736,105 
Right of use asset50,585 134,907 
Operating lease liability(53,614)(140,136)
Prepaid expenses and other assets3,008,520 (1,720,352)
Net cash used in operating activities(20,650,862)(17,629,313)
Cash flows from investing activities:
Purchases of property and equipment(16,538) 
Proceeds from disposal of property and equipment 2,266 
Net cash (used in) provided by investing activities(16,538)2,266 
Cash flows from financing activities:
Contingent consideration milestone payment (2,000,000)
Net cash used in financing activities (2,000,000)
Effect of exchange rates on cash 45 (14,415)
Net decrease in cash(20,667,355)(19,641,462)
Cash at beginning of period51,189,088 91,348,967 
Cash at end of period$30,521,733 $71,707,505 
Supplementary disclosure of cash flow information:
Cash paid for interest$ $941 
Supplementary disclosure of non-cash financing activities:
Conversion of Series C convertible preferred stock $1,000 $5,000 
Issuance of common stock in conjunction with milestone payment 5,008 
Stock-based liability awards reversed to additional paid-in capital2,983,006  

The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited).
7

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Business Overview
Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment of hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
We are developing rencofilstat as our lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. Many closely related isoforms of cyclophilins exist in humans. Cyclophilins A, B, and D are the best characterized cyclophilin isoforms. Inhibition of cyclophilins has been shown in scientific literature to have therapeutic effects in a variety of experimental models, including liver disease models.
We have completed a number of Phase 1 and Phase 2 clinical trials. In May 2023, we announced that our Phase 2a study ("ALTITUDE-NASH") met its primary endpoint by demonstrating improved liver function and was well tolerated after four months of treatment with once daily oral rencofilstat administered to NASH subjects with stage 3 or greater fibrosis. All additional secondary efficacy and safety endpoints were also met. These observations provide further evidence that builds on previous findings from a shorter 28-day Phase 2a ("AMBITION") trial. Taken together, the AMBITION and ALTITUDE-NASH trials reinforce rencofilstat’s direct antifibrotic mode of action and increase our confidence level that we anticipate observing fibrosis reductions in our ongoing 12-month Phase 2b ("ASCEND-NASH") clinical trial.
In June 2023, we announced that the Data and Safety Monitoring Board ("DSMB") met to review the current data for the ASCEND-NASH 2b study and has issued a “study may proceed without modification” clearance. This, the first planned DSMB meeting, occurred on schedule, and all labs, electrocardiogram's, adverse events, and protocol deviations were reviewed, focusing on any potential safety signals from the placebo-controlled trial.
2. Basis of Presentation
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2022, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, contained in our Annual Report on Form 10-K filed with the SEC on April 10, 2023.
Principles of Consolidation
The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split
On May 3, 2023, our Board of Directors declared a 1-for-20 reverse stock split of the outstanding shares of our common stock in order to satisfy requirements for the continued listing of our common stock on Nasdaq. The reverse stock split was effective May 11, 2023. All applicable share and per share information in these condensed consolidated financial statements on Form 10-Q have been adjusted retrospectively to give effect to the reverse stock split for all periods presented. The reverse stock split did not reduce the number of authorized shares of common stock and will not alter the par value.
Going Concern
As of June 30, 2023, we had $30.5 million in cash, an accumulated deficit of $203.0 million, and working capital of $25.1 million. For the six months ended June 30, 2023, cash used in operating activities was $20.7 million and we had a net loss of $27.3 million. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research,
8

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
development and clinical trials of rencofilstat. We are unable to predict the extent of any future losses or when we will become profitable, if at all.
These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We will be required to raise additional capital within the next year to continue the development and commercialization of our current product candidate and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.
3. Summary of Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022, included in our Annual Report on Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.
Cash
As of June 30, 2023 and December 31, 2022, cash was $30.5 million and $51.2 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. At certain times, our cash balances with any one financial institution may exceed Federal Deposit Insurance Corporation insurance limits. We believe it mitigates our risk by depositing our cash balances with high credit, quality financial institutions. We have never experienced losses related to these balances.
Fair Value of Financial Instruments
Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.
ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:
Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.
Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
9

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Financial instruments consist of cash, accounts payable, and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature, except for contingent consideration, which is recorded at fair value at the end of each reporting period. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 5 for additional information on the fair value of the contingent consideration.
Property, equipment and depreciation
As of June 30, 2023 and December 31, 2022, we had $0.1 million and $0.1 million, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, and furniture and fixtures. There were no adjustments to the carrying value of property and equipment at June 30, 2023 or December 31, 2022.
In-Process Research & Development
The annual, or interim (if events or changes in circumstances indicate that it is more likely than not that the asset is impaired), In-Process Research and Development ("IPR&D") impairment test is performed by comparing the fair value of the asset to the asset’s carrying amount. When testing indefinite-lived intangibles for impairment, we may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not that the asset is impaired. Alternatively, we may bypass this qualitative assessment for our indefinite-lived intangible asset and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.
We performed a qualitative assessment of IPR&D at June 30, 2023 and a quantitative assessment for fiscal year 2022 and determined that the asset was not impaired.
Income Taxes
We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.
We continue to maintain a full valuation allowance for our U.S and foreign net deferred tax assets.
Under the provisions of the Internal Revenue Code, the net operating loss (NOL) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The utilization of these NOLs is subject to limitations based on past and future changes in our ownership pursuant to Section 382. We completed a Section 382 study of transactions in our stock through December 31, 2021 and concluded that we have experienced ownership changes since inception that we believe under Section 382 and 383 of the
10

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Internal Revenue Code will result in limitations on our ability to use certain pre-ownership change NOLs and credits. We are not aware of any ownership changes in 2023 or 2022. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our consolidated financial statements could be further limited. Similar provisions of state tax law may also apply to limit the use of accumulated state tax attributes.
Contingencies
In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.
Research and Development
Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.
We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.
Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At June 30, 2023 and December 31, 2022, we had prepaid research and development costs of $1.9 million and $4.7 million, respectively.
Foreign Exchange
The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Assets and liabilities of Hepion Research Corp. are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was $87,651 and $90,168 at June 30, 2023 and December 31, 2022, respectively. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in general and administrative expense within the consolidated statements of operations. The impact of foreign exchange losses (gains) was $30,661 and $2,678 for the three months ended June 30, 2023 and 2022, respectively, and was $56,095 and $(32,518) for the six months ended June 30, 2023 and 2022, respectively.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.
Net loss per share
Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.
11

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Recent Accounting Pronouncements
There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the six months ended June 30, 2023.
4. Stockholders’ Equity
Series A Convertible Preferred Stock
On October 14, 2014, our Board of Directors authorized the sale and issuance of up to 1,250,000 shares of Series A Convertible Preferred Stock (the “Series A”). All shares of the Series A were issued between October 2014 and February 2015. Each share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. As of June 30, 2023, there were 85,581 shares outstanding. During the six months ended June 30, 2023 and 2022, no shares of the Series A were converted. If we sell common stock or equivalents at an effective price per share that is lower than the conversion price, the conversion price may be reduced to the lower conversion price. The Series A will be automatically convertible into common stock in the event of a fundamental transaction as defined in the offering.
Series C Convertible Preferred Stock Issuance
On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consisted of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 4,446 common stock warrants that expired in July 2023. As of June 30, 2023, there were 1,800 shares of Series C outstanding. During the six months ended June 30, 2023, 1 share of the Series C was converted into 1 share of our common stock and during the six months ended June 30, 2022, 5 shares of the Series C were converted into 2 shares of our common stock. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $0.08 per share (subject to adjustments upon the occurrence of certain dilutive events).
5. Fair Value Measurements
The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2023 and December 31, 2022.
Fair Value Measurement at Reporting Date Using
DescriptionFair value(Level 1)(Level 2)(Level 3)
As of June 30, 2023:
Contingent consideration$2,420,000 $ $ $2,420,000 
As of December 31, 2022:
Contingent consideration$2,460,000 $ $ $2,460,000 
Contingent consideration was recorded for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin) on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model.
At June 30, 2023 and December 31, 2022, the assumptions we used to calculate the fair value were as follows:
Assumptions
June 30,
2023
December 31,
2022
Discount rate8.5%8.5%
Stock pricen/an/a
Projected milestone achievement datesMar 2024Jun 2029Dec 2023Dec 2028
Probability of success of milestone achievements13 %40%13 %40%
As of June 30, 2023, $2,046,290 was classified as a non-current liability based upon management's best estimate using
12

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
the latest available information. Management reviewed the assumptions and for the six months ended June 30, 2023, the only change made was to the milestone achievement dates.
The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2023.
Acquisition-related Contingent Consideration
Liabilities:
Balance at December 31, 2022$2,460,000 
Change in fair value recorded in earnings(40,000)
Balance at June 30, 2023$2,420,000 
6. Property and Equipment, net
Property and equipment are stated at cost and depreciated using the straight-line method, based on useful lives as follows:
Estimated Useful Life (in years)June 30,
2023
December 31,
2022
Equipment3 years$346,671 $326,382 
Furniture and fixtures7 years62,183 62,183 
Less: Accumulated depreciation(348,084)(306,945)
$60,770 $81,620 
Depreciation expense for the three months ended June 30, 2023 and 2022 was $18,328 and $18,529, respectively, and was $36,366 and $41,258 for the six months ended June 30, 2023 and 2022, respectively.
7. Indefinite-lived Intangible Assets
IPR&D
Our IPR&D asset consisted of the following at:
Indefinite-lived
Intangible Asset
Rencofilstat balance at December 31, 2022$3,190,000 
Change during the six months ended June 30, 2023 
Rencofilstat balance at June 30, 2023$3,190,000 
No impairment losses were recorded on IPR&D during the six months ended June 30, 2023 and 2022.
8. Accrued Liabilities
Accrued liabilities consisted of the following:
June 30,
2023
December 31,
2022
Payroll and related costs$724,100 $838,683 
Stock-based compensation  1,906,401 
Research and development2,009,215 1,716,035 
Professional fees237,399 246,664 
Other138,080 92,200 
Total accrued expenses$3,108,794 $4,799,983 

13

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
9. Accounting for Share-Based Payments
In April 2023, our board of directors approved the 2023 Omnibus Equity Incentive Plan (the 2023 Plan), which became effective in June 2023 upon stockholder approval. The 2023 Plan allows for the grant of up to 500,000 awards for the purpose of attracting, motivating and retaining employees (including officers), non-employee directors and non-employee consultants. At June 30, 2023, there were no awards granted from the 2023 Plan.
On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Plan), which expired in June 2023 and we are no longer making grants under it. Stock options granted under the 2013 Plan typically vest after three years of continuous service from the grant date and will have a contractual term of ten years. We granted options during the three months ended June 30, 2022 and 2021, and at the time that these grants were made, we did not have any options available for grant under the Plan. We accounted for these option grants as liability-classified awards requiring us to measure the fair value of the awards each reporting period since there were not enough shares available at the time of the grant. With the approval of the 2023 Plan, these awards are no longer accounted for as liability-classified and the cumulative liability of $2,983,006 was recorded to additional paid-in capital.
We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
General and administrative$(22,743)$127,483 $1,170,717 $1,210,584 
Research and development39,671 35,025 776,964 493,374 
Total stock-based compensation expense$16,928 $162,508 $1,947,681 $1,703,958 
A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:
Number of OptionsExercise Price
Per Share
Weighted
Average Exercise Price Per Share
Intrinsic
Value
Weighted
Average Remaining Contractual Team
Balance outstanding, December 31, 2022444,749 $13.80 -$40,320.00 $46.20 $ 8.13 years
Granted $ -$ $ $ 
Adjustment for stock split48 $ -$ $ $ 
Exercised $ -$ $ $ 
Forfeited(112)$34.00 -$34.00 $34.00 $ 
Cancelled(139)$34.00 -$34.00 $34.00 $ 
Balance outstanding, June 30, 2023444,546 $13.80 -$40,320.00 $47.12 $ 7.63 years
Awards outstanding, vested awards and those expected to vest at June 30, 2023443,256 $13.80 -$40,320.00 $47.17 $ 7.63 years
Vested and exercisable at June 30, 2023360,609 $13.80 -$40,320.00 $50.15 $ 7.56 years
The total fair value of awards vested during the six months ended June 30, 2023 and 2022 was $2.2 million and $4.0 million, respectively.
As of June 30, 2023, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was $0.8 million to be recognized over a weighted-average remaining vesting period of approximately 0.8 years.
14

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate the fair value of stock option awards when granted to employees.
Six Months Ended
June 30,
20232022
Stock price$ $13.80 
Risk-free interest rate %3.26 %
Dividend yield  
Expected volatility %116.7 %
Expected term (in years)0.06.0
Risk-free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.
Dividend yield—We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.
Expected volatility—We base expected volatility on the trading price of our common stock.
Expected term—The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.
SAB No. 110, Share-Based Payment, (“SAB No. 110”) expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. For the expected term, we have “plain-vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.
10. Loss per Share
Basic and diluted net loss per common share was determined by dividing net loss by the weighted-average common shares outstanding during the period.
The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:
Three Months Ended
June 30,
Six Months Ended
June 30,
Basic and diluted net loss per common share:2023202220232022
Numerator:
Net loss$(14,079,547)$(19,911,299)$(27,339,468)$(26,840,984)
Denominator:
Weighted average common shares outstanding3,826,505 3,811,481 3,819,035 3,811,463 
Net loss per share of common stock—basic and diluted$(3.68)$(5.22)$(7.16)$(7.04)
15

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following outstanding securities at June 30, 2023 and 2022 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:
Six Months Ended
June 30,
20232022
Common shares issuable upon conversion of Series A preferred stock159 159 
Common shares issuable upon conversion of Series C preferred stock829 830 
Stock options444,546 444,749 
Warrants – equity classified215,559 215,559 
Total661,093 661,297 
The equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding.
11. Commitments and Contingencies
Contractual Obligations
In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. The lease expired on March 31, 2023 and we are currently leasing this space on a month-to-month basis. We are currently negotiating with the landlord for a new lease agreement. In October 2019, we entered into a 3-year lease for office and research laboratory space in Edmonton, Canada, which expired on September 30, 2022 and we are leasing this space on a month-to-month basis. We are currently negotiating with the landlord for a new lease agreement.
Legal Proceedings
We are involved in various legal proceedings. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our consolidated financial condition or results of operations.
Leases
We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property and equipment), and (2) the customer has the right to control the use of the identified asset.
Operating leases where we are the lessee are included under the caption “Right of Use Assets” ("ROU") on our consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.
The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Rent expense for the three months ended June 30, 2023 and 2022 was $0.1 million and $0.1 million, respectively, and was $0.2 million and $0.2 million for the six months ended June 30, 2023 and 2022, respectively.
12. Subsequent Events
None.
16

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with our condensed consolidated financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements. You can identify these statements by forward-looking words such as “plan,” “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. Forward-looking statements include information concerning possible or assumed future business success or financial results. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K as of and for the year ended December 31, 2022 filed with the United States Securities and Exchange Commission (“SEC”) on April 10, 2023. Accordingly, to the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of us, please be advised that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in forward-looking statements, and you should not unduly rely on such statements.
Business Overview
We are a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment of hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
We are developing rencofilstat as our lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. Many closely related isoforms of cyclophilins exist in humans. Cyclophilins A, B, and D are the best characterized cyclophilin isoforms. Inhibition of cyclophilins has been shown in scientific literature to have therapeutic effects in a variety of experimental models, including liver disease models.
We have completed a number of Phase 1 and Phase 2 clinical trials. In May 2023, we announced that our Phase 2a study ("ALTITUDE-NASH") met its primary endpoint by demonstrating improved liver function and was well tolerated after four months of treatment with once daily oral rencofilstat administered to NASH subjects with stage 3 or greater fibrosis. All additional secondary efficacy and safety endpoints were also met. These observations provide further evidence that builds on previous findings from a shorter 28-day Phase 2a ("AMBITION") trial. Taken together, the AMBITION and ALTITUDE-NASH trials reinforce rencofilstat’s direct antifibrotic mode of action and increase our confidence level that we anticipate observing fibrosis reductions in our ongoing 12-month Phase 2b ("ASCEND-NASH") clinical trial.
In June 2023, we announced that the Data and Safety Monitoring Board ("DSMB") met to review the current data for the ASCEND-NASH 2b study and has issued a “study may proceed without modification” clearance. This, the first planned DSMB meeting, occurred on schedule, and all labs, electrocardiogram's, adverse events, and protocol deviations were reviewed, focusing on any potential safety signals from the placebo-controlled trial.
NASH is the form of liver disease that is triggered by what has come to be known as the “Western diet”, characterized especially by high-fat, high-sugar, and processed foods. Among the effects of a prolonged Western diet is fat accumulation in liver cells (steatosis) which is described as NAFLD and can predispose cells to injury. NAFLD may evolve into NASH when the fatty liver begins to progress through stages of cell injury, inflammation, fibrosis, and carcinogenesis. People who develop NASH typically have additional predisposing conditions such as diabetes and hypertension, but the exact biochemical events that trigger and maintain the progression are not well known. Many people in the early stages of disease do not have significant clinical symptoms and therefore are unaware that they have it. Once NASH is diagnosed, it is a major health concern as the liver often becomes fibrotic and puts individuals at increased risk of developing cirrhosis and other complications. Individuals with advanced liver fibrosis have a significantly higher risk of developing liver cancer, although cancer may also arise in some patients before significant hepatitis or fibrosis. NASH is increasing worldwide at an alarming rate due to the spread of the Western diet, obesity, and other related conditions. Approximately 4-5% of the global population is estimated to have NASH, including the USA, and NASH is quickly becoming the most common reason for individuals requiring a liver transplant in the USA. Considering the serious outcomes linked to advancing NASH, the economic and social burden of the disease is
17

enormous. There are no simple blood tests to diagnose or track the progression of NASH, and currently there are no drugs that are specifically approved to treat the disease.
HCC is a major type of liver cancer, accounting for approximately 85% – 90% of all cases. NASH, hepatitis viral infections, and alcohol consumption are all major causes of HCC. Globally, over 700,000 people die each year from liver cancer which is second only to lung cancer among all cancer-related deaths. The high mortality is due to the fact that only around half of all people who develop HCC (in developed countries) receive the diagnosis early enough to have an opportunity for therapeutic intervention. Additionally, recurrence rates are high, and current treatment options remain limited.
HCC is a type of cancer in which the tissue microenvironment plays a major role in its development. In most cases HCC is preceded by significant, long-term damage to liver cells, inflammation, and fibrosis. One-third of people with cirrhosis, a very advanced stage of liver disease, will eventually progress to HCC. The chronic injury to the liver leads to many genetic mutations that eventually lead to transformation of cells and formation of tumors. The noxious tissue microenvironment also promotes cancer by altering the function of immune cells and endothelial cells which form tumor-supporting blood vessels. These various events underscore the importance of halting liver injury and scarring as early and effectively as possible to prevent cancer development.
Artificial Intelligence (AI)
We have created a proprietary AI tool called, “AI-POWR to optimize the outcomes of our current clinical programs and to potentially identify novel indications for Rencofilstat and possibly identify new targets and new drug molecules to broaden our pipeline.
AI-POWR™ is our acronym for Artificial Intelligence - Precision Medicine; Omics that include genomics, proteomics, metabolomics, transcriptomics, and lipidomics; World database access; and Response and clinical outcomes. AI-POWR™ allows for the selection of novel drug targets, biomarkers, and appropriate patient populations. AI-POWR™ is used to identify responders from big data sources using our multi-omics approach, while modelling inputs and scenarios to increase response rates. The components of AI-POWR™ include access to publicly available databases processed via machine learning algorithms. We believe AI outputs will allow for improved response outcomes through enhanced patient selection, biomarker selection and drug target selection. We believe AI outputs will help identify responders a priori and reduce the need for large sample sizes through study design enrichment.
We intend to use AI-POWR™ to help identify which NASH patients will best respond to Rencofilstat. It is anticipated that applying this proprietary platform to our drug development program will ultimately save time, resources, and money. In so doing, we believe that AI-POWR™ is a risk-mitigation strategy that should reap benefits all the way through from clinical trials to commercialization. The AI-POWRplatform is continually updated with in-house and published data to further refine the accuracy of the neural network.
We believe that NASH is a heterogenous disease, and we need to have a better understanding of interactions among proteins, genes, lipids, metabolites, and other disease variables to help predict disease progression, regression, and responses to Rencofilstat. All of this is further complicated by variable drug concentrations, patient traits and temporal factors. AI-POWR™ is designed to address many of the typical challenges in drug development, as we believe we can use our proprietary platform to shorten development timelines and increase the delta between placebo and treatment groups. AI-POWR™ will be used to drive our Phase 2b Ascend-NASH program and identify additional potential indications for Rencofilstat to expand our footprint in the cyclophilin inhibition therapeutic space.
FINANCIAL OPERATIONS OVERVIEW
From our inception in May 2013 through June 30, 2023, we have an accumulated deficit of $203.0 million and we have not generated any revenue from operations. We expect to incur additional losses to perform further research and development activities and do not currently have any commercial biopharmaceutical products. We do not expect to have such for several years, if at all.
Our product development efforts are in their early stages and we cannot make estimates of the costs or the time they will take to complete. The risk of completion of any program is high because of the many uncertainties involved in bringing new drugs to market including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, the extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of research and development expenses and competing technologies being developed by organizations with significantly greater resources.
CRITICAL ACCOUNTING ESTIMATES
Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses, income taxes and
18

related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.
During the six months ended June 30, 2023, there were no significant changes to our critical accounting estimates as described in the financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2022.
RECENT ACCOUNTING PRONOUNCEMENTS
Please refer to Note 3 of Notes to Condensed Consolidated Financial Statements, Recent Accounting Pronouncements, in this Quarterly Report on Form 10-Q.
RESULTS OF OPERATIONS
Comparison of the three months ended June 30, 2023 and 2022:
Three Months Ended
June 30,
20232022Change
Revenues$— $— $— 
Costs and Expenses:
Research and development11,880,669 15,701,955 (3,821,286)
General and administrative2,284,961 2,425,242 (140,281)
Goodwill impairment loss— 1,870,924 (1,870,924)
Loss from operations(14,165,630)(19,998,121)5,832,491 
Other income (expense):
Interest expense(2,351)(3,178)827 
Change in fair value of contingent consideration88,434 90,000 (1,566)
Loss before income taxes(14,079,547)(19,911,299)5,831,752 
Income tax benefit (expense)— — — 
Net loss$(14,079,547)$(19,911,299)$5,831,752 
We had no revenues during the three months ended June 30, 2023 and 2022, respectively, because we do not have any commercial biopharmaceutical products and we do not expect to have such products for several years, if at all.
Research and development expenses for the three months ended June 30, 2023 and 2022 was $11.9 million and $15.7 million, respectively. The decrease of $3.8 million was primarily due to a $8.8 million decrease in drug development costs offset by a $4.8 million increase in clinical trial costs primarily for our phase 2b study and a $0.1 million increase in travel costs.
General and administrative expenses for the three months ended June 30, 2023 and 2022 was $2.3 million and $2.4 million, respectively. The decrease of $0.1 million was primarily due to a decrease of $0.2 million for stock-based compensation expense and a decrease of $0.3 million in consulting costs. This was offset by an increase of $0.2 million increase in professional fees and a $0.1 million increase in compensation costs.











19

Comparison of the six months ended June 30, 2023 and 2022:
Six Months Ended
June 30,
20232022Change
Revenues$— $— $— 
Costs and Expenses:
Research and development21,678,328 20,013,089 1,665,239 
General and administrative5,696,467 5,366,576 329,891 
Goodwill impairment loss— 1,870,924 (1,870,924)
Loss from operations(27,374,795)(27,250,589)(124,206)
Other income (expense):
Interest expense(4,673)(5,387)714 
Change in fair value of derivative instruments – warrants and contingent consideration40,000 414,992 (374,992)
Loss before income taxes(27,339,468)(26,840,984)(498,484)
Income tax (expense) benefit— — — 
Net loss$(27,339,468)$(26,840,984)$(498,484)
We had no revenues during the six months ended June 30, 2023 and 2022, respectively, because we do not have any commercial biopharmaceutical products and we do not expect to have such products for several years, if at all.
Research and development expenses for the six months ended June 30, 2023 and 2022 was $21.7 million and $20.0 million, respectively. The increase of $1.7 million was primarily due to an increase of $10.0 million in clinical trial costs for our phase 2b study. Also, there was an increase in compensation costs of $0.4 million due to an increase in headcount and a $0.3 million increase in stock-based compensation costs. This was offset by a decrease of $8.7 million in drug development costs and a $0.4 million decrease in consulting costs.
General and administrative expenses for the six months ended June 30, 2023 and 2022 was $5.7 million and $5.4 million, respectively. The increase of $0.3 million was primarily related to an increase of $0.3 million increase in compensation costs, a $0.2 million increase in professional fees and a $0.1 million increase in travel costs. This was offset by a decrease of $0.4 million in consulting costs.
Liquidity and Capital Resources
Sources of Liquidity
We have funded our operations through June 30, 2023 primarily through the issuance of convertible preferred stock, the issuance of convertible debt, and issuances of shares of our common stock through at-the market offerings.
Future Funding Requirements
We have no products approved for commercial sale. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and clinical trials of our product candidate. As a result, we are not profitable and have incurred losses in each period since our inception in 2013. As of June 30, 2023, we had an accumulated deficit of $203.0 million. We expect to continue to incur significant losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:
pursue the clinical and preclinical development of our current product candidate;
leverage our technologies to advance product candidates into preclinical and clinical development;
seek regulatory approvals for our product candidate that successfully complete clinical trials, if any;
attract, hire and retain additional clinical, quality control and scientific personnel;
establish our manufacturing capabilities through third parties and scale-up manufacturing to provide adequate supply for clinical trials and commercialization;
expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;
20

expand and protect our intellectual property portfolio;
establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;
acquire or in-license other product candidates and technologies; and
incur additional legal, accounting and other expenses in operating our business, including ongoing costs associated with operating as a public company.
Even if we succeed in commercializing our product candidate, we will continue to incur substantial research and development and other expenditures to potentially develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital.
We will require substantial additional financing and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our non-replicating and replicating technologies and our product candidate derived from these technologies. Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs as well as any future product candidates we may choose to pursue, as well as the gradual gaining of control over our required manufacturing capabilities and other corporate uses. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current or future product candidates.
Our future capital requirements depend on many factors, including:
the scope, progress, results and costs of researching and developing our current and future product candidate and programs, and of conducting preclinical studies and clinical trials;
the number and development requirements of other product candidates that we may pursue, and other indications for our current product candidate that we may pursue;
the stability, scale and yields during the manufacturing process as we scale-up production and formulation of our product candidate for later stages of development and commercialization;
the timing of, and the costs involved in, obtaining regulatory and marketing approvals and developing our ability to establish sales and marketing capabilities, if any, for our current and future product candidates we develop if clinical trials are successful;
our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;
the cost of commercialization activities for our current and future product candidates that we may develop, whether alone or with a collaborator;
the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;
the timing, receipt and amount of sales of, or royalties on, our future products, if any; and
A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will need additional funds to meet operational needs and capital requirements associated with such operating plans.
The condensed consolidated financial statements as of and for the six months ended June 30, 2023 have been prepared under the assumption that we will continue as a going concern within one year after the financial statements are issued. Due to our accumulated deficit and our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern without additional capital becoming available to attain further
21

operating efficiencies and, ultimately, to generate revenue. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We will be required to raise additional capital to continue the development and commercialization of our current product candidate and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct, delay, scale back or discontinue the development and/or commercialization of one or more product candidates; seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.
Cash Flows
The following table summarizes our cash flows for the following periods:
Six Months Ended
June 30,
20232022
Net cash provided by (used in):
Operating activities$(20,650,862)$(17,629,313)
Investing activities(16,538)2,266 
Financing activities— (2,000,000)
As of June 30, 2023, we had working capital of $25.1 million compared to working capital of $48.6 million as of December 31, 2022. The decrease of $23.5 million in working capital is primarily related to our cash spend for the six months ended June 30, 2023.
Operating Activities:
As of June 30, 2023, we had $30.5 million in cash. Net cash used in operating activities was $20.7 million for the six months ended June 30, 2023 consisting primarily of our net loss of $27.3 million. Changes in non-cash operating activities was $0.9 million, primarily for stock-based compensation. Changes in working capital accounts had a positive impact of $5.8 million on cash primarily for a decrease in prepaid expenses and other assets of $3.0 million and an increase in accounts payable and accrued expenses of $2.8 million.
Net cash used in operating activities was $17.6 million for the six months ended June 30, 2022 consisting primarily of our net loss of $26.8 million. Changes in non-cash operating activities was $3.2 million, primarily for stock-based compensation, goodwill impairment and the change in fair value of the contingent consideration. Changes in working capital accounts had a positive impact of $6.0 million on cash primarily for an increase in accounts payable and accrued expenses of $7.7 million offset by an increase in prepaid expenses of $1.7 million.
Investing Activities:
Net cash used in investing activities was nominal for the six months ended June 30, 2023 and 2022.
Financing Activities:
There was no cash provided by or used in financing activities for the six months ended June 30, 2023.
Net cash used in financing activities was $2.0 million for the six months ended June 30, 2022 for the contingent consideration milestone payment per the Ciclofilin acquisition merger agreement.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Based on an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of June 30, 2023, our Principal Executive Officer and Principal Financial Officer have concluded that that we have material weaknesses in our control environment and period end financial close and reporting process as described below and therefore our disclosure controls and procedures were not effective.
22

During 2022, we identified a material weakness in our internal controls related to the proper design and implementation of controls over formal review, approval, and evaluation of non-core, complex accounting transactions.
During 2022, we identified a material weakness in internal control related to the proper design and implementation of certain controls over our income tax provision and management’s review of the income tax provision. We utilize a third-party to assist in the preparation of our tax provision. Specifically, we did not sufficiently design and implement controls related to the completeness and accuracy of certain aspects of the tax provision and the completeness and accuracy income tax disclosures.
Remediation of Material Weaknesses
We are committed to the remediation of the material weaknesses described above, as well as the continued improvement of our internal control over financial reporting. We plan on implementing several remedial actions to improve our internal controls, including:
We are utilizing the services of external consultants for non-routine and\or technical accounting issues as they arise.
Expanding and improving our review process for complex accounting transactions. We plan to further improve this process by enhancing access to accounting literature, identification of third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals.
Management, with the assistance of a third party, will perform an evaluation of the processes and procedures around our tax provision processes, internal control design gaps, and recommend process enhancements.
Implementing enhancements and process improvements, including the design and implementation of well-defined controls and related control attributes regarding income tax provision and income tax disclosures.
Developing a detailed timeline of the tax provision calculation, to ensure that sufficient time is allocated to complete the process as designed.
As we continue our evaluation and improve our internal control over financial reporting, management may identify and take additional measures to address control deficiencies. We cannot assure you that we will be successful in remediating the material weaknesses in a timely manner.
Changes in Internal Control over Financial Reporting
Except as noted above, there have been no changes in our internal controls over financial reporting during the three months ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23

PART II. OTHER INFORMATION
ITEM 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in our Form 10-K for the year ended December 31, 2022.
ITEM 6. EXHIBITS
101.INSXBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation Linkbase
101.DEFXBRL Taxonomy Extension Definition Linkbase
101.LABXBRL Taxonomy Label Linkbase
101.PREXBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File (formatted as Inline XBRL in Exhibit 101)

24

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
HEPION PHARMACEUTICALS, INC. (Registrant)
Date: 08/14/2023By:/s/ ROBERT FOSTER
Robert Foster
Chief Executive Officer
(Principal Executive Officer)
Date: 08/14/2023By:/s/ JOHN CAVAN
John Cavan
Chief Financial Officer
(Principal Financial and Accounting Officer)

25
EX-31.1 2 hepa-q2202310xqxexx311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATIONS
I, Robert Foster, certify that:
1)I have reviewed this report on Form 10-Q of Hepion Pharmaceuticals, Inc.
2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 14, 2023
/s/ Robert Foster
Robert Foster
Chief Executive Officer and Director
(Principal Executive Officer)


EX-31.2 3 hepa-q2202310xqxexx312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATIONS
I, John Cavan, certify that:
1)I have reviewed this report on Form 10-Q of Hepion Pharmaceuticals, Inc.
2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 14, 2023/s/ John Cavan
John Cavan
Chief Financial Officer
(Principal Financial and Accounting Officer)


EX-32.1 4 hepa-q2202310xqxexx321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
HEPION PHARMACEUTICALS, INC.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2023
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I am the Chief Executive Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended June 30, 2023 and filed with the Securities and Exchange Commission (“Form 10-Q”).
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 14, 2023/s/ Robert Foster
Robert Foster
Chief Executive Officer and Director
(Principal Executive Officer)


EX-32.2 5 hepa-q2202310xqxexx322.htm EX-32.2 Document

EXHIBIT 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
HEPION PHARMACEUTICALS, INC.
FORM 10-Q FOR THE QUARTER ENDED JUNE 30, 2023
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I am the Chief Financial Officer of Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended June 30, 2023 and filed with the Securities and Exchange Commission (“Form 10-Q”).
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 14, 2023/s/ John Cavan
John Cavan
Chief Financial Officer
(Principal Financial and Accounting Officer)


EX-101.SCH 6 hepa-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Business Overview link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Indefinite-lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Accounting for Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Indefinite-lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Accounting for Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Summary of Significant Accounting Policies - Property, Equipment and Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Summary of Significant Accounting Policies - Foreign Exchange (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Stockholders' Equity - Series C Preferred Stock Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Fair Value Measurements - Schedule of Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Fair Value Measurements - Assumptions Used to Calculate Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Fair Value Measurements - Activity for Fair Value of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Property and Equipment, net - PPE (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Indefinite-lived Intangible Assets - IPR&D (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Accounting for Share-Based Payments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Accounting for Share-Based Payments - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Accounting for Share-Based Payments - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - Loss per Share - Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hepa-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hepa-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hepa-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Professional fees Accrued Professional Fees, Current Change in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Segment Information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Business Overview Business Overview [Text Block] The entire disclosure for Business Overview Footnote. Preferred Stock Preferred Stock [Member] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Stock issued as a result of conversion (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Supplementary disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Equity Award [Domain] Award Type [Domain] Entity Filer Category Entity Filer Category Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Statement [Table] Statement [Table] Contingent consideration Non-current portion of contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Net loss per share Earnings Per Share, Policy [Policy Text Block] Indefinite-lived Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Exercise price range one Exercise Price Range One [Member] Represents exercise price range one. Deferred tax liability Deferred Income Tax Liabilities, Net Accounts payable Accounts Payable, Current Vested and exercisable at the end of the period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Balance at beginning of the period Balance at end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Convertible preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Commitments and contingencies (see Note 11) Commitments and Contingencies Impairment of IPR&D Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Vested and exercisable at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Convertible preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Stockholders' Equity Equity [Text Block] Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Awards outstanding, vested awards and those expected to vest at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Short-term portion of contingent consideration Business Combination, Contingent Consideration, Liability, Current Class of Stock [Axis] Class of Stock [Axis] Other Other Accrued Liabilities, Current Dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Exercise price range five Exercise Price Range Five [Member] Exercise Price Range Five Depreciation Depreciation, Depletion and Amortization Stock-based compensation Deferred Compensation Share-Based Arrangements, Liability, Current Furniture and fixtures Furniture and Fixtures [Member] Current liabilities: Liabilities, Current [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Convertible preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Convertible preferred stock Preferred Stock, Value, Issued Working capital Working Capital Refers to capital comprising of short-term assets and liabilities which is used to perform day to day business operations. Contingent consideration milestone payment Payment for Contingent Consideration Liability, Financing Activities Diluted (in dollars per share) Net loss per share of common stock—diluted (in dollars per share) Earnings Per Share, Diluted Impairment of goodwill Goodwill, Impairment Loss Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Schedule of Assumptions Used to Calculate Fair Value Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Exercise price range four Exercise Price Range Four [Member] Exercise Price Range Four Awards outstanding, vested awards and those expected to vest at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Level 3) Fair Value, Inputs, Level 3 [Member] Subsequent Events [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Balance outstanding at the beginning of the period (in shares) Balance outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Trading Symbol Trading Symbol Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Convertible preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Conversion of Series C to common (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities (Level 2) Fair Value, Inputs, Level 2 [Member] Net loss Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Foreign Exchange Foreign Currency Transactions and Translations Policy [Policy Text Block] Granted Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value Amount of the intrinsic value of stock options granted during the reporting period. Exercise Price Per Share Share Based Compensation Arrangement by Share Based Payment Award, Options Exercise Price [Abstract] No definition available. Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Exercise price range seven Exercise Price Range Seven [Member] Exercise Price Range Seven Stockholders' equity: Equity, Attributable to Parent [Abstract] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Document Fiscal Period Focus Document Fiscal Period Focus Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rent expense Operating Lease, Expense Balance outstanding at the beginning of the period (in dollars per share) Balance outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Exercise Price Range [Domain] Exercise Price Range [Domain] Schedule of Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Common Stock Common Stock [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (Level 1) Fair Value, Inputs, Level 1 [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Loss per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Carrying value adjustments Property, Plant and Equipment, Gross, Period Increase (Decrease) Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Exercise price range three Exercise Price Range Three [Member] Represents Exercise Price Range Three. Document Fiscal Year Focus Document Fiscal Year Focus Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Term (in years) Lessee, Operating Lease, Term of Contract Entity Small Business Entity Small Business Minimum Minimum [Member] Local Phone Number Local Phone Number Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Exercise price, low end of the range (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Research and development Research and Development Expenses Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Corporate Office Space Office Space [Member] Representing information pertaining to office space . Cash Cash Measurement Frequency [Axis] Measurement Frequency [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Warrants Warrants – equity classified Warrant [Member] Assets Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Operating lease liability Increase (Decrease) in Operating Lease Liability Depreciation Depreciation Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Accumulated Deficit Retained Earnings [Member] Schedule of Stock Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Total liabilities and stockholders' equity Liabilities and Equity Other income (expense): Nonoperating Income (Expense) [Abstract] Warrants issued (in shares) Warrants Number Issued Represents information pertaining to the number of warrants issued. Risk free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic (in dollars per share) Net loss per share of common stock—basic (in dollars per share) Earnings Per Share, Basic Right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost related to non-vested stock Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Foreign exchange Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation Cash Cash and Cash Equivalents, Policy [Policy Text Block] Payables and Accruals [Abstract] Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Schedule of Outstanding Securities Excluded from the Computation of Basic and Diluted Weighted Shares Outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Change during period Indefinite-Lived Intangible Assets, Period Increase (Decrease) Entity Address, City or Town Entity Address, City or Town Research and development Research and Development Expense [Member] Adjustment for stock split Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Adjustment for Stock Split, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Adjustment for Stock Split, Intrinsic Value Stock-based liability awards reversed to additional paid-in capital Stock-Based Liability Awards Reversed To Additional Paid-In Capital Stock-Based Liability Awards Reversed To Additional Paid-In Capital Issuance of common stock in conjunction with milestone payment Stock Issued Awards outstanding, vested awards and those expected to vest at the end of the period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Total fair value of awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Total anti-dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Principles of Consolidation Consolidation, Policy [Policy Text Block] Document Quarterly Report Document Quarterly Report Right of use asset Increase (Decrease) in Right Of Use Asset Increase (Decrease) in Right Of Use Asset Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Interest expense Interest Expense Probability of success of milestone achievements Probability Of Milestone Achievements Represents the probability of a milestone achievement occurring. Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Document Transition Report Document Transition Report General and administrative General and Administrative Expense [Member] Shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Property and equipment Property, Plant and Equipment, Gross Balance outstanding term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Intrinsic Value Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Contingent consideration, fair value measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Use of Estimates Use of Estimates, Policy [Policy Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Discount rate Measurement Input, Discount Rate [Member] Operating lease liabilities, current Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Entity Shell Company Entity Shell Company Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Cash at beginning of period Cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Acquisition-related Contingent Consideration Contingent Consideration [Member] Represents Acquisition related contingent consideration. Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Statement of Comprehensive Income [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Adjustment for stock split (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Adjustment For Stock Split Adjustment for Stock Splits, Shares Stock options Employee Stock Option [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income Taxes Income Tax, Policy [Policy Text Block] Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Stock price (in dollars per share) Share Price Balance outstanding at the beginning of the period Balance outstanding at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other assets Other Assets Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Exercise price, high end of the range (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Change in fair value of contingent consideration Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Accounting for Share-Based Payments Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Document Period End Date Document Period End Date Weighted Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vested and exercisable at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Entity Central Index Key Entity Central Index Key Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures, Intrinsic Value Total stock-based compensation expense Share-Based Payment Arrangement, Expense Conversion ratio Preferred Stock, Convertible, Conversion Ratio Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income tax benefit (expense) Income Tax Expense (Benefit) Income Statement [Abstract] Income Statement [Abstract] Conversion of Series C convertible preferred stock Conversion of Stock, Amount Converted Office and Research Laboratory Office And Research Laboratory [Member] This member stans for office and research laboratory member Issuance of common stock, net (in shares) Stock Issued During Period, Shares, New Issues Cost and expenses: Costs and Expenses [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Payroll and related costs Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Issuance of common stock in connection with stock split (in shares) Stock Issued During Period, Shares, Reverse Stock Splits Number of operating segments Number of Operating Segments Exercise price range six Exercise Price Range Six [Member] Exercise Price Range Six Total other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent In-process research and development In-process research and development, beginning balance In-process research and development, ending balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Issuance of common stock, net Stock Issued During Period, Value, New Issues Equity [Abstract] Revenues Revenue from Contract with Customer, Excluding Assessed Tax Class of Stock [Line Items] Class of Stock [Line Items] Amendment Flag Amendment Flag Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Statistical Measurement [Axis] Statistical Measurement [Axis] Stock-based liability awards converted to equity Adjustment To Additional Paid In Capital, Stock-Based Liability Awards Converted Adjustment To Additional Paid In Capital, Stock-Based Liability Awards Converted Exercise price range eight Exercise Price Range Eight [Member] Exercise Price Range Eight Entity Interactive Data Current Entity Interactive Data Current Estimated useful life (in years) Property, Plant and Equipment, Useful Life Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding In-Process Research & Development Goodwill and Intangible Assets, Policy [Policy Text Block] Diluted (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Indefinite-lived Intangible Assets [Roll Forward] Indefinite-Lived Intangible Assets [Roll Forward] Supplementary disclosure of non-cash financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Exercise Price Range [Axis] Exercise Price Range [Axis] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital, Common Stock Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional Paid in Capital Additional Paid-in Capital [Member] Current assets: Assets, Current [Abstract] Cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Entity Address, State or Province Entity Address, State or Province Cover [Abstract] Cover [Abstract] Equipment Equipment [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Subsequent Events Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring basis Fair Value, Recurring [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Series A Common shares issuable upon conversion of Series A preferred stock Series A Preferred Stock [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Net loss per common share: (see Note 10) Earnings Per Share, Basic [Abstract] Total operating expenses Operating Expenses Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Net decrease in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Renewal term (in years) Lessee, Operating Lease, Renewal Term Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations, Intrinsic Value Equity Component [Domain] Equity Component [Domain] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Adjustment for stock split (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Adjustment for Stock Split, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Adjustment for Stock Split, Weighted Average Exercise Price Prepaid research and development costs Contract with Customer, Asset, after Allowance for Credit Loss Schedule of Changes in Fair Value of Contingent Consideration Schedule Of Fair Value For Contingent Consideration [Table Text Block] Represents tabular information of changes in fair value of contingent consideration. Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Exercise price range two Exercise Price Range Two [Member] Represents exercise price range two. Loss from operations Operating Income (Loss) Measurement Input Type [Domain] Measurement Input Type [Domain] Vested and exercisable at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Preferred shares converted into common stock (in shares) Conversion of Stock, Shares Converted Total liabilities Liabilities Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Issuance of common stock in connection with stock split Adjustments to Additional Paid in Capital, Stock Split Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Series C Common shares issuable upon conversion of Series C preferred stock Series C Preferred Stock [Member] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Changes in Stockholders' Equity Statement [Line Items] Conversion of Series C to common Stock Issued During Period, Value, Conversion of Convertible Securities Property, equipment and depreciation Property, Plant and Equipment, Policy [Policy Text Block] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Awards outstanding, vested awards and those expected to vest at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Weighted Average Remaining Contractual Team Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 3,838,289 and 3,811,481 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Exercise price range nine Exercise Price Range Nine [Member] Exercise Price Range Nine General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] EX-101.PRE 10 hepa-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 hepa-20230630_g1.jpg begin 644 hepa-20230630_g1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page - shares
6 Months Ended
Jun. 30, 2023
Aug. 07, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-36856  
Entity Registrant Name HEPION PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-2783806  
Entity Address, Address Line One 399 Thornall Street  
Entity Address, Address Line Two First Floor  
Entity Address, City or Town Edison  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08837  
City Area Code 732  
Local Phone Number 902-4000  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol HEPA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   3,838,289
Entity Central Index Key 0001583771  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash $ 30,521,733 $ 51,189,088
Prepaid expenses 2,240,723 5,306,985
Total current assets 32,762,456 56,496,073
Property and equipment, net 60,770 81,620
Right-of-use assets 0 50,585
In-process research and development 3,190,000 3,190,000
Other assets 488,884 426,174
Total assets 36,502,110 60,244,452
Current liabilities:    
Accounts payable 4,191,225 2,665,896
Accrued expenses 3,108,794 4,799,983
Operating lease liabilities, current 0 53,614
Short-term portion of contingent consideration 373,710 366,229
Total current liabilities 7,673,729 7,885,722
Contingent consideration 2,046,290 2,093,771
Deferred tax liability 409,022 409,022
Total liabilities 10,129,041 10,388,515
Commitments and contingencies (see Note 11)
Stockholders' equity:    
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 3,838,289 and 3,811,481 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 384 381
Additional paid-in capital 227,806,020 223,950,940
Accumulated other comprehensive loss (87,651) (90,168)
Accumulated deficit (203,040,812) (175,701,344)
Total stockholders' equity 26,373,069 49,855,937
Total liabilities and stockholders' equity 36,502,110 60,244,452
Series A    
Stockholders' equity:    
Convertible preferred stock 855,808 855,808
Series C    
Stockholders' equity:    
Convertible preferred stock $ 839,320 $ 840,320
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 120,000,000 120,000,000
Common stock, shares issued (in shares) 3,838,289 3,811,481
Common stock, shares outstanding (in shares) 3,838,289 3,811,481
Series A    
Convertible preferred stock, par value (in dollars per share) $ 10 $ 10
Convertible preferred stock, shares issued (in shares) 85,581 85,581
Convertible preferred stock, shares outstanding (in shares) 85,581 85,581
Series C    
Convertible preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Convertible preferred stock, shares issued (in shares) 1,800 1,801
Convertible preferred stock, shares outstanding (in shares) 1,800 1,801
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenues $ 0 $ 0 $ 0 $ 0
Cost and expenses:        
Research and development 11,880,669 15,701,955 21,678,328 20,013,089
General and administrative 2,284,961 2,425,242 5,696,467 5,366,576
Impairment of goodwill 0 1,870,924 0 1,870,924
Total operating expenses 14,165,630 19,998,121 27,374,795 27,250,589
Loss from operations (14,165,630) (19,998,121) (27,374,795) (27,250,589)
Other income (expense):        
Interest expense (2,351) (3,178) (4,673) (5,387)
Change in fair value of contingent consideration 88,434 90,000 40,000 414,992
Loss before income taxes (14,079,547) (19,911,299) (27,339,468) (26,840,984)
Income tax benefit (expense) 0 0 0 0
Net loss $ (14,079,547) $ (19,911,299) $ (27,339,468) $ (26,840,984)
Weighted-average common shares outstanding:        
Basic (in shares) 3,826,505 3,811,481 3,819,035 3,811,463
Diluted (in shares) 3,826,505 3,811,481 3,819,035 3,811,463
Net loss per common share: (see Note 10)        
Basic (in dollars per share) $ (3.68) $ (5.22) $ (7.16) $ (7.04)
Diluted (in dollars per share) $ (3.68) $ (5.22) $ (7.16) $ (7.04)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net loss $ (14,079,547) $ (19,911,299) $ (27,339,468) $ (26,840,984)
Other comprehensive income (loss):        
Foreign currency translation (16,836) (39,113) 2,517 (29,967)
Total other comprehensive income (loss) (16,836) (39,113) 2,517 (29,967)
Comprehensive loss $ (14,096,383) $ (19,950,412) $ (27,336,951) $ (26,870,951)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
Total
Preferred Stock
Series A
Preferred Stock
Series C
Common Stock
Additional Paid in Capital
Accumulated other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   85,581 1,806 3,811,263      
Beginning balance at Dec. 31, 2021 $ 92,995,003 $ 855,808 $ 845,320 $ 381 $ 224,794,789 $ 0 $ (133,501,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (6,929,685)           (6,929,685)
Other comprehensive income (loss) 9,146         9,146  
Stock-based compensation expense 556,610       556,610    
Conversion of Series C to common (in shares)     (5) 2      
Conversion of Series C to common 0   $ (5,000)   5,000    
Issuance of common stock, net (in shares)       216      
Issuance of common stock, net 5,008       5,008    
Ending balance (in shares) at Mar. 31, 2022   85,581 1,801 3,811,481      
Ending balance at Mar. 31, 2022 86,636,082 $ 855,808 $ 840,320 $ 381 225,361,407 9,146 (140,430,980)
Beginning balance (in shares) at Dec. 31, 2021   85,581 1,806 3,811,263      
Beginning balance at Dec. 31, 2021 92,995,003 $ 855,808 $ 845,320 $ 381 224,794,789 0 (133,501,295)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (26,840,984)            
Other comprehensive income (loss) (29,967)            
Ending balance (in shares) at Jun. 30, 2022   85,581 1,801 3,811,481      
Ending balance at Jun. 30, 2022 67,320,321 $ 855,808 $ 840,320 $ 381 225,996,058 (29,967) (160,342,279)
Beginning balance (in shares) at Mar. 31, 2022   85,581 1,801 3,811,481      
Beginning balance at Mar. 31, 2022 86,636,082 $ 855,808 $ 840,320 $ 381 225,361,407 9,146 (140,430,980)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (19,911,299)           (19,911,299)
Other comprehensive income (loss) (39,113)         (39,113)  
Stock-based compensation expense 634,651       634,651    
Ending balance (in shares) at Jun. 30, 2022   85,581 1,801 3,811,481      
Ending balance at Jun. 30, 2022 67,320,321 $ 855,808 $ 840,320 $ 381 225,996,058 (29,967) (160,342,279)
Beginning balance (in shares) at Dec. 31, 2022   85,581 1,801 3,811,481      
Beginning balance at Dec. 31, 2022 49,855,937 $ 855,808 $ 840,320 $ 381 223,950,940 (90,168) (175,701,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (13,259,921)           (13,259,921)
Other comprehensive income (loss) 19,353         19,353  
Stock-based compensation expense 537,123       537,123    
Conversion of Series C to common (in shares)     (1) 1      
Conversion of Series C to common 0   $ (1,000)   1,000    
Ending balance (in shares) at Mar. 31, 2023   85,581 1,800 3,811,482      
Ending balance at Mar. 31, 2023 37,152,492 $ 855,808 $ 839,320 $ 381 224,489,063 (70,815) (188,961,265)
Beginning balance (in shares) at Dec. 31, 2022   85,581 1,801 3,811,481      
Beginning balance at Dec. 31, 2022 49,855,937 $ 855,808 $ 840,320 $ 381 223,950,940 (90,168) (175,701,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (27,339,468)            
Other comprehensive income (loss) 2,517            
Stock-based liability awards converted to equity 2,983,006            
Ending balance (in shares) at Jun. 30, 2023   85,581 1,800 3,838,289      
Ending balance at Jun. 30, 2023 26,373,069 $ 855,808 $ 839,320 $ 384 227,806,020 (87,651) (203,040,812)
Beginning balance (in shares) at Mar. 31, 2023   85,581 1,800 3,811,482      
Beginning balance at Mar. 31, 2023 37,152,492 $ 855,808 $ 839,320 $ 381 224,489,063 (70,815) (188,961,265)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss (14,079,547)           (14,079,547)
Other comprehensive income (loss) (16,836)         (16,836)  
Stock-based compensation expense 333,954       333,954    
Stock-based liability awards converted to equity 2,983,006       2,983,006    
Issuance of common stock in connection with stock split (in shares)       26,807      
Issuance of common stock in connection with stock split 0     $ 3 (3)    
Ending balance (in shares) at Jun. 30, 2023   85,581 1,800 3,838,289      
Ending balance at Jun. 30, 2023 $ 26,373,069 $ 855,808 $ 839,320 $ 384 $ 227,806,020 $ (87,651) $ (203,040,812)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (27,339,468) $ (26,840,984)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 871,077 1,703,958
Depreciation 36,366 41,257
Change in fair value of contingent consideration (40,000) (414,992)
Impairment of goodwill 0 1,870,924
Changes in operating assets and liabilities:    
Accounts payable and accrued expenses 2,815,672 7,736,105
Right of use asset 50,585 134,907
Operating lease liability (53,614) (140,136)
Prepaid expenses and other assets 3,008,520 (1,720,352)
Net cash used in operating activities (20,650,862) (17,629,313)
Cash flows from investing activities:    
Purchases of property and equipment (16,538) 0
Proceeds from disposal of property and equipment 0 2,266
Net cash (used in) provided by investing activities (16,538) 2,266
Cash flows from financing activities:    
Contingent consideration milestone payment 0 (2,000,000)
Net cash used in financing activities 0 (2,000,000)
Effect of exchange rates on cash 45 (14,415)
Net decrease in cash (20,667,355) (19,641,462)
Cash at beginning of period 51,189,088 91,348,967
Cash at end of period 30,521,733 71,707,505
Supplementary disclosure of cash flow information:    
Cash paid for interest 0 941
Supplementary disclosure of non-cash financing activities:    
Conversion of Series C convertible preferred stock 1,000 5,000
Issuance of common stock in conjunction with milestone payment 0 5,008
Stock-based liability awards reversed to additional paid-in capital $ 2,983,006 $ 0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Business Overview
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Overview Business Overview
Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment of hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
We are developing rencofilstat as our lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. Many closely related isoforms of cyclophilins exist in humans. Cyclophilins A, B, and D are the best characterized cyclophilin isoforms. Inhibition of cyclophilins has been shown in scientific literature to have therapeutic effects in a variety of experimental models, including liver disease models.
We have completed a number of Phase 1 and Phase 2 clinical trials. In May 2023, we announced that our Phase 2a study ("ALTITUDE-NASH") met its primary endpoint by demonstrating improved liver function and was well tolerated after four months of treatment with once daily oral rencofilstat administered to NASH subjects with stage 3 or greater fibrosis. All additional secondary efficacy and safety endpoints were also met. These observations provide further evidence that builds on previous findings from a shorter 28-day Phase 2a ("AMBITION") trial. Taken together, the AMBITION and ALTITUDE-NASH trials reinforce rencofilstat’s direct antifibrotic mode of action and increase our confidence level that we anticipate observing fibrosis reductions in our ongoing 12-month Phase 2b ("ASCEND-NASH") clinical trial.
In June 2023, we announced that the Data and Safety Monitoring Board ("DSMB") met to review the current data for the ASCEND-NASH 2b study and has issued a “study may proceed without modification” clearance. This, the first planned DSMB meeting, occurred on schedule, and all labs, electrocardiogram's, adverse events, and protocol deviations were reviewed, focusing on any potential safety signals from the placebo-controlled trial.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2022, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, contained in our Annual Report on Form 10-K filed with the SEC on April 10, 2023.
Principles of Consolidation
The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split
On May 3, 2023, our Board of Directors declared a 1-for-20 reverse stock split of the outstanding shares of our common stock in order to satisfy requirements for the continued listing of our common stock on Nasdaq. The reverse stock split was effective May 11, 2023. All applicable share and per share information in these condensed consolidated financial statements on Form 10-Q have been adjusted retrospectively to give effect to the reverse stock split for all periods presented. The reverse stock split did not reduce the number of authorized shares of common stock and will not alter the par value.
Going Concern
As of June 30, 2023, we had $30.5 million in cash, an accumulated deficit of $203.0 million, and working capital of $25.1 million. For the six months ended June 30, 2023, cash used in operating activities was $20.7 million and we had a net loss of $27.3 million. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research,
development and clinical trials of rencofilstat. We are unable to predict the extent of any future losses or when we will become profitable, if at all.
These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We will be required to raise additional capital within the next year to continue the development and commercialization of our current product candidate and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022, included in our Annual Report on Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.
Cash
As of June 30, 2023 and December 31, 2022, cash was $30.5 million and $51.2 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. At certain times, our cash balances with any one financial institution may exceed Federal Deposit Insurance Corporation insurance limits. We believe it mitigates our risk by depositing our cash balances with high credit, quality financial institutions. We have never experienced losses related to these balances.
Fair Value of Financial Instruments
Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.
ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:
Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.
Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Financial instruments consist of cash, accounts payable, and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature, except for contingent consideration, which is recorded at fair value at the end of each reporting period. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 5 for additional information on the fair value of the contingent consideration.
Property, equipment and depreciation
As of June 30, 2023 and December 31, 2022, we had $0.1 million and $0.1 million, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, and furniture and fixtures. There were no adjustments to the carrying value of property and equipment at June 30, 2023 or December 31, 2022.
In-Process Research & Development
The annual, or interim (if events or changes in circumstances indicate that it is more likely than not that the asset is impaired), In-Process Research and Development ("IPR&D") impairment test is performed by comparing the fair value of the asset to the asset’s carrying amount. When testing indefinite-lived intangibles for impairment, we may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not that the asset is impaired. Alternatively, we may bypass this qualitative assessment for our indefinite-lived intangible asset and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.
We performed a qualitative assessment of IPR&D at June 30, 2023 and a quantitative assessment for fiscal year 2022 and determined that the asset was not impaired.
Income Taxes
We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.
We continue to maintain a full valuation allowance for our U.S and foreign net deferred tax assets.
Under the provisions of the Internal Revenue Code, the net operating loss (NOL) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The utilization of these NOLs is subject to limitations based on past and future changes in our ownership pursuant to Section 382. We completed a Section 382 study of transactions in our stock through December 31, 2021 and concluded that we have experienced ownership changes since inception that we believe under Section 382 and 383 of the
Internal Revenue Code will result in limitations on our ability to use certain pre-ownership change NOLs and credits. We are not aware of any ownership changes in 2023 or 2022. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our consolidated financial statements could be further limited. Similar provisions of state tax law may also apply to limit the use of accumulated state tax attributes.
Contingencies
In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.
Research and Development
Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.
We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.
Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At June 30, 2023 and December 31, 2022, we had prepaid research and development costs of $1.9 million and $4.7 million, respectively.
Foreign Exchange
The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Assets and liabilities of Hepion Research Corp. are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was $87,651 and $90,168 at June 30, 2023 and December 31, 2022, respectively. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in general and administrative expense within the consolidated statements of operations. The impact of foreign exchange losses (gains) was $30,661 and $2,678 for the three months ended June 30, 2023 and 2022, respectively, and was $56,095 and $(32,518) for the six months ended June 30, 2023 and 2022, respectively.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.
Net loss per share
Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.
Recent Accounting Pronouncements
There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the six months ended June 30, 2023.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Series A Convertible Preferred Stock
On October 14, 2014, our Board of Directors authorized the sale and issuance of up to 1,250,000 shares of Series A Convertible Preferred Stock (the “Series A”). All shares of the Series A were issued between October 2014 and February 2015. Each share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. As of June 30, 2023, there were 85,581 shares outstanding. During the six months ended June 30, 2023 and 2022, no shares of the Series A were converted. If we sell common stock or equivalents at an effective price per share that is lower than the conversion price, the conversion price may be reduced to the lower conversion price. The Series A will be automatically convertible into common stock in the event of a fundamental transaction as defined in the offering.
Series C Convertible Preferred Stock Issuance
On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consisted of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 4,446 common stock warrants that expired in July 2023. As of June 30, 2023, there were 1,800 shares of Series C outstanding. During the six months ended June 30, 2023, 1 share of the Series C was converted into 1 share of our common stock and during the six months ended June 30, 2022, 5 shares of the Series C were converted into 2 shares of our common stock. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $0.08 per share (subject to adjustments upon the occurrence of certain dilutive events).
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2023 and December 31, 2022.
Fair Value Measurement at Reporting Date Using
DescriptionFair value(Level 1)(Level 2)(Level 3)
As of June 30, 2023:
Contingent consideration$2,420,000 $— $— $2,420,000 
As of December 31, 2022:
Contingent consideration$2,460,000 $— $— $2,460,000 
Contingent consideration was recorded for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin) on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model.
At June 30, 2023 and December 31, 2022, the assumptions we used to calculate the fair value were as follows:
Assumptions
June 30,
2023
December 31,
2022
Discount rate8.5%8.5%
Stock pricen/an/a
Projected milestone achievement datesMar 2024Jun 2029Dec 2023Dec 2028
Probability of success of milestone achievements13 %40%13 %40%
As of June 30, 2023, $2,046,290 was classified as a non-current liability based upon management's best estimate using
the latest available information. Management reviewed the assumptions and for the six months ended June 30, 2023, the only change made was to the milestone achievement dates.
The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2023.
Acquisition-related Contingent Consideration
Liabilities:
Balance at December 31, 2022$2,460,000 
Change in fair value recorded in earnings(40,000)
Balance at June 30, 2023$2,420,000 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, net
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment are stated at cost and depreciated using the straight-line method, based on useful lives as follows:
Estimated Useful Life (in years)June 30,
2023
December 31,
2022
Equipment3 years$346,671 $326,382 
Furniture and fixtures7 years62,183 62,183 
Less: Accumulated depreciation(348,084)(306,945)
$60,770 $81,620 
Depreciation expense for the three months ended June 30, 2023 and 2022 was $18,328 and $18,529, respectively, and was $36,366 and $41,258 for the six months ended June 30, 2023 and 2022, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Indefinite-lived Intangible Assets
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Indefinite-lived Intangible Assets Indefinite-lived Intangible Assets
IPR&D
Our IPR&D asset consisted of the following at:
Indefinite-lived
Intangible Asset
Rencofilstat balance at December 31, 2022$3,190,000 
Change during the six months ended June 30, 2023— 
Rencofilstat balance at June 30, 2023$3,190,000 
No impairment losses were recorded on IPR&D during the six months ended June 30, 2023 and 2022.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Liabilities
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Accrued Liabilities Accrued Liabilities
Accrued liabilities consisted of the following:
June 30,
2023
December 31,
2022
Payroll and related costs$724,100 $838,683 
Stock-based compensation — 1,906,401 
Research and development2,009,215 1,716,035 
Professional fees237,399 246,664 
Other138,080 92,200 
Total accrued expenses$3,108,794 $4,799,983 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting for Share-Based Payments
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Accounting for Share-Based Payments Accounting for Share-Based Payments
In April 2023, our board of directors approved the 2023 Omnibus Equity Incentive Plan (the 2023 Plan), which became effective in June 2023 upon stockholder approval. The 2023 Plan allows for the grant of up to 500,000 awards for the purpose of attracting, motivating and retaining employees (including officers), non-employee directors and non-employee consultants. At June 30, 2023, there were no awards granted from the 2023 Plan.
On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Plan), which expired in June 2023 and we are no longer making grants under it. Stock options granted under the 2013 Plan typically vest after three years of continuous service from the grant date and will have a contractual term of ten years. We granted options during the three months ended June 30, 2022 and 2021, and at the time that these grants were made, we did not have any options available for grant under the Plan. We accounted for these option grants as liability-classified awards requiring us to measure the fair value of the awards each reporting period since there were not enough shares available at the time of the grant. With the approval of the 2023 Plan, these awards are no longer accounted for as liability-classified and the cumulative liability of $2,983,006 was recorded to additional paid-in capital.
We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
General and administrative$(22,743)$127,483 $1,170,717 $1,210,584 
Research and development39,671 35,025 776,964 493,374 
Total stock-based compensation expense$16,928 $162,508 $1,947,681 $1,703,958 
A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:
Number of OptionsExercise Price
Per Share
Weighted
Average Exercise Price Per Share
Intrinsic
Value
Weighted
Average Remaining Contractual Team
Balance outstanding, December 31, 2022444,749 $13.80 -$40,320.00 $46.20 $— 8.13 years
Granted— $— -$— $— $— 
Adjustment for stock split48 $— -$— $— $— 
Exercised— $— -$— $— $— 
Forfeited(112)$34.00 -$34.00 $34.00 $— 
Cancelled(139)$34.00 -$34.00 $34.00 $— 
Balance outstanding, June 30, 2023444,546 $13.80 -$40,320.00 $47.12 $— 7.63 years
Awards outstanding, vested awards and those expected to vest at June 30, 2023443,256 $13.80 -$40,320.00 $47.17 $— 7.63 years
Vested and exercisable at June 30, 2023360,609 $13.80 -$40,320.00 $50.15 $— 7.56 years
The total fair value of awards vested during the six months ended June 30, 2023 and 2022 was $2.2 million and $4.0 million, respectively.
As of June 30, 2023, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was $0.8 million to be recognized over a weighted-average remaining vesting period of approximately 0.8 years.
The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate the fair value of stock option awards when granted to employees.
Six Months Ended
June 30,
20232022
Stock price$— $13.80 
Risk-free interest rate— %3.26 %
Dividend yield— — 
Expected volatility— %116.7 %
Expected term (in years)0.06.0
Risk-free interest rate—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.
Dividend yield—We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.
Expected volatility—We base expected volatility on the trading price of our common stock.
Expected term—The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.
SAB No. 110, Share-Based Payment, (“SAB No. 110”) expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. For the expected term, we have “plain-vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Loss per Share Loss per Share
Basic and diluted net loss per common share was determined by dividing net loss by the weighted-average common shares outstanding during the period.
The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:
Three Months Ended
June 30,
Six Months Ended
June 30,
Basic and diluted net loss per common share:2023202220232022
Numerator:
Net loss$(14,079,547)$(19,911,299)$(27,339,468)$(26,840,984)
Denominator:
Weighted average common shares outstanding3,826,505 3,811,481 3,819,035 3,811,463 
Net loss per share of common stock—basic and diluted$(3.68)$(5.22)$(7.16)$(7.04)
The following outstanding securities at June 30, 2023 and 2022 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:
Six Months Ended
June 30,
20232022
Common shares issuable upon conversion of Series A preferred stock159 159 
Common shares issuable upon conversion of Series C preferred stock829 830 
Stock options444,546 444,749 
Warrants – equity classified215,559 215,559 
Total661,093 661,297 
The equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Contractual Obligations
In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. The lease expired on March 31, 2023 and we are currently leasing this space on a month-to-month basis. We are currently negotiating with the landlord for a new lease agreement. In October 2019, we entered into a 3-year lease for office and research laboratory space in Edmonton, Canada, which expired on September 30, 2022 and we are leasing this space on a month-to-month basis. We are currently negotiating with the landlord for a new lease agreement.
Legal Proceedings
We are involved in various legal proceedings. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our consolidated financial condition or results of operations.
Leases
We account for leases in accordance with ASC Topic 842, Leases, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property and equipment), and (2) the customer has the right to control the use of the identified asset.
Operating leases where we are the lessee are included under the caption “Right of Use Assets” ("ROU") on our consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.
The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Rent expense for the three months ended June 30, 2023 and 2022 was $0.1 million and $0.1 million, respectively, and was $0.2 million and $0.2 million for the six months ended June 30, 2023 and 2022, respectively.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsNone
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2022, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, contained in our Annual Report on Form 10-K filed with the SEC on April 10, 2023.
Principles of Consolidation
Principles of Consolidation
The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Cash
Cash
As of June 30, 2023 and December 31, 2022, cash was $30.5 million and $51.2 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. At certain times, our cash balances with any one financial institution may exceed Federal Deposit Insurance Corporation insurance limits. We believe it mitigates our risk by depositing our cash balances with high credit, quality financial institutions. We have never experienced losses related to these balances.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.
ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:
Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.
Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.
To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Financial instruments consist of cash, accounts payable, and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature, except for contingent consideration, which is recorded at fair value at the end of each reporting period. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value.
Property, equipment and depreciation
Property, equipment and depreciation
As of June 30, 2023 and December 31, 2022, we had $0.1 million and $0.1 million, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, and furniture and fixtures. There were no adjustments to the carrying value of property and equipment at June 30, 2023 or December 31, 2022.
In-Process Research & Development
In-Process Research & Development
The annual, or interim (if events or changes in circumstances indicate that it is more likely than not that the asset is impaired), In-Process Research and Development ("IPR&D") impairment test is performed by comparing the fair value of the asset to the asset’s carrying amount. When testing indefinite-lived intangibles for impairment, we may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not that the asset is impaired. Alternatively, we may bypass this qualitative assessment for our indefinite-lived intangible asset and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.
We performed a qualitative assessment of IPR&D at June 30, 2023 and a quantitative assessment for fiscal year 2022 and determined that the asset was not impaired.
Income Taxes
Income Taxes
We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.
We continue to maintain a full valuation allowance for our U.S and foreign net deferred tax assets.
Under the provisions of the Internal Revenue Code, the net operating loss (NOL) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The utilization of these NOLs is subject to limitations based on past and future changes in our ownership pursuant to Section 382. We completed a Section 382 study of transactions in our stock through December 31, 2021 and concluded that we have experienced ownership changes since inception that we believe under Section 382 and 383 of the
Internal Revenue Code will result in limitations on our ability to use certain pre-ownership change NOLs and credits. We are not aware of any ownership changes in 2023 or 2022. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our consolidated financial statements could be further limited. Similar provisions of state tax law may also apply to limit the use of accumulated state tax attributes.
Contingencies
Contingencies
In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.
Research and Development
Research and Development
Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, Research and Development, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.
We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.
Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense.
Foreign Exchange Foreign ExchangeThe functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Assets and liabilities of Hepion Research Corp. are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was $87,651 and $90,168 at June 30, 2023 and December 31, 2022, respectively. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in general and administrative expense within the consolidated statements of operations. The impact of foreign exchange losses (gains) was $30,661 and $2,678 for the three months ended June 30, 2023 and 2022, respectively, and was $56,095 and $(32,518) for the six months ended June 30, 2023 and 2022, respectively.
Segment Information
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.
Net loss per share
Net loss per share
Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the six months ended June 30, 2023.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis
The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2023 and December 31, 2022.
Fair Value Measurement at Reporting Date Using
DescriptionFair value(Level 1)(Level 2)(Level 3)
As of June 30, 2023:
Contingent consideration$2,420,000 $— $— $2,420,000 
As of December 31, 2022:
Contingent consideration$2,460,000 $— $— $2,460,000 
Schedule of Assumptions Used to Calculate Fair Value
At June 30, 2023 and December 31, 2022, the assumptions we used to calculate the fair value were as follows:
Assumptions
June 30,
2023
December 31,
2022
Discount rate8.5%8.5%
Stock pricen/an/a
Projected milestone achievement datesMar 2024Jun 2029Dec 2023Dec 2028
Probability of success of milestone achievements13 %40%13 %40%
Schedule of Changes in Fair Value of Contingent Consideration
The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2023.
Acquisition-related Contingent Consideration
Liabilities:
Balance at December 31, 2022$2,460,000 
Change in fair value recorded in earnings(40,000)
Balance at June 30, 2023$2,420,000 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, net (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method, based on useful lives as follows:
Estimated Useful Life (in years)June 30,
2023
December 31,
2022
Equipment3 years$346,671 $326,382 
Furniture and fixtures7 years62,183 62,183 
Less: Accumulated depreciation(348,084)(306,945)
$60,770 $81,620 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Indefinite-lived Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Our IPR&D asset consisted of the following at:
Indefinite-lived
Intangible Asset
Rencofilstat balance at December 31, 2022$3,190,000 
Change during the six months ended June 30, 2023— 
Rencofilstat balance at June 30, 2023$3,190,000 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued liabilities consisted of the following:
June 30,
2023
December 31,
2022
Payroll and related costs$724,100 $838,683 
Stock-based compensation — 1,906,401 
Research and development2,009,215 1,716,035 
Professional fees237,399 246,664 
Other138,080 92,200 
Total accrued expenses$3,108,794 $4,799,983 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting for Share-Based Payments (Tables)
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Based Compensation Expense We recorded stock-based compensation expense as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
General and administrative$(22,743)$127,483 $1,170,717 $1,210,584 
Research and development39,671 35,025 776,964 493,374 
Total stock-based compensation expense$16,928 $162,508 $1,947,681 $1,703,958 
Schedule of Stock Option Activity
A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:
Number of OptionsExercise Price
Per Share
Weighted
Average Exercise Price Per Share
Intrinsic
Value
Weighted
Average Remaining Contractual Team
Balance outstanding, December 31, 2022444,749 $13.80 -$40,320.00 $46.20 $— 8.13 years
Granted— $— -$— $— $— 
Adjustment for stock split48 $— -$— $— $— 
Exercised— $— -$— $— $— 
Forfeited(112)$34.00 -$34.00 $34.00 $— 
Cancelled(139)$34.00 -$34.00 $34.00 $— 
Balance outstanding, June 30, 2023444,546 $13.80 -$40,320.00 $47.12 $— 7.63 years
Awards outstanding, vested awards and those expected to vest at June 30, 2023443,256 $13.80 -$40,320.00 $47.17 $— 7.63 years
Vested and exercisable at June 30, 2023360,609 $13.80 -$40,320.00 $50.15 $— 7.56 years
Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options
The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate the fair value of stock option awards when granted to employees.
Six Months Ended
June 30,
20232022
Stock price$— $13.80 
Risk-free interest rate— %3.26 %
Dividend yield— — 
Expected volatility— %116.7 %
Expected term (in years)0.06.0
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share (Tables)
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Loss Per Share
The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:
Three Months Ended
June 30,
Six Months Ended
June 30,
Basic and diluted net loss per common share:2023202220232022
Numerator:
Net loss$(14,079,547)$(19,911,299)$(27,339,468)$(26,840,984)
Denominator:
Weighted average common shares outstanding3,826,505 3,811,481 3,819,035 3,811,463 
Net loss per share of common stock—basic and diluted$(3.68)$(5.22)$(7.16)$(7.04)
Schedule of Outstanding Securities Excluded from the Computation of Basic and Diluted Weighted Shares Outstanding
The following outstanding securities at June 30, 2023 and 2022 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:
Six Months Ended
June 30,
20232022
Common shares issuable upon conversion of Series A preferred stock159 159 
Common shares issuable upon conversion of Series C preferred stock829 830 
Stock options444,546 444,749 
Warrants – equity classified215,559 215,559 
Total661,093 661,297 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation - Additional Information (Details)
3 Months Ended 6 Months Ended
May 03, 2023
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]                
Cash   $ 30,521,733       $ 30,521,733   $ 51,189,088
Accumulated deficit   203,040,812       203,040,812   $ 175,701,344
Working capital   25,100,000       25,100,000    
Net cash used in operating activities           20,650,862 $ 17,629,313  
Net loss   $ 14,079,547 $ 13,259,921 $ 19,911,299 $ 6,929,685 $ 27,339,468 $ 26,840,984  
Stock split, conversion ratio 0.05              
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Cash (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Cash $ 30,521,733 $ 51,189,088
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Property, Equipment and Depreciation (Details) - USD ($)
12 Months Ended
Dec. 31, 2022
Jun. 30, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, net $ 81,620 $ 60,770
Carrying value adjustments $ 0  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Research and Development (Details) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Prepaid research and development costs $ 1.9 $ 4.7
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Foreign Exchange (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Accounting Policies [Abstract]          
Accumulated other comprehensive loss $ (87,651)   $ (87,651)   $ (90,168)
Foreign exchange $ 30,661 $ 2,678 $ 56,095 $ (32,518)  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Segment Information (Details)
6 Months Ended
Jun. 30, 2023
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity - Series A Convertible Preferred Stock (Details) - Series A - shares
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Oct. 14, 2014
Class of Stock [Line Items]        
Convertible preferred stock, shares authorized (in shares)       1,250,000
Convertible preferred stock, shares outstanding (in shares) 85,581 85,581    
Stock issued as a result of conversion (in shares) 0   0  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity - Series C Preferred Stock Issuances (Details)
6 Months Ended
Jul. 03, 2018
$ / shares
shares
Jun. 30, 2023
$ / shares
shares
Jun. 30, 2022
shares
Dec. 31, 2022
$ / shares
shares
Class of Stock [Line Items]        
Preferred shares converted into common stock (in shares)   1 2  
Series C        
Class of Stock [Line Items]        
Convertible preferred stock, shares issued (in shares)   1,800   1,801
Issuance of common stock, net (in shares) 10,826      
Convertible preferred stock, par value (in dollars per share) | $ / shares $ 1,000 $ 1,000   $ 1,000
Convertible preferred stock, shares outstanding (in shares)   1,800   1,801
Stock issued as a result of conversion (in shares)   1 5  
Conversion ratio 0.08      
Preferred Stock | Series C        
Class of Stock [Line Items]        
Convertible preferred stock, shares issued (in shares) 1      
Warrants        
Class of Stock [Line Items]        
Warrants issued (in shares) 4,446      
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Schedule of Liabilities Measured on Recurring Basis (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 2,046,290 $ 2,093,771
Recurring basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 2,420,000 2,460,000
Recurring basis | (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0 0
Recurring basis | (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0 0
Recurring basis | (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 2,420,000 $ 2,460,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Additional Information (Details)
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Non-current portion of contingent consideration $ 2,046,290 $ 2,093,771
Discount rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, fair value measurement input 0.085 0.085
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Assumptions Used to Calculate Fair Value (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Probability of success of milestone achievements 13.00% 13.00%
Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Probability of success of milestone achievements 40.00% 40.00%
Discount rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, fair value measurement input 0.085 0.085
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurements - Activity for Fair Value of Contingent Consideration (Details) - Acquisition-related Contingent Consideration - (Level 3) - Recurring basis
6 Months Ended
Jun. 30, 2023
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance at beginning of the period $ 2,460,000
Change in fair value recorded in earnings (40,000)
Balance at end of the period $ 2,420,000
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment, net - PPE (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Less: Accumulated depreciation $ (348,084)   $ (348,084)   $ (306,945)
Property and equipment, net 60,770   60,770   81,620
Depreciation 18,328 $ 18,529 36,366 $ 41,258  
Equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 346,671   $ 346,671   326,382
Estimated useful life (in years) 3 years   3 years    
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 62,183   $ 62,183   $ 62,183
Estimated useful life (in years) 7 years   7 years    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Indefinite-lived Intangible Assets - IPR&D (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Indefinite-lived Intangible Assets [Roll Forward]    
In-process research and development, beginning balance $ 3,190,000  
Change during period 0  
In-process research and development, ending balance 3,190,000  
Impairment of IPR&D $ 0 $ 0
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Accrued Liabilities (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Payroll and related costs $ 724,100 $ 838,683
Stock-based compensation 0 1,906,401
Research and development 2,009,215 1,716,035
Professional fees 237,399 246,664
Other 138,080 92,200
Accrued expenses $ 3,108,794 $ 4,799,983
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting for Share-Based Payments - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 03, 2013
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares authorized (in shares)   500,000 500,000  
Vesting period (in years) 3 years      
Contractual term (in years) 10 years      
Total fair value of awards vested     $ 2,200,000 $ 4,000,000
Unrecognized compensation cost related to non-vested stock   $ 800,000 $ 800,000  
Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized (in years)     9 months 18 days  
Stock-based liability awards converted to equity   $ 2,983,006 $ 2,983,006  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting for Share-Based Payments - Stock-Based Compensation (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 16,928 $ 162,508 $ 1,947,681 $ 1,703,958
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense (22,743) 127,483 1,170,717 1,210,584
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 39,671 $ 35,025 $ 776,964 $ 493,374
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting for Share-Based Payments - Stock Option Activity (Details) - Stock options - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Number of Options    
Balance outstanding at the beginning of the period (in shares) 444,749  
Granted (in shares) 0  
Adjustment for stock split (in shares) 48  
Exercised (in shares) 0  
Forfeited (in shares) (112)  
Cancelled (in shares) (139)  
Balance outstanding at the end of the period (in shares) 444,546 444,749
Awards outstanding, vested awards and those expected to vest at the end of the period (in shares) 443,256  
Vested and exercisable at the end of the period (in shares) 360,609  
Weighted Average Exercise Price Per Share    
Balance outstanding at the beginning of the period (in dollars per share) $ 46.20  
Granted (in dollars per share) 0  
Adjustment for stock split (in dollars per share) 0  
Exercised (in dollars per share) 0  
Forfeited (in dollars per share) 34.00  
Cancelled (in dollars per share) 34.00  
Balance outstanding at the end of the period (in dollars per share) 47.12 $ 46.20
Awards outstanding, vested awards and those expected to vest at the end of the period (in dollars per share) 47.17  
Vested and exercisable at the end of the period (in dollars per share) $ 50.15  
Intrinsic Value    
Balance outstanding at the beginning of the period $ 0  
Adjustment for stock split 0  
Granted 0  
Exercised 0  
Forfeited 0  
Cancelled 0  
Balance outstanding at the end of the period 0 $ 0
Awards outstanding, vested awards and those expected to vest at the end of the period 0  
Vested and exercisable at the end of the period $ 0  
Weighted Average Remaining Contractual Team    
Balance outstanding term (in years) 7 years 7 months 17 days 8 years 1 month 17 days
Awards outstanding, vested awards and those expected to vest at the end of the period (in years) 7 years 7 months 17 days  
Vested and exercisable at the end of the period (in years) 7 years 6 months 21 days  
Exercise price range one    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) $ 13.80  
Exercise price, high end of the range (in dollars per share) 40,320  
Exercise price range two    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 0  
Exercise price, high end of the range (in dollars per share) 0  
Exercise price range three    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 0  
Exercise price, high end of the range (in dollars per share) 0  
Exercise price range four    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 0  
Exercise price, high end of the range (in dollars per share) 0  
Exercise price range five    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 34.00  
Exercise price, high end of the range (in dollars per share) 34.00  
Exercise price range six    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 34.00  
Exercise price, high end of the range (in dollars per share) 34.00  
Exercise price range seven    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 13.80  
Exercise price, high end of the range (in dollars per share) 40,320  
Exercise price range eight    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 13.80  
Exercise price, high end of the range (in dollars per share) 40,320  
Exercise price range nine    
Exercise Price Per Share    
Exercise price, low end of the range (in dollars per share) 13.80  
Exercise price, high end of the range (in dollars per share) $ 40,320  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) - Stock options - $ / shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Stock price (in dollars per share) $ 0 $ 13.80
Risk free interest rate (as a percent) 0.00% 3.26%
Dividend yield (as a percent) 0.00% 0.00%
Expected volatility (as a percent) 0.00% 116.70%
Expected term (in years) 0 years 6 years
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Numerator:            
Net loss $ (14,079,547) $ (13,259,921) $ (19,911,299) $ (6,929,685) $ (27,339,468) $ (26,840,984)
Denominator:            
Weighted average common shares outstanding (in shares) 3,826,505   3,811,481   3,819,035 3,811,463
Weighted average common shares outstanding (in shares) 3,826,505   3,811,481   3,819,035 3,811,463
Net loss per share of common stock—basic (in dollars per share) $ (3.68)   $ (5.22)   $ (7.16) $ (7.04)
Net loss per share of common stock—diluted (in dollars per share) $ (3.68)   $ (5.22)   $ (7.16) $ (7.04)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Loss per Share - Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding (Details) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total anti-dilutive securities (in shares) 661,093 661,297
Common shares issuable upon conversion of Series A preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total anti-dilutive securities (in shares) 159 159
Common shares issuable upon conversion of Series C preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total anti-dilutive securities (in shares) 829 830
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total anti-dilutive securities (in shares) 444,546 444,749
Warrants – equity classified    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total anti-dilutive securities (in shares) 215,559 215,559
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Oct. 31, 2019
Dec. 31, 2018
Lessee, Lease, Description [Line Items]            
Rent expense $ 0.1 $ 0.1 $ 0.2 $ 0.2    
Corporate Office Space            
Lessee, Lease, Description [Line Items]            
Renewal term (in years)           5 years
Office and Research Laboratory            
Lessee, Lease, Description [Line Items]            
Term (in years)         3 years  
XML 60 hepa-20230630_htm.xml IDEA: XBRL DOCUMENT 0001583771 2023-01-01 2023-06-30 0001583771 2023-08-07 0001583771 2023-06-30 0001583771 2022-12-31 0001583771 us-gaap:SeriesAPreferredStockMember 2023-06-30 0001583771 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001583771 us-gaap:SeriesCPreferredStockMember 2023-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001583771 2023-04-01 2023-06-30 0001583771 2022-04-01 2022-06-30 0001583771 2022-01-01 2022-06-30 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001583771 us-gaap:CommonStockMember 2022-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001583771 us-gaap:RetainedEarningsMember 2022-12-31 0001583771 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001583771 2023-01-01 2023-03-31 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001583771 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001583771 us-gaap:CommonStockMember 2023-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001583771 us-gaap:RetainedEarningsMember 2023-03-31 0001583771 2023-03-31 0001583771 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001583771 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001583771 us-gaap:CommonStockMember 2023-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001583771 us-gaap:RetainedEarningsMember 2023-06-30 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001583771 us-gaap:CommonStockMember 2021-12-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001583771 us-gaap:RetainedEarningsMember 2021-12-31 0001583771 2021-12-31 0001583771 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001583771 2022-01-01 2022-03-31 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001583771 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001583771 us-gaap:CommonStockMember 2022-03-31 0001583771 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001583771 us-gaap:RetainedEarningsMember 2022-03-31 0001583771 2022-03-31 0001583771 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001583771 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0001583771 us-gaap:CommonStockMember 2022-06-30 0001583771 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001583771 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001583771 us-gaap:RetainedEarningsMember 2022-06-30 0001583771 2022-06-30 0001583771 2023-05-03 2023-05-03 0001583771 2022-01-01 2022-12-31 0001583771 us-gaap:SeriesAPreferredStockMember 2014-10-14 0001583771 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001583771 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2018-07-03 0001583771 us-gaap:SeriesCPreferredStockMember 2018-07-03 2018-07-03 0001583771 us-gaap:SeriesCPreferredStockMember 2018-07-03 0001583771 us-gaap:WarrantMember 2018-07-03 2018-07-03 0001583771 us-gaap:SeriesCPreferredStockMember 2022-06-30 0001583771 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001583771 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001583771 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001583771 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001583771 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001583771 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001583771 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001583771 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001583771 us-gaap:MeasurementInputDiscountRateMember 2023-06-30 0001583771 us-gaap:MeasurementInputDiscountRateMember 2022-12-31 0001583771 srt:MinimumMember 2023-01-01 2023-06-30 0001583771 srt:MaximumMember 2023-01-01 2023-06-30 0001583771 srt:MinimumMember 2022-01-01 2022-12-31 0001583771 srt:MaximumMember 2022-01-01 2022-12-31 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-06-30 0001583771 us-gaap:FairValueInputsLevel3Member hepa:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001583771 us-gaap:EquipmentMember 2023-06-30 0001583771 us-gaap:EquipmentMember 2022-12-31 0001583771 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001583771 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001583771 2013-06-03 2013-06-03 0001583771 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001583771 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001583771 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001583771 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001583771 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001583771 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001583771 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001583771 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2022-12-31 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeOneMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001583771 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeTwoMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeThreeMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeFourMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeFiveMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeSixMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeSevenMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeEightMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember hepa:ExercisePriceRangeNineMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2022-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001583771 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-06-30 0001583771 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2023-01-01 2023-06-30 0001583771 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001583771 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001583771 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001583771 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001583771 hepa:OfficeSpaceMember 2018-12-31 0001583771 hepa:OfficeAndResearchLaboratoryMember 2019-10-31 shares iso4217:USD iso4217:USD shares pure hepa:segment 0001583771 --12-31 2023 Q2 false 0.05 10-Q true 2023-06-30 false 001-36856 HEPION PHARMACEUTICALS, INC. DE 46-2783806 399 Thornall Street First Floor Edison NJ 08837 732 902-4000 Common Stock, par value $0.0001 per share HEPA NASDAQ Yes Yes Non-accelerated Filer true false false 3838289 30521733 51189088 2240723 5306985 32762456 56496073 60770 81620 0 50585 3190000 3190000 488884 426174 36502110 60244452 4191225 2665896 3108794 4799983 0 53614 373710 366229 7673729 7885722 2046290 2093771 409022 409022 10129041 10388515 10 10 85581 85581 85581 85581 855808 855808 1000 1000 1800 1800 1801 1801 839320 840320 0.0001 0.0001 120000000 120000000 3838289 3838289 3811481 3811481 384 381 227806020 223950940 -87651 -90168 -203040812 -175701344 26373069 49855937 36502110 60244452 0 0 0 0 11880669 15701955 21678328 20013089 2284961 2425242 5696467 5366576 0 1870924 0 1870924 14165630 19998121 27374795 27250589 -14165630 -19998121 -27374795 -27250589 2351 3178 4673 5387 -88434 -90000 -40000 -414992 -14079547 -19911299 -27339468 -26840984 0 0 0 0 -14079547 -19911299 -27339468 -26840984 3826505 3826505 3811481 3811481 3819035 3819035 3811463 3811463 -3.68 -3.68 -5.22 -5.22 -7.16 -7.16 -7.04 -7.04 -14079547 -19911299 -27339468 -26840984 -16836 -39113 2517 -29967 -16836 -39113 2517 -29967 -14096383 -19950412 -27336951 -26870951 85581 855808 1801 840320 3811481 381 223950940 -90168 -175701344 49855937 -13259921 -13259921 19353 19353 537123 537123 -1 -1000 1 1000 0 85581 855808 1800 839320 3811482 381 224489063 -70815 -188961265 37152492 -14079547 -14079547 -16836 -16836 333954 333954 2983006 2983006 26807 -3 3 0 85581 855808 1800 839320 3838289 384 227806020 -87651 -203040812 26373069 85581 855808 1806 845320 3811263 381 224794789 0 -133501295 92995003 -6929685 -6929685 9146 9146 556610 556610 -5 -5000 2 5000 0 216 5008 5008 85581 855808 1801 840320 3811481 381 225361407 9146 -140430980 86636082 -19911299 -19911299 -39113 -39113 634651 634651 85581 855808 1801 840320 3811481 381 225996058 -29967 -160342279 67320321 -27339468 -26840984 871077 1703958 36366 41257 -40000 -414992 0 1870924 2815672 7736105 -50585 -134907 -53614 -140136 -3008520 1720352 -20650862 -17629313 16538 0 0 2266 -16538 2266 0 2000000 0 -2000000 45 -14415 -20667355 -19641462 51189088 91348967 30521733 71707505 0 941 1000 5000 0 5008 2983006 0 Business Overview<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hepion Pharmaceuticals, Inc. (we, our, or us) is a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and shows potential for the treatment of hepatocellular carcinoma (“HCC”) associated with non-alcoholic steatohepatitis (“NASH”), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing rencofilstat as our lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. Many closely related isoforms of cyclophilins exist in humans. Cyclophilins A, B, and D are the best characterized cyclophilin isoforms. Inhibition of cyclophilins has been shown in scientific literature to have therapeutic effects in a variety of experimental models, including liver disease models. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a number of Phase 1 and Phase 2 clinical trials. In May 2023, we announced that our Phase 2a study ("ALTITUDE-NASH") met its primary endpoint by demonstrating improved liver function and was well tolerated after four months of treatment with once daily oral rencofilstat administered to NASH subjects with stage 3 or greater fibrosis. All additional secondary efficacy and safety endpoints were also met. These observations provide further evidence that builds on previous findings from a shorter 28-day Phase 2a ("AMBITION") trial. Taken together, the AMBITION and ALTITUDE-NASH trials reinforce rencofilstat’s direct antifibrotic mode of action and increase our confidence level that we anticipate observing fibrosis reductions in our ongoing 12-month Phase 2b ("ASCEND-NASH") clinical trial.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we announced that the Data and Safety Monitoring Board ("DSMB") met to review the current data for the ASCEND-NASH 2b study and has issued a “study may proceed without modification” clearance. This, the first planned DSMB meeting, occurred on schedule, and all labs, electrocardiogram's, adverse events, and protocol deviations were reviewed, focusing on any potential safety signals from the placebo-controlled trial.</span></div> Basis of Presentation<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2022, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, contained in our Annual Report on Form 10-K filed with the SEC on April 10, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2023, our Board of Directors declared a 1-for-20 reverse stock split of the outstanding shares of our common stock in order to satisfy requirements for the continued listing of our common stock on Nasdaq. The reverse stock split was effective May 11, 2023. All applicable share and per share information in these condensed consolidated financial statements on Form 10-Q have been adjusted retrospectively to give effect to the reverse stock split for all periods presented. The reverse stock split did not reduce the number of authorized shares of common stock and will not alter the par value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, we had $30.5 million in cash, an accumulated deficit of $203.0 million, and working capital of $25.1 million. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, cash used in operating activities was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.7 million</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we had a net loss of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$27.3 million</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have not generated revenue to date and have incurred substantial losses and negative cash flows from operations since our inception. We have historically funded our operations through issuances of convertible debt, common stock and preferred stock. We expect to continue to incur losses for the next several years as we expand our research, </span></div><div style="margin-bottom:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and clinical trials of rencofilstat. We are unable to predict the extent of any future losses or when we will become profitable, if at all. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed consolidated financial statements have been prepared under the assumption that we will continue as a going concern. Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to attain further operating efficiencies and, ultimately, to generate revenue. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to raise additional capital within the next year to continue the development and commercialization of our current product candidate and to continue to fund operations at the current cash expenditure levels. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct business. If we are unable to raise additional capital when required or on acceptable terms, we may have to (i) significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on unfavorable terms.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The consolidated balance sheet as of December 31, 2022, was derived from the audited annual consolidated financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022, contained in our Annual Report on Form 10-K filed with the SEC on April 10, 2023.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include our accounts and the accounts of our subsidiaries, Contravir Research Inc. and Hepion Research Corp, which conduct their operations in Canada. All intercompany balances and transactions have been eliminated in consolidation.</span></div> 30500000 -203000000 25100000 -20700000 -27300000 Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2022, included in our Annual Report on Form 10-K. Since the date of such consolidated financial statements, there have been no changes to our significant accounting policies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, cash was $30.5 million and $51.2 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. At certain times, our cash balances with any one financial institution may exceed Federal Deposit Insurance Corporation insurance limits. We believe it mitigates our risk by depositing our cash balances with high credit, quality financial institutions. We have never experienced losses related to these balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification (“ASC”) Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments consist of cash, accounts payable, and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature, except for contingent consideration, which is recorded at fair value at the end of each reporting period. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. See Note 5 for additional information on the fair value of the contingent consideration.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, equipment and depreciation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, we had $0.1 million and $0.1 million, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, and furniture and fixtures. There were no adjustments to the carrying value of property and equipment at June 30, 2023 or December 31, 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research &amp; Development</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual, or interim (if events or changes in circumstances indicate that it is more likely than not that the asset is impaired), In-Process Research and Development ("IPR&amp;D") impairment test is performed by comparing the fair value of the asset to the asset’s carrying amount. When testing indefinite-lived intangibles for impairment, we may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not that the asset is impaired. Alternatively, we may bypass this qualitative assessment for our indefinite-lived intangible asset and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. If IPR&amp;D becomes impaired or is abandoned, the carrying value of the IPR&amp;D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed a qualitative assessment of IPR&amp;D at June 30, 2023 and a quantitative assessment for fiscal year 2022 and determined that the asset was not impaired.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to maintain a full valuation allowance for our U.S and foreign net deferred tax assets. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the net operating loss (NOL) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The utilization of these NOLs is subject to limitations based on past and future changes in our ownership pursuant to Section 382. We completed a Section 382 study of transactions in our stock through December 31, 2021 and concluded that we have experienced ownership changes since inception that we believe under Section 382 and 383 of the </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal Revenue Code will result in limitations on our ability to use certain pre-ownership change NOLs and credits. We are not aware of any ownership changes in 2023 or 2022. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our consolidated financial statements could be further limited. Similar provisions of state tax law may also apply to limit the use of accumulated state tax attributes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. At June 30, 2023 and December 31, 2022, we had prepaid research and development costs of $1.9 million and $4.7 million, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Assets and liabilities of Hepion Research Corp. are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was $87,651 and $90,168 at June 30, 2023 and December 31, 2022, respectively. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in general and administrative expense within the consolidated statements of operations. The impact of foreign exchange losses (gains) was $30,661 and $2,678 for the three months ended June 30, 2023 and 2022, respectively, and was $56,095 and $(32,518) for the six months ended June 30, 2023 and 2022, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net loss per share</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share is presented in conformity with ASC Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the six months ended June 30, 2023.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, cash was $30.5 million and $51.2 million, respectively, consisting of checking accounts held at U.S. and Canadian commercial banks. At certain times, our cash balances with any one financial institution may exceed Federal Deposit Insurance Corporation insurance limits. We believe it mitigates our risk by depositing our cash balances with high credit, quality financial institutions. We have never experienced losses related to these balances.</span></div> 30500000 51200000 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification (“ASC”) Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes among the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that we can access.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by us in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div>Financial instruments consist of cash, accounts payable, and contingent consideration. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature, except for contingent consideration, which is recorded at fair value at the end of each reporting period. We recorded contingent consideration from the 2016 acquisition of Ciclofilin, which is required to be carried at fair value. <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, equipment and depreciation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, we had $0.1 million and $0.1 million, respectively, of property and equipment, consisting primarily of lab equipment, computer equipment, and furniture and fixtures. There were no adjustments to the carrying value of property and equipment at June 30, 2023 or December 31, 2022.</span></div> 100000 100000 0 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Process Research &amp; Development</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual, or interim (if events or changes in circumstances indicate that it is more likely than not that the asset is impaired), In-Process Research and Development ("IPR&amp;D") impairment test is performed by comparing the fair value of the asset to the asset’s carrying amount. When testing indefinite-lived intangibles for impairment, we may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not that the asset is impaired. Alternatively, we may bypass this qualitative assessment for our indefinite-lived intangible asset and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. If IPR&amp;D becomes impaired or is abandoned, the carrying value of the IPR&amp;D is written down to the revised fair value with the related impairment charge recognized in the period in which the impairment occurs. If the carrying value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed a qualitative assessment of IPR&amp;D at June 30, 2023 and a quantitative assessment for fiscal year 2022 and determined that the asset was not impaired.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We reduce the measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not that we will not realize some or all of the deferred tax asset. We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is “more-likely-than-not” that the position will be sustained upon examination. Potential interest and penalties associated with unrecognized tax positions are recognized in income tax expense.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to maintain a full valuation allowance for our U.S and foreign net deferred tax assets. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of the Internal Revenue Code, the net operating loss (NOL) and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, respectively, as well as similar state tax provisions. This could limit the amount of tax attributes that we can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The utilization of these NOLs is subject to limitations based on past and future changes in our ownership pursuant to Section 382. We completed a Section 382 study of transactions in our stock through December 31, 2021 and concluded that we have experienced ownership changes since inception that we believe under Section 382 and 383 of the </span></div>Internal Revenue Code will result in limitations on our ability to use certain pre-ownership change NOLs and credits. We are not aware of any ownership changes in 2023 or 2022. In addition, we may experience subsequent ownership changes as a result of future equity offerings or other changes in the ownership of our stock, some of which are beyond our control. As a result, the amount of the NOLs and tax credit carryforwards presented in our consolidated financial statements could be further limited. Similar provisions of state tax law may also apply to limit the use of accumulated state tax attributes. <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to loss contingencies, such as legal proceedings and claims arising out of our business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 450”), we record accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. In accordance with this guidance, we do not recognize gain contingencies until realized.</span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Development</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, which include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, application and filing for regulatory approval of proposed products, purchased in-process research and development, license costs, regulatory and scientific consulting fees, as well as contract research, insurance and FDA consultants, are accounted for in accordance with ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 730”). Also, as prescribed by this guidance, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any commercial biopharmaceutical products and do not expect to have such for several years, if at all. Accordingly, our research and development costs are expensed as incurred. While certain of our research and development costs may have future benefits, our policy of expensing all research and development expenditures is predicated on the fact that we have no history of successful commercialization of product candidates to base any estimate of the number of future periods that would be benefited.</span></div>Also as prescribed by ASC 730, non-refundable advance payments for goods or services that will be used or rendered for future research and development activities should be deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts would be recognized as an expense. 1900000 4700000 Foreign ExchangeThe functional currency of Hepion Pharmaceuticals, Inc. and ContraVir Research Inc. is the U.S. dollar. The functional currency of Hepion Research Corp. is the Canadian dollar. Assets and liabilities of Hepion Research Corp. are translated into U.S. dollars using period-end exchange rates; income and expenses are translated using the average exchange rates for the reporting period. Unrealized foreign currency translation adjustments are deferred in accumulated other comprehensive loss, a separate component of shareholders’ equity. The amount of currency translation adjustment was $87,651 and $90,168 at June 30, 2023 and December 31, 2022, respectively. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiaries at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in general and administrative expense within the consolidated statements of operations. The impact of foreign exchange losses (gains) was $30,661 and $2,678 for the three months ended June 30, 2023 and 2022, respectively, and was $56,095 and $(32,518) for the six months ended June 30, 2023 and 2022, respectively. -87651 -90168 30661 2678 56095 -32518 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision maker views our operations and manages the business in one segment.</span></div> 1 <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net loss per share</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share is presented in conformity with ASC Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 260”) for all periods presented. In accordance with this guidance, basic and diluted net loss per common share was determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period.</span><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div> <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recent accounting pronouncements that will have a material effect on our condensed consolidated financial statements for the six months ended June 30, 2023.</span></div> Stockholders’ Equity<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 14, 2014, our Board of Directors authorized the sale and issuance of up to 1,250,000 shares of Series A Convertible Preferred Stock (the “Series A”). All shares of the Series A were issued between October 2014 and February 2015. Each share of the Series A is convertible at the option of the holder into the number of shares of common stock determined by dividing the stated value of such share by the conversion price that is subject to adjustment. As of June 30, 2023, there were 85,581 shares outstanding. During the six months ended June 30, 2023 and 2022, no shares of the Series A were converted. If we sell common stock or equivalents at an effective price per share that is lower than the conversion price, the conversion price may be reduced to the lower conversion price. The Series A will be automatically convertible into common stock in the event of a fundamental transaction as defined in the offering.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Convertible Preferred Stock Issuance</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2018, we completed a rights offering pursuant to our effective registration statement on Form S-1. We offered for sale units in the rights offering and each unit sold in connection with the rights offering consisted of 1 share of our Series C Convertible Preferred Stock, or Series C, and common stock warrants (the “Rights Offering”). Upon completion of the offering, pursuant to the rights offering, we sold an aggregate of 10,826 units at an offering price of $1,000 per unit comprised of 10,826 shares of Series C and 4,446 common stock warrants that expired in July 2023. As of June 30, 2023, there were 1,800 shares of Series C outstanding. During the six months ended June 30, 2023, 1 share of the Series C was converted into 1 share of our common stock and during the six months ended June 30, 2022, 5 shares of the Series C were converted into 2 shares of our common stock. Each share of Series C is convertible into common stock at any time at the option of the holder thereof at the conversion price then in effect. The conversion price for the Series C is determined by dividing the stated value of $1,000 per share by $0.08 per share (subject to adjustments upon the occurrence of certain dilutive events).</span></div> 1250000 85581 0 0 1 10826 1000 10826 4446 1800 1 1 5 2 1000 0.08 Fair Value Measurements<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration was recorded for the acquisition of Ciclofilin Pharmaceuticals, Inc. (Ciclofilin) on June 10, 2016. The contingent consideration represented the acquisition date fair value of potential future payments, to be paid in cash and our stock, upon the achievement of certain milestones and was estimated based on a probability-weighted discounted cash flow model. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and December 31, 2022, the assumptions we used to calculate the fair value were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock price</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected milestone achievement dates</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mar 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dec 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dec 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of success of milestone achievements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, $2,046,290 was classified as a non-current liability based upon management's best estimate using </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the latest available information. Management reviewed the assumptions and for the six months ended June 30, 2023, the only change made was to the milestone achievement dates.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2023.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition-related Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy at June 30, 2023 and December 31, 2022.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of June 30, 2023:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2022:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2420000 0 0 2420000 2460000 0 0 2460000 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and December 31, 2022, the assumptions we used to calculate the fair value were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assumptions</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock price</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected milestone achievement dates</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mar 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dec 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dec 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of success of milestone achievements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40%</span></td></tr></table></div> 0.085 0.085 0.13 0.40 0.13 0.40 2046290 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the change in fair value of the contingent consideration for the six months ended June 30, 2023.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition-related Contingent Consideration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2460000 -40000 2420000 Property and Equipment, net<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method, based on useful lives as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,945)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,770 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,620 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation expense for the three months ended June 30, 2023 and 2022 was $18,328 and $18,529, respectively, and was $36,366 and $41,258 for the six months ended June 30, 2023 and 2022, respectively. <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method, based on useful lives as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348,084)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306,945)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,770 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,620 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P3Y 346671 326382 P7Y 62183 62183 348084 306945 60770 81620 18328 18529 36366 41258 Indefinite-lived Intangible Assets<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPR&amp;D</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IPR&amp;D asset consisted of the following at:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-lived<br/>Intangible Asset</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rencofilstat balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the six months ended June 30, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rencofilstat balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No impairment losses were recorded on IPR&amp;D during the six months ended June 30, 2023 and 2022.</span></div> <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IPR&amp;D asset consisted of the following at:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-lived<br/>Intangible Asset</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rencofilstat balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the six months ended June 30, 2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rencofilstat balance at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3190000 0 3190000 0 0 Accrued Liabilities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,108,794 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799,983 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div> <div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,009,215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716,035 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,664 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,108,794 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,799,983 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div> 724100 838683 0 1906401 2009215 1716035 237399 246664 138080 92200 3108794 4799983 Accounting for Share-Based Payments<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, our board of directors approved the 2023 Omnibus Equity Incentive Plan (the 2023 Plan), which became effective in June 2023 upon stockholder approval. The 2023 Plan allows for the grant of up to 500,000 awards for the purpose of attracting, motivating and retaining employees (including officers), non-employee directors and non-employee consultants. At June 30, 2023, there were no awards granted from the 2023 Plan. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2013, we adopted the 2013 Equity Incentive Plan (the 2013 Plan), which expired in June 2023 and we are no longer making grants under it. Stock options granted under the 2013 Plan typically vest after three years of continuous service from the grant date and will have a contractual term of ten years. We granted options during the three months ended June 30, 2022 and 2021, and at the time that these grants were made, we did not have any options available for grant under the Plan. We accounted for these option grants as liability-classified awards requiring us to measure the fair value of the awards each reporting period since there were not enough shares available at the time of the grant. With the approval of the 2023 Plan, these awards are no longer accounted for as liability-classified and the cumulative liability of $2,983,006 was recorded to additional paid-in capital. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify stock-based compensation expense in our condensed consolidated statement of operations in the same way the award recipient's payroll costs are classified or in which the award recipients' service payments are classified. We recorded stock-based compensation expense as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,717 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,508 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947,681 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703,958 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Remaining Contractual Team</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.13 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for stock split</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding, vested awards and those expected to vest at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,256 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56 years</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of awards vested during the six months ended June 30, 2023 and 2022 was $2.2 million and $4.0 million, respectively.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the unrecognized compensation cost related to non-vested stock options outstanding, net of expected forfeitures, was $0.8 million to be recognized over a weighted-average remaining vesting period of approximately 0.8 years.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate the fair value of stock option awards when granted to employees.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Based on the daily yield curve rates for U.S. Treasury obligations with maturities which correspond to the expected term of our stock options.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—We have not paid any dividends on our common stock since inception and do not anticipate paying dividends on our common stock in the foreseeable future.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—We base expected volatility on the trading price of our common stock.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method provided in SAB No. 107, which SAB No. 107, options are considered to be “plain vanilla” if they have the following basic characteristics: (i) granted “at-the-money”; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SAB No. 110, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“SAB No. 110”) expresses the views of the Staff of the SEC with respect to extending the use of the simplified method, as discussed in SAB No. 107, in developing an estimate of the expected term of “plain vanilla” share options in accordance with ASC 718. For the expected term, we have “plain-vanilla” stock options, and therefore used a simple average of the vesting period and the contractual term for options granted as permitted by SAB No. 107.</span></div> 500000 P3Y P10Y 2983006 We recorded stock-based compensation expense as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170,717 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,210,584 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,508 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947,681 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,703,958 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -22743 127483 1170717 1210584 39671 35025 776964 493374 16928 162508 1947681 1703958 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2013 Plan and 2023 Plan is presented as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Remaining Contractual Team</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,749 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.13 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for stock split</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding, vested awards and those expected to vest at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,256 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,320.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56 years</span></td></tr></table></div> 444749 13.80 40320 46.20 0 P8Y1M17D 0 0 0 0 0 48 0 0 0 0 0 0 0 0 0 112 34.00 34.00 34.00 0 139 34.00 34.00 34.00 0 444546 13.80 40320 47.12 0 P7Y7M17D 443256 13.80 40320 47.17 0 P7Y7M17D 360609 13.80 40320 50.15 0 P7Y6M21D 2200000 4000000 800000 P0Y9M18D <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions are used in the Black-Scholes valuation model to estimate the fair value of stock option awards when granted to employees.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div> 0 13.80 0 0.0326 0 0 0 1.167 P0Y P6Y Loss per Share<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share was determined by dividing net loss by the weighted-average common shares outstanding during the period. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and diluted net loss per common share:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,079,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,911,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,339,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,840,984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock—basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding securities at June 30, 2023 and 2022 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of Series A preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of Series C preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants – equity classified</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,093 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,297 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity classified warrants disclosed above have been excluded from the computation of basic and diluted earnings per share because the exercise price of the warrants exceeds the average market price of our common stock for the period they were outstanding.</span></div> <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basic and diluted net loss per common share:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,079,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,911,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,339,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,840,984)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,826,505 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811,463 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock—basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.16)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.04)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -14079547 -19911299 -27339468 -26840984 3826505 3826505 3811481 3811481 3819035 3819035 3811463 3811463 -3.68 -3.68 -5.22 -5.22 -7.16 -7.16 -7.04 -7.04 <div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding securities at June 30, 2023 and 2022 have been excluded from the computation of basic and diluted weighted shares outstanding, as they would have been anti-dilutive:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of Series A preferred stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable upon conversion of Series C preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,546 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants – equity classified</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,093 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,297 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 159 159 829 830 444546 444749 215559 215559 661093 661297 Commitments and Contingencies<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, we entered into a lease for corporate office space in Edison, New Jersey. In December 2017, we entered an amendment to the lease for corporate office space in Edison, New Jersey expanding the office footprint and extending the lease for an approximate 5-year period. The lease expired on March 31, 2023 and we are currently leasing this space on a month-to-month basis. We are currently negotiating with the landlord for a new lease agreement. In October 2019, we entered into a 3-year lease for office and research laboratory space in Edmonton, Canada, which expired on September 30, 2022 and we are leasing this space on a month-to-month basis. We are currently negotiating with the landlord for a new lease agreement. </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal proceedings. Significant judgment is required to determine both the likelihood and the estimated amount of a loss related to such matters. Additionally, while any litigation contains an element of uncertainty, we have at this time no reason to believe that the outcome of such proceedings or claims will have a material adverse effect on our consolidated financial condition or results of operations.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for leases in accordance with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (“ASC 842”). We determine if an arrangement is a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property or equipment for a period in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property and equipment), and (2) the customer has the right to control the use of the identified asset.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases where we are the lessee are included under the caption “Right of Use Assets” ("ROU") on our consolidated balance sheets. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. Key estimates and judgments include how we determine (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the three months ended June 30, 2023 and 2022 was $0.1 million and $0.1 million, respectively, and was $0.2 million and $0.2 million for the six months ended June 30, 2023 and 2022, respectively.</span></div> P5Y P3Y 100000 100000 200000 200000 Subsequent EventsNone EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( (R!#E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " ",@0Y7C_ZQ"NX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VE%)'1S43PI""XHWD(RNQML_I",M/OVMG6WB^@#>,S,+]]\ M ].9)$W,^)QCPDP.R]7H^U"D21MV($H2H)@#>EWJ*1&FYBYFKVEZYCTD;3[T M'J'A_ 8\DK::-,S *JU$ICIKI,FH*>83WIH5GSYSO\"L >S18Z "HA; U#PQ M'<>^@PM@AA%F7[X+:%?B4OT3NW2 G9)C<6MJ&(9Z:)?/ MC<^"JH-?=Z&^ %!+ P04 " ",@0Y7F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M (R!#E<-.&%1\04 ,8? 8 >&PO=V]R:W-H965T&UL MM9EK<^(V%(;_BH9V.NU,"+9,@&P),\0A#=M=E@UL.]M./PA;@&=MB\HR)/^^ M1S;8248<7,_R)?'MO.C1]=51?R?DMV3-N2)/41@G-XVU4IMWK5;BK7G$DDNQ MX3&\60H9,06W7!.-LA#BF[X9^S<-2Y>(A]Q36H+!ORUW>1AJ)2C'OWO1 M1O&;.O#E]4']/H,'F 5+N"O"/P-?K6\:O0;Q^9*EH7H4NP>^![K2>IX(D^PO MV>7?MML-XJ6)$M$^&$H0!7'^GSWM*^)E #T20/P7G'U 5G.MO&09 MUAU3;-"78D>D_AK4]$56-UDTT 2Q;L:9DO V@#@U<,662S*%%B--DJR9Y$F_ MI4!8OVYY>Y';7(0>$>F0CR)6ZX2,8I_[K^-;4*"B5/10JEN*"KY/XTOB6!>$ M6M0QE,?%PX?IZI)875/XJ^(X124YF9Z#5M+?PT6B)/2[?TPUE"NTS0IZ,+Y+ M-LSC-PT8;0F76]X8_/2#W;%^->%])[%7L.T"MHVI#^Z$E\(X563^O.$F4CS< MMIJ?34AH5$VDJP+IJAK2YY1)Q67X3![Y1DAEPL.EE$Q-E>*B437Q.@5>IQK> ME,M ^'H4$I@,C(V'*Q7C[NC 0^-KP5@#RW4*%:!>B;W01M/QIPF9/@P?/P[=T9?YV!U^F%WDY1Q/W$L3."I9 M$]RVRC76JH(^CCTAH;LRW7,OR$S!&"5"$E>DL9+/\-\WUL<)];N1B1@/JHO\ MPE;859#G[(F,?1BSP3+P,FZD8Y^0;'>:M-MS>I:Q:^/!=7EIR4NK\ Y]']23 MB\,%^0#?D4^QN5UQ2>?ZFLS70L8L#*&S2+!X1G!4I2YX:8ULU(S@X/.=,(+C MDO>!3!2Y#X4P=1,7CZX+7-HC&SC>"YVL1'VA)P?),(4Z.*!=3E+ MSV3C3N*>%]NR ;)LF6A2DG/UJ7@&Z3#6QSLR2 L1;.8:)H::(H;G/ ]/M! MO"*SYV@A0A/\"0$PCD-C+N$<3HF63HGBMN;0G&3TY*U9O.)'??$)HBE;R1FTJI=V_YEBUK2EA24F.^Z83B5V.6RL6CZG*65HA6LD+C M6'&9IR?U-IP=P(VEM*FQ>P!6LA#3.1B=T)B)N,L_C M( ,B?BYHY#V'$Z*E$Z*5G- LTD;\-DW@=6+NM?5R1WA87;S2_]!*_F<4<;G2 MH_(W4%!KL C1AL7F=L4%C^96\+BZH*7]H;A[.;3CFD,[8G@U4T=X7%V\T@;1 M2MFCUVO\+$OIDT^I E,;ZP742/R=#,Z^'G*UJTQ-GR-M!P[LVVGONM_:FA!+ M)T0KY9!) MMK9?.3@U+*M[0J[9M&G3,8+BD75!2_/CX)ZE2.F^)+V'A\;Y]838L9PU'E:7 ML;0_#FY6WC+NL_3'*7&YS\8M&!Y4E_'% 1EN5(8 Z.>0(3-.,2<$CDZJ>-S_ M!6N]."G5ZUUV@)P03V=@\T/3XFEQ2#W,CF9;Y>?Y"?='II?+A(1\":'691?F M.YD?&N%4$I$V>6:,Y]+_0&\7PJA#C?Z!XJC^\%_4$L#!!0 ( M (R!#E>PSA\/: 8 -<; 8 >&PO=V]R:W-H965T&UL MK5E_;]LV$/TJA%MT&V#')/4[30RT+H9UP-:@6;>_&8F.A4JB*]).LD^_HZQ8 MDDG1"68#B27K[OB.//(]4EK)7:7,[G,EWSDLD+L>$5 M/%F)NF0*;NO[N=S4G&6-4UG,*<;AO&1Y-5E<-;_=U(LKL55%7O&;&LEM6;+Z MZ2,OQ,/UA$R>?_B:WZ^5_F&^N-JP>W[+U;?-30UW\T.4+"]Y)7-1H9JOKB*@K9 M_$H'0KE2A;9T!0YM7^FSVV'=%S(/Z( VT=Z$L=O-:AZ;GY'EF3UB>F MV.*J%@^HUM8035\T?=-X0S9YI8?Q5M7P- <_M5B**H-!X1F"*RF*/&,*;CZR M@E4I1[\V[,X4;)"K=\C5X6-EY[FNX6' M THB#\9GUP=O&@:$Q F.XX/A )A_ .8[@=W4?,/R#/''C:X]:0.YCQ#TVJ;4 MQQ$]QFC:!1X.DSBP0PP.$ ,GQ+^$8@5,P'ZUV& &1O,>C4+J!^$13M,P"/TD MQ)%G!QH>@(8G^A*6]%H](59!A_[8YAM89-4455S9\(8&#( 0X2.PIE5,0HKM M2*,#TLB)M*&(F5C-MI([>C0RVCY&9UH$.!@;\/B +G:B^US--K5(N91(ST16 MI^NF2S.^ ZYK.M6&-C;'GR08/D>83]L-4"<'U(D3]1>UYK6C,Q.C63^&CW^$ MSF)&0Q+Y=G $=^2"7S"+QN&U[H-N"0-,"3GN/XMEB*GO^P$= =EC0/(B2BAR M=I<7NW:."@Z;LE]+TF42LT$WV,@K?1G A&9N:';\1-\'=KD6M9HK7 M)=K E9;48H524>DT]'2 2YEG35ZBLH*W<%_D1>;4M=B%(:7)2 H=\Q$W]0TY MNM?G5K0FIT4AP.W!:.%:#.,XB.C80M/Q'W$3X/(UG6N2',5^2!.C=VV&B1=% M9 1N1XC$S8B?^(I#UV9(L<=#[SY9P9KLYN,$]WJLQ7K2;@BU8T'BIL%])9RJ M )/E"";0HSXYQFFS]* (R(C(H!TC4CWU$VWMTJDW]>B@.J7/S6*53W9]V%GY=MS M11MFW=MVNOE6CSLLL5(G_^Y-3 E]_Q9?@/XCP, UVK%BRQ&P"))K5O/WB% \ MA:?Z;_\3E,M6P9J=_\NS*?*FL1=/:9PT101WA$S]F#R;YE)JUM3/Q%9)!1>: MG)A"L!WG^[2>]^2-%6RS>7G'Z_91N]^>:BF\X6) M=M* GI &69;KU1,FOMY,SO(*I6R3PT)@!6IR/Z51C$%$'J^H5E,O"7#BCZAU MV@D%ZA8*H&>VY;9HSEA$H]U344+!K?7!V Z$@Y#6M8N:*F 61V%PO'+9[!), MPI$-.^WD G7+A3[PC*_R-+<*&FIR_8QB#_LX)L=L8+,E41!AXODC\H9VVH"^ M1!M(RUICA6UR/@U!S.#P6!U8+/TD#@)@W!'(G3R@;GE@D%@S,U^<@JD#1K92 M%DOW5HIVDH&Z)<,MKS7N#U: 3M=7+^=GBC9,M!,<-#D3B3F%RZNS/E.TX7%B M)UZ\4^*EVG'8*\!^$4$#K3QL*M1ZSFCNV6&FQ#@^*LC3=D.\G=3PG*3^7(Y+ M*[BSJHMS11LFVJD+SWVJ_>)R],YZN'VN:,.L>\?;)\ZW7UF.YG%V["6>P?\V M.Q][QO'GO/?61;_R^H/5]WDE4<%7X(@O(BCH>O\6:7^CQ*9Y$7,GE!)E<[GF M#,9,&\#SE0#EW][H=SN'=WF+_P!02P,$% @ C($.5Q9%1= L P [@P M !@ !X;"]W;W)KZQP,!9\BX2)UFRFD:U-AM9N"#/;.%="WR4:IX(I9Y'>%(B0 M;DE.2825[MQABED(:&Z();J:80%,Q:!(B.E[] &]13:2L1Z58UMI'8;-#HLY M[_(YO0-S?EVS#NHZU\ASO&X#?'HV^7 *O7 (OX^L=7((D MT0^47NKP\1JE6* -IFM 5X2AB%.*A40IB-SN^R:[.?\PXS=YLPF M5&VUAM7D=TOYW3/DYWN"\%K%7) _>BN-C7RT47M.WJ^(^ 2+EN5]_;T]3UN[[GCW:T-\6Y;L\_L/;]4GG_?.7Z92D59A%AJS;Y M_1/E-\4=D3\HY0^.RI^#(%KP;9.THTA37&YDBD.86+IZ2! ;L()W;]R!\[$I MH2]$5C,Y+$T.6_:(;4 HLJ" -/T2A-#/U2NR/9]N4,V#W50Y&E)SX9^OLV&J,. M/7TO-=]M*_H7S22WH;8W>&F,VO5B5PZCYDO@&Q8KPB2BL-0PIS/4>)$?KO.. MXFEV/EUPI4^[63/6'R0@3("^O^14[B5-U/MEKO9M.I6FU%PM6MW(D4OEG+ M+.$:;K/-5.TRP0UG06, MY08%XH]('-79-/&CX@'[0B[T3&\[@J\HI\>ER2FV^_OYMJ&#XGF:ZJH1[* MH5C/4"9Y*U.]522 (4/$?CEL[PS83T%VK9V=M#^P0<)?]^DM,8T?"#.8B8=2*8!9_9P_%\BHXWHF\UH)B -@YJ&Y^-YZ-;RW4'Y/XL4 M=K2X4,]#V%:CO-3E+0OF +<["^99OD-;^A&-A;]](&1ZC.,:$>YT)M*M,%T$]U_"9U9)\E2FX MSG0AUJ_%^H-B?Y<:XBS+!B;=U(4'D^MWIV!1QW;,MFH$Z/N^1UDK(Y9=('-- MUW+]UHH(,""S#;LOT:G1]'?&H -^DTJ1=2:3DQ.@BT-[-Z,SA5<]\E$H[@ , MVN,"'#KHA+,FEP[N.^_U5F0D*EN)\L>7I1D 6DC747W+@\5[D%7@%;S50FO)Z#)CS0-+AWN<(O:]"36,A.GQ:GY,UZ<*ZI6?3*@ MCEAN6ST&]7U*F>^W/8! H3Z9ON6T>Q$4ZGB6X7L]>Q1MVF(ZV.R=7KY /+@C M%>M(-U4*=89]=6>^#EE>AP2#D$NQ3>M)AWO/=T*3&"*/"G,ZKQR]4<:@/5%& MH'U1QJ##46Z:3NH.[D*?BU^M1/B*'V")0RF H"F<9D6X[*%HS%=AFGIC^FPPWR U?1BMQ$I\C@2[#;L)H>&!*.N^B,[QM5_T%!K-O6?O%'8.YM]1I MY2@.,WKV#]9TS&RX8SY?G2^4SUXF'X%A\A$8)A^%=>1/SPXM$I%MBM,B!2MO MG^KR9^OZ:7TB];HXAVD]?Z"S!46>+^DL*,^;&OKR^.LMSS91JD@LUC"4<>M" M.;_PM02P,$% M @ C($.5Y,Q_$5; P (4E3/G:%!M.<%8;5:7I6%9@5KB@1C*NUVYX,F9;61:4W' DME6%^:]K4K+] MQ+"-NX6/Q3J7:L%,QAN\)@LB/V]N.,S,CB4K*D)%P2CB9#4QKNS1/%+X&O"E M('MQ,$8JDB5CMVKR.IL8EMH0*4DJ%0.&QXY,25DJ(MC&CY;3Z%PJP\/Q'?O+ M.G:(98D%F;+R:Y')?&)$!LK("F]+^9'M7Y$V'E_QI:P4]2_:-]@@,%"Z%9)5 MK3'LH"IH\\0_6QT.#(!';^"T!LZQ@?> @=L:N*=Z\%H#[U0/?FM0AVXVL=?" MS;#$R9BS/>(*#6QJ4*M?6X->!55ULI -2^(<=R7,U^IJ>;.[IP M_L_[_)^]]\1PNX)P:S[W ;XN\_<3_YJFK"+HV]522 Y?^'==[AMV3\^N3KV1 MV."43 P@%H3OB)$\>60'U@N=\..^\B9!NF$KAM[0=1'SG7((/*L M./(Z9"]DOPO9'ZS*#S(G'*6]S;1Y'KD$$4 M6H?()GCSH(NJ"%_7[:N Y&ZI;.[/;K7KD*_JQO!H_=H>36W-^@PZZJ8!_D/? MM./O,%\75*"2K,"5=1E"IGC3XC83R39U#[=D$CK">IC#OP+"%0#>KQB3=Q/E MH/N?D?P&4$L#!!0 ( (R!#E>10'/)9 P &E[ 8 >&PO=V]R:W-H M965T&ULO9U=<]LV&H7_"L?=Z;8S=4T _&P3SS02271GNYMI MMKL7.WO!2+3-J22Z(AVW_WY!61$%X!5$*J>Y223KQ0$('(# 0T!Z]=QL?VT? MJJKS?E^O-NWKJX>N>_SNYJ9=/%3KLOVV>:PVZI.[9KLN._5V>W_3/FZK;:M4\O[YB5Q__ M\'-]_]#U?[BY??58WE?OJNZ7Q[=;]>[FH+*LU]6FK9N-MZWN7E_]P+Z38=PG MV$7\NZZ>VZ/77G\I[YOFU_[-C\O75WY?HFI5+;I>HE3_?:AFU6K5*ZER_+87 MO3KDV2<\?OU1/=]=O+J8]V5;S9K5?^IE]_#Z*KGREM5=^;3J?FZ>9;6_H+#7 M6S2K=O>O]_P2&Z=7WN*I[9KU/K$JP;K>O/Q?_KZOB*,$3)Q(P/<)N)& AR<2 MB'T",39!L$\0C"U2N$\0FCG$)Q)$^P21D2"(3B2(]PEB,P?_1()DGR#9M>Y+ M<^S:VK;?/L;?MHI=:_V!EBEUHU8;WIO?NNVZI/:Y6NNYTUFZ5R8K7T MU*NV6=7+LE-OWG7J/V71KO6:.V_V4&[NJ]:K-^J#9O'K0[-:5MOVRR\2SN+O MO>RWI[K[P[OV?GDW][[ZR]>O;CI5LE[_9K$OQ9N74O 3I?A7TY4K(MG,G>RM M\GFUW>[*JXKEO:NVM2KF#X32_"*E&:&4N95FS7K=[.N)2)V[4_^P7-9]GRY7 MWMNR7O8U/BL?:[IVBC-:B\73^FFU:\^F>ZBVJHG7:H![Z$>>#Y7WXV;1K"OO MJ[\W;4NUF1PO/Z_NZD7=Z2(WRHH'/_*#'_E.-3BA^J:ZKS>;>G.O1J15N5FH M\JDZ:!_*;=5^[96=RFKQK2?8-Q[W.:.\N.8HD?Z4&9'202QG@D]+@<6?X" M*29!8IHOQ,$78J(OQGCA13,ZJO.4IVGH^T:ES^S OIW]Q&AH(BP(!?>-IK;# MA.F9W([A/(C3($Y2/;*P(XW\I!UQS80(?<;3\!"J57MPJ/9@EU:"ZWR_]1S1$@NR92;(X4RY!B.5*L M0(I)D)CFR_#@R] Y'/Q#S>I7ZKY%N2RT!MKK2'7[* F-3N_,8JJ#D&(94BQ' MBA5(,3FBI31W1 =W1$YW_',WVUEHLYUZ/]M9G9CMO(FLPJ0L,&[B,V>^4RV# M%,N08CE2K!A3L1*4HV:7^&"7V&F7W=WLNE\!+W>F48XI=POKZO?^=46Y);8N M*@RCB!EWYIDSXZE^08IE2+%\7&T4R#PE2$QS3')P3.)TC%HK?U!3G]XC:GG\ M<;'H=4WOGW[Y=[1HH=SC5)\Z$4**S1-[2#9NFYD=PHVY+;)$!5),@L0TTZ0' MTZ2?9!K***E5U^8(X\QS:NNG]D)"+9;,Y0TRR]R^0CO' IFC!(EI'F#^P-M\ MIPM^;-NGW?I5>6 _6+3]_><;;Z/FM&?&#;?VU($#JC:'JF5[-6V48<:D(8=F M64#5)$I-M]D1UF67VXRT%J,ZH@% 9NY<)UL&J99!U?)1]5% \Y0H-=TS WIE M;O::;98.\/I3N3W -DXZ"$I>V3CT2H2QQ#>B,B*JAZ^!1>6@UU! U21*37?' M &"9F\ :[ACE"&&W812)R$^X.:Z,!+!47.#;!):(LQ$L43S.0Q&QP(_-?FZ' M$HM8(NI:B07"3Q.?1AIL(+',"=0 3T;<&4SNH,&X#FJ'$0]'B"CZZ0CT&@JH MFD2IZ089D"AS,]'+'I$P&\*=>$:RCSS?1XDXZBD)$4?T4;MXIYZ3$*'F@Q(B MY-R3$C9 1Q9]QF*>8$1%*,",BZAPSX@.SX^(S+DFY$Q!.[J](M3E4+8.J MY5"U JHF46JZ00>HR=U0T[4DY383O&9IRIBZU9E# 70S*%0M@ZKE4+4"JB9' M-9ANE %N]=B)((HM)8*4+ *5@A#)R.4-$4BG@;ESE@B]3GT6&>635!R+P]AG(@CH7BH&5"C89\00 HH-H6ISJ%H&5Z<@70*-^F\!$(( M&ZB%(F;<<@X4?T+5,JA:/K)&"FBN$J6F6V=@G\+-/C_UM*%;?O*$"0I+!;4C MTYP3VS'6C!C*-:%J$J6FNV>@G\)-/R\Y=BALUF>>.W3G.MD&D;7LN6;VR4-H MICEQE7:>!31/B5+3S3#P3/$I///XX;P@?0'EF6('3B#($8>*;XLWFF.X/)770&;P9_#,8#3/#$;R3"J.XIE$G-U+B>*=XIE$*,DSJ;@S M/#,8>&;P.7EF .694+4Y5"V#JN50M0*J)E%JND$'GAE294+8>J%5 UB5+3O30@S^!/0)X!<;0Z9-;-!DH\H6H95"V'JA50 M-8E2T_UU] VCX\'HJB[?UZO^MEGVM\M6V:Z'%_U7#'>-5^WNJ*3=;"S(TT3X MYCGSF;LLDQT'):50M1RJ5D#5)$I-=]S 4P,W3QV_J8M<\KK5)\_7;+A)K;"( M, *"$%$B$0DWS\KGT&LHH&H2I::[8^"E@9N7NC=UT8ZP02*/1"S\R-RH'MB< MDUY>$7$4!"'BA'E@.Z>*Q^/$CWQ3KR!"KY/8VN0IJ3CN"S_P$\9/+*\&2!FX M(>6DDV5T@T Y93".4Q)A5!<=RRFAUU! U21*33?(P"D#-Z<\>[*,-L5H5!F, M1)54'-E+QZ!*HGBG4"412J)**NX,J@P&5!FDGQ."0+$E5&T.5@:AE4+8>J%5 U.:K!=*,, M.#=TGV2_B'"$]@GQ:Q8EPEQQNO.>;!\HCX6JY5"U8F3]2E2NNG<&TAJZ2>LE MV[I"XMLHA5!.-JT#Q:]0M0RJEH^LD0*:JT2IZ=89P&KH!JL(\!42G)4$7^ZR M3/82%+5"U?*Q55) LY4H-=U, T4-W13UU/<]]U-RY:7-_J_223&ZM>:$'2=F>_ MRG/F+LQD+T'/[(?$-YN:/J*.SIL#%!2KHM1T=PQ8-9R$5:="=[?ZY('(QI<4 MT2/""*)'1-'0'7H-!51-HM1T=PS(-YRT+W64(V*KDYV [D0DB?.H. KG$7$V M=*>*=P*Z$Z$D=*?B3D'WFZ.?!.Y_A/JG M=,WC[E>"WS==UZQW+Q^J^6FOS83:_WM 5NV?ZZ^9.PMNLT9+SDE6*BPI)MKR9W.*K MA4_, "OQ#V=[=?2,C"D/0GPW+Y_RFXEG$+&"9=JHH/!GQQ:L*(PFP/'CH'32 MS&D&'C\_:_]HC0=C'JAB"U'\RW.]OIDD$Y2S)=T6^HO8_\$.!H5&7R8*9?]' M^UHVCB8HVRHMRL-@0%#RJOY+'P^..!H >MP#R&$ Z0X(!@;XAP&^-;1&9LUZ M3S6=7TNQ1])(@S;S8'UC1X,UO#)AO-<2?N4P3L\7HLHA*"Q'\*1$P7.JX>5> MPQ^(EE9(+-&"JC7Z"!%7:(J^WK]';W[^]7JF87JC9)8=IGI73T4&IHK09U'I MM4(?8,K\=/P,8#?8R3/V=V14X9_;ZBWRO=\0\8COP+-X^7 R L=O7.E;??Z0 M*XV7EM9+2RE*!*DFJ>;5JEZK7'.FKEQNJ]4&;K4FCZ_4AF;L9@*)JIC",:TS_^"LE,(I5Q&UB,C.]+4EMU\2F+?3X,HN9[M MCBUP249)X*5)T$B>P L;>.%H@&[S;Y!0]:K6 HI0)JJ,%PQ5!]SFJWG.3"2W M)BEX]?(PAI<,XX64G?@I:OP4C8;Q7HOL^]04QQQEH@3&4-347)?1M:;P*%A) MC+TX[L2T+X9CST_#Q!W1N$$:CR)]S\#\C ^BBWO3^I$?11UP?:D DS!V0TL: M:,DHM,6:5BMF%M"2V]7EAI_T@$T##_YU\+O$ M<)"FQ&U!VEB0CEKPJ=P U!_H:R]E+939QQQ.1Z-V&V6B:VI;AOZ M1!^@L!D/T"R36\AD]F@2F3F+\T'O<7Q(@L,H)ITX.@3CV(^P%PX$DK38R2AV MVT":A09UMPZ@$RCIS1]Z81)V8?;%L!^DWD!.XY;B\2A_SO]NUEC!H#XVR^O) M"=;O)V8(S@JZ:!UR./"P'PW ;?D8CQ/RG620PVWL[8(0>LWD(4>6G:(XC@BJ8_] M ?PM@^+H5;T@KW9,O:2)P*/4_.IZ="%MIUYHV1F/T_/=5F9K:M8=Y/5&FACJ M)[L&V8\MWQAJC3M3L ?;EA M*TC+Z>0,IW>29\DK"HWZ^>0A%R7S2VD[]4)+YF228-YBKTE>F?%76'"?B/GD'W7;$(0,$'^"!IHFT_$[.;[ASEDG;B_ 1 MD ZF!E:,8C_L8761>AK!AB(:8'72LCH99W6;V%2C![;B5656@ZFK3'*1.U'W M"3K$.$F]I%N(')(I-'Q)&@UT?*1E[:/N2 M,6R'XW"HBR8MXY)XM'3>;S>;PA[<4?EDZ"LKA-K*>N?Y7%9AI=3GOU!-W'5T ME-9?74&$:$SYJ; M32[,NV12 M$HOXS<_?/D[A !6P:.V_R6V/UQ8C\^&FSVOHCNJ82663(3 M*OA%"T3SG!NKH'UY+3AFCH/D ZS'I_YDC2!76?WJ,XAV(W/[.@RI&1R M9>^(%+(G(_7=0O.UN8>ZM;_O\-6BODUJU=276Y^I! )3J&!+4.F]C<'- MLKXOJE^TV-@KEP>AM2CMXYI1Z.", /R^%$(_OY@)FEN[^7]02P,$% @ MC($.5Z@%C7[7!@ 60X !@ !X;"]W;W)KA- -F293<-$MN /U+$Q75BQ&G[<'$?N-Q9+6^XY);D2E9^ M_3U#KA0)38+VQ5YQR9DS9\[,<,_7/GR*+7.BI\ZZ>#%I4^I?S691M]RI>.Q[ M=GC3^-"IA)]A.8M]8%7G0YV=+>;S%[-.&3>Y/,]K#^'RW _)&L+0=2IL MKMGZ]<7D9+)=^&"6;9*%V>5YKY;\R.FW_B'@UVQGI38=NVB\H\#-Q>3JY-7U MF>S/&WXWO(Y[SR215-Y_DA]W]<5D+H#8LDYB0>'?BF_86C$$&'^.-B<[EW)P M_WEK_9<<.V*I5.0;;_\P=6HO)B\G5'.C!IL^^/5;'N/Y2>QI;V/^2^MQ[WQ" M>HC)=^-A(.B,*__5T\C#WSFP& \L,N[B**.\54E=G@>_IB"[84T>K_BL$+,Y[,$L_)RID<3U\7$XALF7M"]=ZF-],;5 M7!^>GP'.#M-BB^EZ\5V#OP[NF$[G4UK,%Z??L7>ZB_$TVSO]AKWW8:F<^:Q$ M!E.Z\2YZ:VI55.%J>@@DM'*QBG=.7U,S]8\)3\$_ DTQ.=D(BFJC.\/MI/V7:_E.;*+EX!T^_\AM?4,BIKA8[1"_F2DSH,2UD/JM]@ M:Z"$%I2V;W4;O#.:+"H\$(PS"C4>T\<6R,JIC(E4WP>O=$M)A24CK8VI@H\& MD1G76(7.5%0BNHBM7T?J?8(744-V"V@'KEON5?(:;66P*I!601OG.T7/?OSA MY6(Q?_WVYB8_G;Q^3BI&#V$EA+DVJ27GW9&RVK<0I*:88-=G@R8!^-;"NZO' MMUL34UJ9 "R[706JER#_$O[[ 8 V&C2V!BE'B*VI3/)(7&"G?6-LA,+IF31W M#G9#-Q]^/SL]@1>XK]BXY38/0)P\XFW@H&+'C0%Y6%%U'40X';J@Z2WGG%M^ M(L!#5'YI.,*9S3%CO_"'%"SET%AN!ZB/Z0\F%7;Y%P@'6%44Y9&%I*CS:.Z# MQ:$/^UNR&@6''T!-:K%4&5?'S-3(098%-8/3VZI7%'O6ID$BM$6B9 TJ!2^ M1>P^;SJ$ EE;1++':BP> B\'B5*B2V .:K$UT(NPA"63_0B'.55Y&F%-TG0O M-0)[F%6;'5=P+5G), Z\\9.)28RV0Z<AMH,0=ZB+\7V61W90="9,*7)#5V$K M3*)?8>]):>OY>0%FCA2;24&_H MV>3JWQ_O/OYV^^9(BG'RG#K^)=.I=.^E6!:'8Q\\IBO V>H5MB-K[^H< M8H-<*[TIO5$UDL5MV!(&L@]ZO5 CG1=SCGPEPRZW5*'*KTPM11=R";#\DDA* MA0[&HD1!#$;DROA!>K,3(> A^$[JL_4R0FCQ\JA&_G8Y0G;NK^\^WKU_A\3D M),._^L12;FCR\#7-=;#=E0,X2.@H#1")*> #,.U3*KWWY.?7$5H,(!''1?;@ M2\0MNLSMXTM6(>&0-2M)!'O-&*>5EE:BS:K#<=-+RR@TB5BV:8#_>M"%-Y2- M&/)NZ67+R>(H"V,;?R7Q/]Z\>7>[U>:AX+/><:7B;PI>N)'+8P;_6!*+*YT, M"G%X[56HX>3V\?YZ5#YD)4G"]):S>@A!M%F+C>V0W(,D&$L=B0/I)";&(5?N M..'*VPY)A4@TC^,1WQ!"K[28+*%Q!B(^1B\#_C+@2W(;$]#E>HO8<%RP BFG MW(&]SA#SW4(^:VK,C-(DT$,J.TL_@+(UR/5QFA+@MBLW>%&,LFFJ43O65AYY%H<6NJ_!'4 A!Y MQ)3D?>U^.-N[[F,\+?-'#483UR#I+U;;G!T M?OSS3Q,*Y4.F_$B^SQ\/E4_X%,F/-:;AZU]@$A(1 P" M- !*HWS]GFZ E.31.(YW7V9$$FATGSY]NLF+K?/O0ZU4%/>-L>%R5,?8OIA, M0EFK1H;"MY:&;>]',U&_8VW>EU'NC&YNFCE6MVI^*Z]];B:#%8JW2@;M+/" MJ]7E:#%[_!46R=.X]7;RN+D=3.';$L95 WSORFJUA?CGX8B4JM9&?B6[?]2>5XGI&] MTIG ?\4VKYV.1-F%Z)J\&1XTVJ;_\C[C\#D;YGG#G/U.![&7+V645Q?>;86G MU;!&/SA4W@WGM*6DW$6/IQK[XM6U##H(MQ*W7@5EHR2L+B81IFG!I,QFKI.9 M^2-FGHLWSL8ZB%>V4M7Q_@E<&OR:]WY=SS]I\.^=+<39="SFT_G9)^R=#7&> ML;VS1^S]XM?2ZC\XO+&X<38XHRN9F&&KH_ )CA^UE;;4TH@[W%2@80SBWXME MB!Y$^L\IA)(#3T\[0,7U(K2R5)>CEL[R&S6Z^N:KV?/I^2?">SJ$]_13UC\_ MC5]@1IR^^\\:%Z*SLJMT5)4H'5)O0_J5T<7%:@ R[(&LY4:)I5)6 (M6>EKG M# 1"V[6(M4*Y?^BTSZMQ,MV[4V7G==0J<,9>W9>UM&N%9#:-#JP2WW[SU0_S M^?3\[M4-_YJ=?\=K95FZSD:RWGH-=UH#*VMEE9?&[.BY:LE;;?FH=Y9#XM3S M^8M&>5W*X8!WQ5TA_K98W ['0!^Q.V)9 ^];Y^FT0KQ.!EVK;696(RW4CB(; M\R/RK6FEW9%W7P8G(C)=!5/&"%G]#M7@^V.QK759#X^=1:B6M,S 18#IZG,VXO.?P$T\J&-Y0A-XU"9B,A+2VPT%_#L.RBZ)R2)AU\0B32H?2N- A MGIY9<&TGABPFS_\/F0BUZPQL$X,ETPE[?N]L:D%;'>NCT/[<(+$7XF%(N$]A2W.B&C.B=R4PT7"\RV3%*00U-[$;/KD'W#!8-W@ M)LJ(GB]0,P8+DA@7D(&AA.#)L98^P/%+>$Q>YI)-"/1UTF4YH 6A6P9=:>DA M"*SH4.:-]H@K _0_K4M"][]DVK)M>'!C?-M7QOD7E=&.@%[,>MXCH-\$3>H MU$H68F%,(GX.JV=U]LU+&V29=NV%31F-=BVSJ)2'(!5P9:,\U/,NNO*]N&N- MCN(7*][(G3A+*(\YQFLG?<4U \J6T7DJD]*P8$HQ>P(&/)E/P;5D+K"YP.:R M:&(. \"VHE2$6GHUX(=@&J"2]A U/"J0RC[ R;#:'6MPSS5BD[8=SC M,H?'4@.UFT M@_I+7#O@_:\':4MJB$VH->]"F_PSK(=K\C3Y3)?QD<@(*E(=.*M=%7H95=7C M8%2:JQS/0$;%EFW'=4REWL7:>?T'G-IG\ AN@F:K<239D":JE"LT5K&1IE,0 M.4>I0I&4RJ.@V01&+#6,6*@'!1@J\?79M'B&2=.8#&TI0SW&$52 7=,9AA1S MKRX3R[Z>3\^*:;]CG)S!),[%+UL=@3LO>U;,^E4%8<\^!GTOFC0Z)@7[R"LZ M770AJU T>Y"BD>AH44#[0_+A^^)L6%:(WU3*/,&6 MAH&4^8T"PRG%Q!\VQ\L@3^B9E 9(#XHJ$J7(=E8"J]:2V MO/197\?P 27C6BHT/KS$G$E102L!&;OLE2T=V@U5)#M#18V>2R&DT:/2299Q M1"1#W/0(EH@^WOL'][8URA:>< $L%2('\SUL1S(V%AK[J"I,D4?6_W%0I;0D M4"1RT' *<8DS>B<&- &1%&N7VR"57B%>)I038,,,!I!2-I)7M)WN]UDX)E&N MU0V'PAVS2M,!6''$S,,=A(;?K\RT@S"Y+M*;"#PH?\0GA GOP:,!9X_=9H M!-#H,8MTKN.^C(>A]+.=K=SQ G2'P3XW'Z?F)%B$P_Q@BYZ A2 M"B3NF..9HOL9%/YZJ0'F"6!R(H;JXVPR;EPB)4 M!L\[)B(U,A]C98WHBN,)&*D;P('"+L$G@(,H>>\#J(CXQ3 M)GLP]GGGCS0DBHD%RC>@.C73OGS=H1[T)?< 0#H@T'A/G&7. &T0/PSOCVFX M8B&LG4$Y![R5[3@D3]RBMK2V&DQ#(:$YFR[I] )4('WM>6/725[Z",9L1MN- M,QO*I?FF=""C'.BC,4I!1O"L<5X] MI%XXQ_%TOE+OL=T 0P?*T91+?>?A>F8"1FOIC:9),.)%F@#%42036P)FV[^ M52IHSY%S@[()@$Q')BV&@I7K]-EPN#M\=%VD;XW[Y>F+[1OIUQKR8-0*6S&! M/1NEN/N+Z%K^\KAT,;J&?]9X+5:>%N#YRN'--E_0 <.GZ*O_ E!+ P04 M" ",@0Y7BR"\Z;<4 ").P &0 'AL+W=O3N"P[>3AU'C D9@8QAV M4J/)K]^ONP$2G(NLG+,OMH8$&HV^]P?PY=KY+V%I3*ON5U4=7ATMV[;Y_N0D M%$NSTF'J&E/CS=SYE6[QTR].0N.-+GG2JCHY/SV].EEI6Q^]?LG//OC7+UW7 M5K8V'[P*W6JE_>:-J=SZU='947KPT2Z6+3TX>?VRT0MS:]K/S0>/7R<]E=*N M3!VLJY4W\U='-V??OWE&XWG K]:L0_:WHIW,G/M"/]Z7KXY.B2%3F:(E"AK_ MW9FWIJJ($-CX(](\ZI>DB?G?B?H[WCOV,M/!O'75;[9LEZ^.KH]4:>:ZJ]J/ M;OU/$_=S2?0*5P7^5ZUE[+.+(U5TH76K.!DWH@SEYNK6+FH[ MMX6N6W53%*ZK6ULOU =7V<*:\/*DQ7HTZZ2(M-\([?,#M*_43ZYNET']6)>F M',\_ 9\]L^>)V3?G#Q+\KZZ>JHO3B3H_/;]X@-Y%O_D+IG=Q@-Z>7:K_N9F% MUL-8_G??AH7>L_WTR(&^#XTNS*LC>$@P_LXX/99S^VSAZC_ M/U7UGZ*M/@=#PWX,K853X,&GI5'8;J.]9D?#R\)!XW4P)?T5,+/$R%+-;:WK MPNI*A18/X-MM4+:F011>;+N!];=+]7EZ.U7_N+GY +?_H[,0)4R^1HR@&:IU M^/7%*--SH.M2Z8"XTA #0;5+W2H]G\/S\;X;(A-4V7G2PC". M?C7&6U=.U=NE!H,LRL-"T9ZFSBD<8@U;#^M!OHAA/)WH"U7ZM5[:8DG/-FIF M"KY*VSY*CC AGK$QVBM#(4?]8 JSFH&IBS,.&N<3D"VJKA3Z#DS= MU#5MY2,+0\%\*=BKL]/C_Y["%>K"C'0;.@CDJZQ,: XVL]1W!I(SM:J=*J*2 M8+[NZ\* 4G58JANV L0]T\<]5NR>C14T?JV#^N;B='J)7%%5G/8P^IO+L^EY M>C(AM36&LV&UF?!N;.#%R=J7IOA"?T>>@EH:Z!8FSDY)U-["%4NKR6U7*^-Y M[S-=?P'/-ZTJC&\UZ0ZI&X*@K3)G,UU!3M@_>[BN$6NPJ4%ZM@8/;<<19*4W ML/S"0+SO3&D\7O\ _03;JOC*;YQ/,UF MT;@T517$!WU1SFGW'LY<6.O'%5T*7#2:;P &Y%"OKA.#, MM&ORC#Q$47E5*C8 _P4%*3Q,JR=N1ID4G$"5==.UX2F;(:D,P6A$X$E7[XY& M\-E^QJ$F_LF\Q061PUJX7Z-I+VN.:EV@D4AP>!X#,*@*.,G?:5I%]28#6%]T*!B3V'6U+6=HV#!9RR,Q#!YX# ME^<8R_K5"_4O M4K(ZHY]GYR\H0.@M?^P0\7]',X)??W2._F.=\!:DKXI[%1F(E@O$KU@Q9;9% MJA>-P4A(-P7H0(QC9LX?8&;, :T7$/0K[0^LML/C9 ^)@>7'T$N;E4(3?E*[ M-BU"KK-RI:F$L-10&H:89_S,R0?71\2U5#A =[#B%D;(T37]VI;1Q0,RRF,! M+3**B\1ASHSD(^7N*--6!VQR"G.,7MJ:Y'7T^RXMKVP>P44"O($Q*Q74G6V: MAFQ%;28K(IY(]65:@_:@[ON+C,6A0W @_GM7+H1;RI:^A)U3C2-$%G ;FIT& M82M4OA#'J 8ZUFQ:BMPW6P5;PVRJ(-J=G(?D:Q;.VS^EJ(S* 0=;E8*,9Z4] M?Q$@!QI'94;<\5Y?SF5*@^"[Q(-,IC:FWHB$1< 8OD>SAS3Z;@]_(16$7 VB M))H,I6"C-V*G9$%97Y1B'NMG2@UAV"[M$G&R "Z4R]@V@;.A'L7&0PM1DA\6 MVOL-5Z+2#DV2*S6-=_?<5^0;*ZG,<)%B6**8/R9-*A@-]COA>K)I4XC>RWE: MP5*I1M:S4\=$DS=4?J YTQB\VXW]9H;IAY9*79)!\7YV!0G#B*D4%?-^:]$# MS1%OQBRQH7/^FAD6C]UF$"T+3/QG!#=UR5O594^L&C M#/ MG(GX:-A_N%FFK PU,]V_T*ZLJ5I&:W(Z/1OW*MF#[58%M)O(!H_M.1EU M,8CJ"!ZV8C0#1_ IHQG:\,A7DD2%$.. MKM5;:2_&_1R2GL9R@79VQ#)%P7\,25-*1$L:# 4!]:U>-2\PF$LQ)D:0B^;& M=2(A%ENR*_7$PBCOF#TR\P$5&%5CG%(H:,60P5&#HV=EOYB*ZX>:,UH?XZ6 MPC"[0@D%(T1WL(]3T?7 YY.C]Q\^,OL_'#V-DP7#X0(RD,^054H$)N7H'N;8 M-4[A(@J>?_3!="M8P F7J-=H%7I()3?"D6W-<<6U(00&V5C$LIC]>\[8,*G_ M)/K8FC1]FH/3'!G>^3BC#0^3!9LIE\" EH83^_])UL@D%0C5.KE!Y'"V:3 6 M<^R83>&4]?4EN<-^A"K? MSU5O11&'&H3#YD]=$#;@T&M-#G@E/1VH8,;:VQ:%C"JIAXPVYR0(.YA<2[)%R_QPPJST(6C[/%47G V_L,+,BHYWMQE9)D#?N'^NYOG.> M2R?N.CFS"+ZR<(QMH$WH.+85R"B<6UMO*71D$6('/JW-(AH<+UY0&^9^%_"0 MD9(Y2I' X0=,ZDY085Y73#U+-QZTN!83Z7C'03U$0(U"R+RKJDWJ-B/3 [QD M_TP8#>8NO%X%=@*!'6U=;,%IHI>'\,Q]VOC-9-%('_(HEQOC3DSGMGGL.UO> M.+>!%, 8)47\F$-CH"BWPP#A>10=AECPOF8@]I.^QP[!@3* MR6S: F-\P@"&K0E;8^'$>OE1HND"T36U9B>A@9XQ1X("BPC\H7JEJ._H=6QW M6&?15LDNPF"J:Q,GTPS2$R&+U*":MB7Q,LH.X1$0ZC>YK+$)E@\Y:4$W@!@/!&/:U;+NF\ [3H =H[BH25"!E4.%<52D2 M[S(QW7:\KNYA;XP15)G[\4VO@[ZLV6/WHADYEAI1@$[ -:H'E,+2!G8-U>ZF M6$H@1X"TU!K)5B.02SL^EAT?TXZ/L<&(Z@[QI5^"18"&(J"T%;B2US#W.G7< M*/X=]?S2RR%440T@!0,:"_'"$!PU 9C-&;.KLZPXEHF<0^4IS=!5D'QASZA%-3HI# MMJ:./;!"+D__SH&<*THR4%;'A)IG@\HRX)< M%GBGTO4-J_4]8*8Q#H\HPB:]6V>U10\DD9=$7 LE5DE^"Y;0-].J;DN/HN"I MNNUFDN7;G9=B4^BAN?++#M['IA1WRCE.=B-BZ6$].16# 0<&L@;C'.AD=&A= M\86,UG6+Y4X7?Y;@L7C0G.R #P?S8\%=,08^<*9_N!3OIZ:CS)'A/][NV19B MRX MY-*,UI#*0DB(*OGDYPT2R3:7HA_>(D<7*35Z$'RM_= )[&P0-!/XD?". M'J/J&]M!1F0#AXU.TV'(T E%,R#(I275S?D0AJ$0:4D.ABJJ89):)[$$F">X MT9/X-RZ>.%)2\JZ*QSZR^&0[#BPS(1T,P_$P:[B)\/4;#D4ZY$JNQIJDKN V MQJUQ(ANB6*77@FI4(:M!AR"6VK[95C$,/"I\(Z>8'*$SB<1A;!5XL:%[->=?6=X09+<0[)GFR M(AF&CJLM,(B:58*/J>^L=SR;(W'TI$FO_+B^F#H?2G"UPF72<,KW[!(]9';" M3\7,6-:3T4$]Q@\']>N$.-,"'ADA'HN15'?%S?5DK!BQDYET:GP\DS6(*7]P M>^T)6$GWE 9#%]JZEG-7'5P-6IO^VD^Y=\^,5RTZRX^8]]+%$CQU*PLME\(R MGDDL5:K20?@@Y#AZ468O"A>&0X38E$B]63+RFVZBU3&ZQGLJ>'J\=.0?_A#E M2L_H(HJC?B1HN&'J2^%"\WE:F+PN7=00D+E*BO9F04X' G*Z<:>KA"3S5:AH M;V1Y'1C05T8B%?A]B#9/DTON#8@TC&#)FMMIE#'@% M:9U)=M^&Z+S[X281T'Q00QX?VR-31F3B =M_3OC)086.[1YCD]T3+AH64=Y\/$O=A*F9E_Z&'3&=SCSHS@Z'(O M!TC)^KVAMH)" M$HKVN15$#D;*EY08_BGI])"ND')Y',FGNHQS9;1W]JN:CGFY,J"$F=^HLJY! M\%GIPG1R,)VL0-0L- 9T@&FPQ[/K&S[,E5I+%F^I5=HZ%^7;4 \Z#(LE;H+W MFN(!0>RV&DJ%&)&_0HUR$',:D_4,DIMS3&5TCRZ_;89[CZPO*5WV$QV[+]N! M'&V4PQ%7T8XKL-K%4\;-&'\'C.P=E"Q?9A# )RP3VWT7S5E9-Z@B8SB^2;"TU [" MD5P@(O0_ O4TI.=1^PQP91R9\Q*-V=V0E)=(.$@(?@2HS6+W7B;L?V R@HCY MU:"$.E#I6 ]HP\T^(/?PH27?=K;EUXP=5O#-V?2[\?'FL^GS_<>;4[IYRH#% MC^D>U"?&6>LBGN!*P! '^:=IB.2'48@(="I7Q%N:'+5_M7Z(K/S.BJ;X-F?I M*F2KZ2/6Z6G0K2'\3-!&ZV0\9'J1#:N4&*YZMU%!HQEF"5,6)CNG8O;\C MQICEB]0NDA[=VC_,]UJCAZ-*D73EJ!-9L=#.L< M+9:\U]?4L0]!SXFJD@+$B"DD,MLXWZ*4E=75$7'*T)!Z1Q0YG&P_X"F-R M-?CZ^>3J4AK4;[X[G9Q=7>\_Q-AC^V-;_;35%F^))UWG)C WW@AEY;:'+2W& M#W/'(!'Z/@O3\MG]^I'6&" 2H&'/]?NL:8=1(DZCWC2'3A%B;Y&N900S M;OSW&>JAO>AVV\!V>(T7?Y5\=R6<>TI9 NS+[9R/)I5D5 ]'GN4F<<)0?;S( M_O4")+]H-&HTL_9R!.6+><6C/\IG4<']UB(K3YBYI^GF^>3J*IK7^>3J^77O M6XSPD1KH>R"YG+]K=;N&)ET'T[Z\FIQ^=RFTGUR<3R[/KI_VY(.]_^O$Z;:, M7 1[GQU6_M)#NT'>]B[-(!H7Q-%!!;&'3 AU:6!")E['E2:C]VCZJ,$;-MIA M'3JU[F_-TC[, &I'^+=86C//L.;2%-S<\_G2,1VPJWG7-1&ZR%9;/ M7)=NS0!O53F^]0$1Q*O()!8Y^T4)%.,>,PC;E$\V'N9 $88M=^JS,R"IL.ES M'0F"N!3KW1 0V!?(13=62?]>X@NP6>;'\^-'06 MYU>P@!^UKQE+( JW3&'<4V!4?UU^'L]^4MW6+_287G;V,/=48)*/,PMKQK,' M;)9.[^Y$8?VD[;/41(!PJH2@1U-9\^>'ICQ..2Y?C%34TNT?)I]]2I3RW$>$ M^ZW/O;RK'1UKB0?(/:A8A7D9G7^U,AX]E)_2V1 &8NC*07\&V2->C_Y*ZG&> M/MWWG=U)]GDD*OP%?P3*:%K=RI>2_=/^.],;^;QR&"X?J?ZD_8)B<67FF'HZ M?7YYI+Q\^"D_6M?PQY8SU[9NQ7\NC8:F: #>SYUKTP]:H/_Z]O6_ 5!+ P04 M " ",@0Y7V+ SFB,% ![#0 &0 'AL+W=O':FSM38_;([HX+XLE#WOY:>R&"1Q?#(HA52]V9F?NS&S,UV[0BJ\,6#K MLA3FX1(+O3[O#7N;B2]RE3N>&,S.*K'"6W1?JQM#HT&+DLD2E95:@<'E>>]B M^.YRS/;>X ^):]MY!HYDH?4/'EQEY[V8"6&!J6,$07]W.,>B8""B\;/![+5+ MLF/W>8/^T<=.L2R$Q;DNOLG,Y>>]:0\R7(JZ<%_T^C=LXIDP7JH+ZW]A'6P3 M6C&MK=-EXTSC4JKP+^X;'3H.T_@)AZ1Q2#SOL)!G^5XX,3LS>@V&K0F-'WRH MWIO(2<6;"$P M^/-B89VA3/CK4(P!8GP8@JOCG:U$BN<]2G^+Y@Y[LU[0.+DH$&ZH!- 8S,![PK6"Z]3I!1H8 MCEE\_M6U@4LM3 9Z">^EH7K2QH*H7:Z-_)N<78Y@!>$)E8&TMA8J1;:N*W : MAE$RB:,XCL'F@J3C-\^B\YJ!.8XD/MTX^.'P]$T?+HJB \BF+>@:#7HB!+5 MMT;:(?<6%J:D0\,^G#!Y'F >\1G+20=F@*YU_KRO>5QCBH#E)1P#Q6 M=R4RJ5=#2"4?3=Z*H/1E;M]3(E"T" M'=\9*R-);)<3*^)IZ\5WVB"6763?J7]0 W6DE5^?J@K;JHH8B!"]5M-)-)D. M6ZJU(PJ*^?3A?6U:7O(>RE#HR(6^"^A%I8J-NSI$XD;P%9Z@RO)3=03])E:^C@4\#$)M[\.^_"M(4K0 M=&\(O:%6DA9HPMA?CE,'N0#9"BS5$EN2C*HYO=?2Y0<]R<82'_3=:;@M8";] M'(DB3K6-8>2)[&S66AC:$%JQVXR^!!+7#8EM3_I::;71M=,<-FRC'5T/A./W MQ8=/&2Q6*Q*;!/:AQ=$T.6E4#.6PW2R?Q63T%%Y*9&&D;<0+"HQX\ M]T&/H_'XY(G0?77A?25-2$2?25SR_]Y8AM'T4-^?_\\>$W6WN--8YD36;OM* M*+J];-B)C4/.GKDJ-;3)X7XVW^MG8=VD8[R_\/XYTP+MG3&/NX;?<^K^="4^ M>@)Y\;FKN*=."CH,Y::9AG;VR(BK=B=.:?_+@=7)P_;8>AGWXVEGZO7!H\K2 MG4$WK2Y-:ZK3YBJ1DC+TC4'K%K7O0[Y]VC?]0Y>O0>="7*)9^6L_"UPK%^[& M[6S[97$1+M1;\_!9\EF8E51TLN"27./^VTDO%.UFX'3EK]<+[>@(\(\Y?1VA M80-ZO]3:;0:\0/N]-?L'4$L#!!0 ( (R!#E>$5!O"U00 <, 9 M>&PO=V]R:W-H965T-V'RSS#0\ X@&(LY6Q M7UR.Z.&QT*4[CW+OJ^E@X&2.A7!]4V%).YFQA? TM8N!JRR*- @5>I#$\610 M"%5&L[.P=F=G9Z;V6I5X9\'512'LTR5JLSJ/AM%ZX5XM@:X1:%JRW2 MC7MW-O $SD<&L@6Z;("29X F<&M*GSMX7Z:8[LH/R*C.LF1MV65R$/#WNNS# M*.Y!$B>C WBCSM-1P!O]V--KY:0V[*R#OR[FSELBQ]_[?&X@Q_LA.6&FKA(2 MSR/*"(=VB='L]8OA)'YWP.!Q9_#X$/K_"-/4%K02A$4H&H@41)E2KDJS*-6_//60L:)E4,19R+NU MM0Q.V:0<2"V<4YFBTS51QQ(H@J@J:RJKA$?0N$0-)@L;6VBY0BNLS)]8"[$% M.[8$*ZY18C$GO-$PK"9]V.\SB]]C9:QGHZY9Y2<7ANBD556H'C<;O40],9)W(OCF,:O7YPFP^3= MSFBSWR!_Y]:/T"<_0&_WGP59"1CS8ECID&XGV&XG^&D'T@GGS/ 8LL_TO^M[I2CMI,G3FU5X&6@GI;)C MZN!'T)U1DD%A4M1]N/@I"O<:VQP]H8&6#E8(-6LEU^BZ9:WY0KY)E!5:%FK3 MVDV)21N 3NN.LNO65+",=]H_>=5\'OB:R#LE$].S!RZ07CR>]Y&T<(KI5D6A&3IKR#=B,/3I>M80Q/P="U3_\!K!T"TH)L9M[_E > M_YSIE J;_'YC48?4VJI.5SN@'S>OT10NA18E,9,*^G>ILUOL]MG?%3E:1F%+ MTN?@:!PDCK>Q=Q-UNT3O>_4'6\U9@7816E B&:=7TZ=UJUV7>]$T=YOC38M, M.;101 2-&8G&_5]/(K!-V]E,O*E"JS&ULE551;]HP$/XKIVR:6BEK0I(&Q@ )NE;;U$JH5;>':0\F MN1"KB9W:3FG__*XKH:=>:4PS#@*= ME5@S?28;%+132%4S0ZY:![I1R'('JJL@"L,TJ!D7WFSBUI9J-I&MJ;C I0+= MUC53+PNLY&;J#;S=PBU?E\8N!+-)P]9XA^:^62KR@IXEYS4*S:4 A<74FP_& MB\3&NX ?'#=ZSP9;R4K*!^M\RZ=>: 5AA9FQ#(P^3WB!566)2,;CEM/K4UK@ MOKUCOW*U4RTKIO%"5C]Y;LJI-_(@QX*UE;F5FZ^XK>?<\F6RTNX7-EUL0AFS M5AM9;\'DUUQT7_:\/8<]P"A\ Q!M 9'3W25R*K\PPV83)3>@;#2Q6<.5ZM D MC@M[*7=&T2XGG)DM%=VO,B_ 1 Z7CRUOZ,2-#P+-)#"4P(8%V99LT9%%;Y"E M<".%*35U/BPK M)LSKHN'7?*6-HG?R^U#I'7-RF-GVSE@W+,.I1\VA43VA-_OP;I"&GX_H3GK= MR3'V_[VEHV2'I1[) *_VL#\NIA"T809S8 8RJ;OSS)%8,^[66\W%&DQI Q6S M#?+1JH$:32ESW_53#M2 ]QDOKI<&"M*/7C4017K1+0/1O'NK_1B<=]W_-[R;H3=, MK;G04&%!T/!L>.Z!ZN92YQC9N%FPDH8FBS-+&N6H; #M%U*:G6,3]'\.LS]0 M2P,$% @ C($.5ROSX16H @ .P8 !D !X;"]W;W)K&ULI55M;]HP$/XKIVSJIXZ$A'8=!20H>V%2-T2U[<.T#R:Y$*M^ MR6RGZ?[]S@FD5 ,T;5^(S[[GN>?LNV-4:W-O"T0'CU(H.PX*Y\IA&-JT0,EL M3Y>HZ"371C)'IMF$MC3(L@8D11A'T64H&5?!9-3L+/_& MX2O'VNZMP6>RUOK>&XML'$1>$ I,G6=@]'G &Q3"$Y&,GUO.H OI@?OK'?N[ M)G?*9N& =7 628LTJXE:X_X#:?"\^7:F&;7ZA;WXLD@+2R3LLM MF!1(KMHO>]S>PQ[@*CH"B+> N-'=!FI4SIECDY'1-1CO36Q^T:3:H$D<5_Y1 M[IRA4TXX-UDH2H$K[O"5H.O)8*$<4QN^%@A3:]'94>@HCO<.TRWGK.6,CW!> MPJU6KK#PELBSY_B0]'4BXYW(67R2\&.E>I!$YQ!'<7*"+^F23AJ^Y C?>ZVS MF@L!3!U(&.;A+5F*XX#ZQ:)YP&!R M]J)_&5V?R&'0Y3 XQ?Z/#_>_G+!8KLZ8+*_G\+DR>Q;SQY!JZE;K"*ES< 5" MK@6U/5<;8&X(?_"O4*4ZY\(ZYJBY!%,IDB?,,46Y1@-)OWGT&%Y"CZSWJ%:"/<:6J+9-&/+TO56RK6] MW>UVDW':#H0G]W:LWC*SX_U10"F'56MX739C(>U=C1LFF5!TQV- M=Z#S7&NW,WR [O]B\AM02P,$% @ C($.5RY44SC' @ [P4 !D !X M;"]W;W)K&ULC51=;]HP%/TK5^G4IZQQ/@B$ A*T MF[9IU5"[CX=I#R:Y(5&=.+--:?_]KAU@3*)H+^3Z^I[CM05HH'G M1K1ZZE7&=.,@T'F%#==7LL.6=DJI&FYHJ=:![A3RPH$:$42,I4'#Z]:;35QN MJ683N3&B;G&I0&^:AJN7!0JYG7JAMT_/!PO$EOO"K[7N-5',=A.5E(^VL7'8NHQ*P@%YL8R]<[];+B&F^D^%$7IIIZ(P\*+/E&F'NY_8"[?@:6 M+Y="NU_8]K5Q[$&^T48V.S I:.JV__+GW3T< 4;L%4"T T1.=W^04WG+#9]- ME-R"LM7$9@/7JD.3N+JUC_)@%.W6A#.S>9ZK#1;PN>:K6M2F1CT)#!';[2#? MD2QZDN@5DA3N9&LJ#>_: HM_\0$).JB*]JH6T5G"3YOV"F+F0\2B^ Q??.@R M=GSQ*WQ+_L)7 C7PM@#7,A<:?LY7VBCZ7_PZU7+/F)QFM+,RUAW/<>K1,&A4 M3^C-+B_"E%V?T9L<]";GV/_W5!BF/HL'L%2R1&TM@PLHD3J)XJ$?9QE$2>JG:0)?J!L%(>E@(P99 MY)-_P5=IJ)[O+@*?K1ZTRF/2/?*'64)Q0M_,STC]J2<.CH:P0;5V5F,O6^$=5^NZU2"P)"B[&@X\4+V]] LC.S?2*VG((%Q8D2.C ML@6T7TII]@M[P,'C9W\ 4$L#!!0 ( (R!#E=< M\NT0D +X8 9 M>&PO=V]R:W-H965TJK(V;T<;:YLWIZG%Z M==GPM;@3]K?F5N/IM)=2R$K41JJ::;%Z.[J>O+F9TGPWX7#M*2"%1BMR2!(Z?>_%.E"4)@AI_!)FC?DM:.!QWTO_J;(\Y(7JY*X_ZRK9\[S48L;XU555@,#2I9^U_^ M$/PP6+!(GEF0A@6IT]MOY+1\SRV_NM1JRS3-AC0:.%/=:B@G:PK*G=7X*K'. M7EWGN6IK*^LU0X39W89K,;Z!F06[Y3MXWYK+4XN-:/II'H3>>*'I,T)G[!=5 MVXUA'^I"%(?K3Z%@KV7::7F3OBCP[VT=LRR)6)JDV0ORLM[JS,G+GI%WQ$QV MK36OU\*-_W&]-%8C8_YYS'@O>WI<-E71&]/P7+P=H4R,T/=B=/7C#Y-9\^E+TO]LO/YOH>QCS:X;+4L7@HBI%M6@N"Z86K%":A29TH;QIM'J'NOL M1KB9[%-5RV6+5/BCE78',3G$H1#9;SDJDT=1$0\-U"\.@T%V MD&2O5ZE00AH ]8V\X-0SK*TI2-+&[(Z"QJ # 'FOO?]^L">SNT;FB-^.W0MC M&5]9-T7#43O!X3^$!QY#/%J%[*(R@\/WCO"Q+K@57D-9EFS#82!WRRBL+2\9 MI%8DRHK:RXW95]$KUBE:M)K,(;E>AR1,S'>2,M01$B$C;9>; :+QVBYJH"HS+)*;YF M@)&>M%(>'L/( #7A22+2Q#=.MILA^==05 MJSX"&"7X=KY_=<,A&W/ YY&%=>%ZX7N1"R4<>+4NW)CO_ M[]8-;%X-JCYX%PZKO[WN!!DG@1Y7=N/?[Y MWFR?*))%Z=G+BLR/*_)[V!2["1^5KD,<;I'-DFB6/)]O9TD\.3O8 OKX+8@B M6E?"ASTM&!K,'K1\ TQZMN%G716FKCF\2N,4Q[2R=,6++Z\0Q^Y%!)PTC6>T MY0XDS[&8ISP/Q4Z NJ[EOQ^#"V$XI)0\!( 89-#8''"K@U#6PG6./G(KG[3H M[2;R:B?QHE<;8I<>TH,&(/3HGNCC'A/&X"<:!W9,J0(')A4&W9^\20W[0>+8 M#%,9B0_TBMSOH8D6/)&)MM)6'>]!HVF-)YSDEIN2 W+OUXA+$O+]A.BG*//'M,"K&Z5\1)'!?9RYA,9O$?@V')VP6?U<=?\93WKT%^-@NJ).W.+:ZJ?Y@]%M\A]!I1PC1I9:E M7 <.LB6*!J>C7JP4)E )T '*=54[QY)T<: J\9A6'^9L_(Q/P"\<)28*22S+ M<>,B3#6DO:=.5=4="P/]I#\AX-3@E9. :$N0&W("& WEX,NB0N[!">BMPK/P MEDHG?BE&T)FHP=[JP93@;E 6=U3TF10<,MPZ?A3>(/K+T)DAH=UWD'#?_XT_ MQ_I:=*>.(5D9,.4AE"\/>@M;#C/#2%2&YXN50!7=2/'BE!N5,M!;K=+\G&94F%TT))$&UUL @[MY-+IAT7'_GHV\/< /J@:7D M.$F (<%0%'X.JG,B7_<%'21S.\;2,;PJ=D'P!>9A8M]@?%C GXA^.SY/AU)W MR1"X+TY][NA"2G181]3<28(H\K^L/1H1V'24&1'079^D-8@/COB.N.\QF(3< MO\:9HW(\0G3D+ 1P;_3Q72Y<=I] PM#1U!B08;59 5=="PWW#1M1K%T:Q_LH M@0\?N_1A$3L)7AQ,#4XD_U&^&>'3[9[N2[OCV9WEJU7_\.&=1XG0_1S4/N#$ M770=MC7]P>])JD7$90MI\M:8(_F&Y\#<_A%W?%3"X(8W^^X=P."%KIB ML.51F^T/KH\O- BQ'U^RP(L-Y8^EA^5NZ,7XV+WDZ>!.N1)Z[6[.J41PH/;7 MR_W;_G+^VM])[Z?[F_U?N%[C6,%*L<+2))Z?C9CVM^7^P:K&W5 OE;6J&PO=V]R:W-H965T[1+/I@\]#,-]]<)!=[ M(>]4CJCA4!:56CJYUO7<\U2:8\G42-18T9>MD"73M)0[3]4266:5RL(+?7_B ME8Q7SFIA]V[D:B$:7? *;R2HIBR9?+C"0NR73N#T&U_Y+M=FPULM:K;#->H_ MZAM)*V] R7B)E>*B HG;I7,9S*]B(V\%_N2X5R=S,)YLA+@SBU^SI>,;0EA@ MJ@T"H^$>K[$H#!#1^-YA.H-)HW@Z[]$_6=_)EPU3>"V*6Y[I?.G,',APRYI" M?Q7[7[#S9VSP4E$H^P_[5C;R'4@;I479*1.#DE?MR Y='$X49L\IA)U":'FW MABS+#TRSU4**/4@C36AF8EVUVD2.5R8I:RWI*R<]O?I=* 4U2ECG3.+"TX1I MOGAIIW_5ZH?/Z$_@LZATKN!CE6%VKN\1EX%0V!.Z"E\$_*VI1A#Y+H1^&+V M%PT.1A8O>@;O(Y,5KW8*;GHGX:_+C=*2ZN'OI_QMX>*GX4R/S%7-4EPZU 0* MY3TZJ[=O@HE_\0+9>" ;OX3^ ]EXC3Y<,<538%4&&2\:C1E4U.9%+Y2*LJ3& M4%9VSQ15LT9)14:"FP?2N><9A>ZH1)LZ)U%;ZIB]9_\F-EC]I MGYA1P(E RDAX3A8EXEF=PIH?SC=>$:JY+4WS%Y[,OC0E!4,+.89/\',0 MN_XT<Y/H2/(80@IUCZM%>O?VS2P,PHO'T2>F MT:BC/!Z%H9U,1\&DF_A$_SS+IP05IE04FA-OIH':'8=VMU9L-'-R%#:(%> A M+1J3H:T4Y8]51U^?3X3'!2IS GF@RZ(ILA,[K-+\O46@6V+^N$".F;X^BSU7 MJK$UW-2TF8J*,J0Z:FNJ11*Y!#HJMBBEH60B"\$XL;]70UT_@IJ%"PXC1.X95*2APIL4H,+P.\-UP^0%DPION7&P6#LCHE3/WX3 MFA4PF02NGT1V#).IS>MCW7T/GW&54E692MT("NW_RB/V1_>Q1#>8LD:AU<<# MRI33HI8\M=5K#Z>>"AE$S&RVA[:A=\<=U?V@(!IY5O+_.D6Z2D'3&\<:&CUU MT'LG5S =!#O[T% $WE2ZO8V'W>$M<]E>X4?Q]B'TFV&E.[S&41H"^;X70_<(8&%YXJW\ 4$L#!!0 ( (R! M#E?()!9>UP8 .40 9 >&PO=V]R:W-H965T^B+38*+O9P]NUCH=./#QU@2)75=N3J>CUM.#_U;7*VIK=!Q;:J=-@^ M)^5K?-_?=WA,-CP9/:9#?-NPUS\SH;$RQ^3K9>45U8BJ?3!!,L."TZ=<^S MNOEGU#U6/T!!&=4WM2%S<_\4KNW\F_?^/9_?J_!56T_4\6RLYK/Y\3WZCG?Q M'HN^XW\3KWIA8^%\; .I7R\6,060YK>[4,A&3NXVPH7T-#:ZH+,1*B526-/H M_,L'1X]GS^X)X607PLE]VO]YROZ#.GEC%%KMU)N%LRO-Q135RUI=M"OP$XDY M.AFK#2EHH$!&V3IYI94C%(M"VU"%#XT/.I'RRZ4M2 DVD%/?&!M]/58_HGI? M48BTG;#F%U10M:# NK^ZH5NCCN&J87<5S*22_J4A1=<-PD6DHJ3;L/0^-0$1 M"!1TG6@OLK?#7C1-\->V8F./'FY)!]50L-Y,U$\[69BP[#6ZSP\Z%*4Z/LI$ M%NT(2X-H11L"HG%;V92-V=BYSGU+55Q2#Y-_* _6L@.H+FB)N5T=W4^'\+S?X'RFE:@_-O@"R*F0.QU MVWKMW5J@46N-E+<1NUFXV0M/U)5=U188:7#I0VM6PEB$$.CW5B('KH8 ,IHZ MJ87O7;,?R=G2>R,@\!+%)#S#2N5;:/%++B\?69F3#] 56Z *,6B$]0MC+!>J M=FXKD#O.%2B&U5S"*)8ZX=#FHEPT*@?X:;/FTE2T M7.+,YC3[EHNZCMY9(X$N;:W1F"",Y1PB:P4%<0I'-HIQ)>0>Q3E$4G/BBD*@ MXX2[O&IK60T&"BESX^+J4OWD&UNH)R?S<;]]K Z^?/!D/I\]X^_X(F]'SPZ% M;OL?[KX/ IVB:Z6P7(#R<-_B+2&!QXL8V"O#4P#_8!,> /1-*686+J->)9)G[N6(P$71L.G1-KX?4+B4W5P=,CN<+4(OP;^Z!B) M(<@!]8$*?2#+E:G$-T,X.I'I!3-7]AS8"4W&^X"D0_<1'8[E_6!^>!.I4L>_ M1(L?;WLX46\RD= W.L)L)*"N+>4# 9)]4RA MP^@%FX@=C]3!Z-V;]Z/#.PF_T$[X*1->'!XN#MA8KF>XEEW ,]>[ !';100X MN0E6V-#*\9EK5(82L&"M7;M#H*T;;4VGO-';;B)(@[,/A8W5(I.;_9NH[_DD M[1I4GA_Z9A=[4%2)^68SK)2.'@J'P6I&S&,)?%9B(UD M+AP?WMJ7X0/8/0OC +4A2(6/J3^I$#0F B: \"3+#UIQ^E-&D 'S 00DL^\W M>]\K;:0=X,N"\)WN QAT=VV4UMU;-C@]BNRB0,Q'G1$NY@XOBKC%U'S?X3.B M(#Q@,/F6S^U;K!Z+]1N0W$V=5 ;?KDJT]X&_&>O4\3V$+2N^%YHNH+N"Z3X= M@")M/)1@D&1)_P$Z=6C)W$[H.,>=B0*[(=E/@Z*!"_? \;J?T7#%I+LR):=U MX7&.?\J3BE9\)>!"?NCDU.:A0_EU5_%[3";J'6=PJ)L%@"'Z195O2,0W)(7[ M#>WN-T);&8 V:%M?S"9'N/(Y)[=7?!DNC/G,:TCNM'S$R\24-\UO;]HO](Y$ M>_UWW+AI9'+7W64ZN'JBWZ[D@AV5%'"^A>Y6=W?XBWQUW8OG'P P(J]X'G&T MQ-;9Y*M'H]RV^Y?D&[G(8EA"&PO=V]R:W-H965TY!PGG3;WM@) \EA+95-:(39+QFQ10@W,Y. MFYJCFYH]LXT!7@91+5D<10M6O UR#E![D;#P,3#H>Z86GXR/]4\C=Y9)S"]=: M_A0E5BE]1TD).]Y*O-/=9QCRN?*\0DL;GJ3K8^/WE!2M15T/8N>@%JI_\\?A M.YP*XF<$\2"(@^_^H.#R(T>>)49WQ/AH1_.#D&I0.W-"^9^R1>-VA=-AMFUS M"P\M*"0W!_>T"4.']9NL&!#K'A$_@UB06ZVPLN1&E5#^JV?.SN@I/GI:QQ>! M7ULU(;/H#8FC>':!-QMSG 7>[*4YDE^KW*)Q%?'[7+H];7Z>YKMD:1M>0$I= M&U@P!Z#9ZU?31?3A@M?YZ'5^B?ZR__&?B&]:P3EK[*1L:C#[T!R6%+I5V%?0 MN#KVWZHON[_A??/>-)F^O*#%]0_03U$THPERC*^DPK-P= L8' MN/V=UGB<^ /&6RG[ U!+ P04 " ",@0Y7L@@]B>T4 >0 &0 'AL M+W=O*G6S[Q&Z=5 MQ9/6]9/SL[.K)VMEFI.7S_G9._?RN>W:VC3ZG2M\MUXK=_^]KNWVQ?E\HY;Z5K?W*UK^:JEV].+D^*2J]4%W=OK?;?^FPH4NB5]K:\W^+K8R]_.:D M*#O?VG68# [6II%_U:<@B&S"]=F1">=APCGS+0LQES^H5KU\[NRV<#0:U.@/ MWBK/!G.F(:W:U+V]%&X5=%+=FV9B%*573%C=E:;NF-&=K4QKM MBT?QK\?/G[18F@@\*<,RW\LRYT>6N2I^M$V[\L7KIM+5[OPG8#GQ?1[Y_OY\ ME.!_=\VTN#B;%.=GYQD,;_M^;N6\=[.;_AC8L]+X9ID?. M])W?J%*_.(&W>.WN],G+K_\QNSI[-L+M-XG;;\:HO_Q>>>-)9^^(=M,JLO A M)K^ 3/'S"C^*KE%=95I=%:6%SAHO?WD(IU+T>&$:U91&U87'1 U/;7VQ4G>Z MF&O=%-CU1CD:9VNX/@FV76DX\N^=<6$T5J9GM[KLG&E)Y*JIBM>?RI5JEKIX M9==KX]G_'WW]C^OS\[-GMZ]?\5^S9X]YK.K5MG$&[&QJ4%GJ1CM5U_?T7F^( M6]/P4A\:WM(M<K38NW M0M!N3$,,@M1:-8ACM+,)OR+>UAO5W!-W7R9.[*CN*I"JZT)5OR$<\/-)L5V9 MVP9;;2A(U6 1PG2TY,Z$1I?:>_+TUA8;47>Q4,9AINWZ'?9LF$9B/G8W M)9O897>N:HS3A:0.Q;+\ 6NLY]H5%S/VRW/PB3<5"-_1#IU=BV"")%33=%CH M83',N[:H+!36V'9')I7Q96U]A_U$RP)K]T72HG#^-VC"KVQ7@S99L&)SPIS? MND9RR]:TJYVM/4R0K!?; >.8YS2T(D*DYV1R1.U>*U=HBIA#LL4:+=*N&#?I M\$;D^9Z-%$914-XJ9F>G_P,6:HQ+;,*-Z/T-?*;& (FBTY' =)D"T^5H1'G7 M.R'V\BI)X4AX^F)BAVK]$KVM +F E0YW@?Q4KQ"X*C4M+BI M:_'#L*WH9($WIQJO2IG5QUE=&\ "%6)!RNIC9J;ND]8?10*>Z$,02L?FR.KT!YC M"OP< 41#'>)2?]H0&03=SO4I-R2M E9G;#4M7G%^95$>%PJ2-\%N@L]B6VD] MR!>8U\><*E3IEY@ZGL%T-8Q8%Q\;NT7ZN"G;CG.33"PYEE8&$GOE%\-6>O#LXH;EB4@IDX0D\4S%(1I/&6YKR[.II= Z'7-Q09& M?W4YFY[')Q/:_$9S#5+?<_ &]F*MD,VL=/F18LQ1!V$\HIEAL*D_RX*'MV _7ZA[V M4VIH^(VN"$!APQOK38L0!^OF?$\QS0;'->DIQ2 4A\6O%)1JHQ&<, O/S%* M%OAQQG^DW%P)3=[Y,)LK5%)%B51N@*1^A^&0HP_R+$MR,&RPJ&/[1Z &+;B< M]9YQ0P@-C!R+.YZ],C 5I+O[@)1['M="E^TXF\#1MA+C[X3@7+=;2F9Y M_*%:NRK8+MU'8$Q$1,!T.Z=:"IS PII-UWJI \B2$&EV"#SJFL/1T^*G_6<< MZ<*?S%M8$ FJ12&(3(P76PY9G:>15&J4,;IRC"^P\QCA[X>3!< M<@2&.Q#"@^BAZPX&_>&0ZP,.0UP6 )/'[+GM)+G\G?OAS .*KA8#>A2]3ND M&7.81EXM%.I.F3JP+]G-N+);PX#8[8I@6X6A;<-@(8?,/!0C8HI$4@42R58'I#JES*%(.BBKR1LXRE/] R8/Q^^H#@MF0ECW+HEP3@)+ MKKOGB>W*:7T*7.&&G7+ VR"J(+14FW]7L*=?/2O^34HN9O1S=OZ, H3:\T<4 M4%Q9XM?OG:5_6">\!6FRA;V*#$3+)>)7@$.9;1D=3'0+(R'=E%2E3O>8.1]A M9I<#6L\C%]7*'5GM@,?) (F>Y3]#+VY64"3\A*K4L BYSMI6NA;" I"H<0?E MB$VBK+;!2UL=O8Y^W\7E"Y-'<)$ ;V"7%=1V/MLT#=F+VDQ61"QME4JC0N*2 M)Q0/&8L]_+<@_EM7+85;RI:N@IT3]!(B2[@-S8Z#L!5"55X:"!UK-BY%[INM M@JUA-@&;]B#G(?GJI77F#\',03G@8 _ R'A6VM-G'G*@<81^PHX'?3F7*0V" M[Q(/,IE[!_KG(/8M 4:@\[/I;!>N9P_VT3IH;P(;/#9QL@/D$4%@J*;F;CH2X.ZP M-?1""+5_QJV>SC4 LTX<<6$^T=^>VU9XMM4<3O)67E1CJ9SCQL==!(K#'!+X MVI4++/9 +&/JGYWU9PEGHZIZVYQ"6Q3"^R;(UVJ]>88%&3H00X.'!W\#76D) M<0ML4F0]VT<&9?&=])N1D?O2=P>5<&@EYPVNP][#4:0V'W7->;3AR)YBG0 ) M##-K0 G@7*#D(4[%#GL^'YV\??>>V?_AY'&8+(T*!E*>"FH"4Q*)N!>4:OG, M>4/G0+@(1L$_4E!))B+8"+72"KB%5J&'!#T1DTRK3VO&2! 89&/F=5NDGC_ZHY>!-E$^SY9EYSQO[#BS(J.#[8:20=I+7$.X6R+:,-9KG:'0D46(@QYAHY?!X'CQDLH1 M^YMTR+B1L4!*]AQ^P*3JI/7)ZXJI9U62 RW&)"(=9SGA/@14='6*'J M"DSWW1_S1VRA8.[2J;5G)Y#>FFE*:EUGV5_T,M:T&]+&KSJ+1NJ81]G<& _R M#9>/N[ZSYXT+XTD!?-Q!V2CD]Q HJOTP0.TV/@F*L6 L>64'X;,'D@QW+']6 MGX:[W./3AP]\"ZB1W[7\KD-@<-D6\Y;Q/7!:NZ*^[:^97]'5 ^W( M^D'A6*1A%< #K2<*[0P^GG7LJ-0<.:6K+R+=2[//^Q#[X>DT'X. M4&BD6RXG(#V^8JX(UL)^H=@ME^G">C@F 3WJYQ?:ZC"99I"> MJ"%)!:1N6Q(OM[@A/.J?NOMH2(Q*LF-FWSIW89.(V-=SK2 MVCEZRD*!X!XY&0LM&!(.ZYI.(P*355<*AUGQ(&P>\C,I@+W2R?.$X(S*2D1% MS0?N'V/80RA@2VD'ID$/4'S5)"A/RH"$J5 -&>*0B>F^XW5-ZI9CC#2CN5Z^ M3SI(<&O [D4SG5:3ML,GTQ3GQ@I;%#C$81] MF-[&(V^-; 5K:8<,F]JB,4(BW0&1,'L1PS0,!>GH&T"_HU.*2@OH(7I[8>31 M?W[Z]^/18,+;]MW\M^3,=W2_C*4("@+74DE&AC/(Q2V2@"E#BZ7EVH(VU"$2 MR'67:0%6QCEA3"MG:1E#U"J3PWX^>8G',>*U=\$CHY6CR.EJR;L9MN$FS[;1 MSJ_,IK<40A\9:O! #7IE:\C>2;]:JDTSC7%X!#B<)+?. M,$]J])"7A+X3H%]%?@N6-A"\2\VZI$=1\+2X[>:2Y=N#EV)3B\XQ(LU.O7=- M*>R4=CQDSA>C%>:]* M=L!GBOEIXJ$8 2!*-@'-)4*:&D] =PQ_R.['8.MY#UO/QP^LXW4#NK(XB%L_ M8WZ\U1;NDL%[G)0PV[>-J!UG^YE5(-[YE[+ MLC/\B'FO;(!I$=$NE=S:R7@FL=01R8V792H[,[@XIB[>G*4J? ':-$NN.E&!,$-ZK](K^4I=V:9U)MG-$J+SYH>;2$#Q M>2@%H(#H=16*Z1%7?$JMB*,*W75#C(UN2"U&;YE5JNA+0 5IR>X9_$;Q&5B0 M-Y_X$0#6#?.2;F01T_$\F&ZG<&0$WX#ML?W/-T$)"5.$!,Y<&&ENA?O,TDFI MZ$"*[J4SH@OD(Y3@-!G$KK?.VKC>S^C#L-B"9O@O<;P1-UJ@S@646Q($ ]0 M(VC#G :8,8?D%ASBN5%&-_OO^WMRK*^Z/DYTUWW9#N24(!W!4?M[%S0TD!7T M8^6CBKZ5M].Z2R@J9AX$W8HO_7&3G& 3*RQ&W@@9FH[!"YUZR@8%@4?\&N\] MA&T_$%?[KPUFX]\)O G%6;R9/QA//X_$S]R5DNO3A#385D4WX1KMNQWK])/^ MGJW'@']$,3 MUQFPN')OJ.B^OL9GF\%+RC/RZLI4 ;N#.< M%3LP3P0+8&#=4FOQ6/VXMJ]TWM@-?=3T2$DZO$VA[.@OD%BIU[U-GMZ9T6J!A:.,JAH!H4G+86 M6'G$S#V.%WTG5U?!T,XG5T^ODY=Q9X340%^ZR7<;1^SOT-H$CO,"EU>3LV\O M98%'%^>3R]GUX[2&-Y\.5R@>(#Z:!OIO.V;CWV/<:KDI\[8_Q1K,!)]-I?@I M=>B\O$VQAGLA#!)#Y @?R6#S*,(VL&@=;CT*\$ZAAB[E.\T^U*]#AZ+I]R=#%*U=&+[*68:5+[BCQ-P2.C_;BHU,\8LMUMMM,Y,)0:?A(;P794I^N MKBU?*H RPHU/4I <+0(6A(#,#,)5IL5/="-ZE(."6I%RHSIKY0OJI$\>)'VE M.IJ0$^PCB'74#OI/0F;C7W3\!^[,E2+6ER@^: :?2Z2@SQ'+\$5%W9'?-H># M!(71S<_TQX)_5'L8Q;DL[B^UT>G07=B.6G2_ME<)$#MK-B1#3:[Y6^/=74:44"^&-E* M2[=9\/.-I:.6HY>@O^+),,5*;EPR3=] MZ;)3_CWHSF@!R-0#D6J(VCB:3OS349NT"S_G2YP_%Y,')?PD^V0;5<&2/TSG M?G73RM?;Z6GZ^/U&/OGNA\N7\S\JMZ346>L%IIY-GR+^.OD877ZT=L,?@,]M MV]HU_[G2"@9$ _!^86T;?] "Z7\)\/+_ 5!+ P04 " ",@0Y7YD,24A@$ M #^"@ &0 'AL+W=OXA# MD;SOOB._.]YDI\V#30$<>\Q4;J=!ZEPQ#D,K4LBX[>D":G(M! M7!O$GG?ER+.\YH[/)D;OF*'=B$8#'ZJW1G(RITNY=P97)=JYV0V7AGWCJ@3V M&;@M#>").\L^?.$K!?9\$CKT0GM#42,N*L3X!<01^ZQSEUKV2YY YCTVB"Y8',6#$WB#)N2!QQN\'O*UM$)IBMJR/^O^N/HH\G" \;PL-3Z+-[S,2D5,#TFGV2 M?"65=!(9UQ>6,)XG[ Z$WN3R'_ITK!4C29]62V-DOF$+;J7MBO DA^X(OZ3 MUEIA8A.R(\4POTH*TJ5AJL76I[$(/,[*+1Q1.J:7'ZU?@A6&%GX2G-S\/OADR?4/]^/XF8T.&=S2U2/ MZ(S9$K,'$#0ZK%?(S\)Z#7WT M"GJ]?D+3EXVF+]^LZ;G%)\$?G<73Q+MUFBVY$J6B\SU<1)=J3WN9O^FR+RH9 MM5CL@)4U$=$0^8^D=F#(J$X .SX*H_%ZY(S*C2[QZ WA7?4NSZJ?>Z?% V:. M%,#RD/N_6Z/_QI<+2602"['3",@%ZGA;"3%!""P!W% (P^::T#%-_$R.JY#W M*_7$%2&OJK1\HM.WI1!@O5XZ/5G6'["S!F88G3V;.*&'4:.'T9OUL$PY*M0R MF1_5L75;O,NV>+N$<=+=_RAG=/O"$R->[4)5%1OQ4F)AX^0W6/G(LNIE!'H9 MCY798W/QO916DLV/!DAQR8L!MY^!,99TQ7.4#M:F9]H^RMME%W^JP(;XX#1P MDZ,_?/Z'WN*\C7V<2>UJTW7_8:LGR%%9ST7[4GS6S3W,VKGN:PO>H, M4>0;B4FE8(VF4>\G3'I3=5O5A].%[W!6VF&_Y(&PO=V]R:W-H965T MQLKNE^M7T!)DNX^M/R%9VX#4'2>SCZSA8"S?$DLA3)^4?% MAO6\8TW>8,WA5DE;&[B2)9:O\1$I[&4F6YGGR4'";ZT\@30.(8F3] !?VJ>= M>K[T/VF',!=,VM?9PZ^SA;&:'LSO?:EWS-E^9E=$8[-B!4X#JA*#^@F#V8=W M@SS^?$!WUNO.#K'/[JDHRU8@J H.YK!/^$'J_<)?/0_L#XAI!&.9Q1*8A4*9 M+GJ)A"RX7V\-ETNPM7/4S-7&1Q<1&K2U*D-?2B507;8&JU: H.(TP Q42E"G M,&.X,I8WGNNA<[GA%<(1E_""3)MCH$>!_E%<8H'- C6D@W#G&M/.$=Y#FN5A M/APX*\G#=)3 =:LEMRWEX817_-G9!H8;2)Z$@U&Z'6[0D)ZSHFB;5GA%?::N MLQREV2B,1]DQ67$>?LI.CRE2'H?#84S&:!#F20S[;C_:*=P&]=*W)T,'VDK; MU7"_VG? LZ[P_[EW[?.6Z267!@16!(U/AJ&PO=V]R:W-H965T1CVH-BT+526/$FNN[\?92=>BB9YL46)/#Q'(CEIE'XP!:*% MIU)(,_4*:ZNQ[YNDP)*9"U6AI)-,Z9)9,G7NFTHC2]N@4OAA$%SY)>/2BR?M MWDK'$U5;P26N-)BZ+)G^.T>AFJDW]'8;:YX7UFWX\:1B.=ZC_5ZM-%E^CY+R M$J7A2H+&;.K-AN/YR/FW#C\X-F9O#4[)1JD'9RS3J1\1;U$( M!T0T_FPQO3ZE"]Q?[] _MMI)RX89O%7B)T]M,?6N/4@Q8[6P:]5\QJV>2X>7 M*&':+S2=[V7D05(;J\IM,#$HN>S^[&E[#WL!U\&1@' ;$+:\NT0MRP6S+)YH MU8!VWH3F%JW4-IK(<>D>Y=YJ.N449^.E) E<RGA M$-F3<(?)?JTU+%?K%M4:9 MJ(P+8YFE1A),)DB>L, $RPUJB(;MNX;P"J+!\'TP"(( ;@L2A)#6V@&[-(8_ M0=F5%;JR BH*[(L"SL^NPV%XPM_KK!)UWLX/0]IK:;LFZW?[ M$37K.O._>S??[IC.N30@,*/0X.+=I0>ZFQF=8575]NE&6>KZ=EG0F$7M'.@\ M4\KN#)>@']SQ/U!+ P04 " ",@0Y7"EGP5-D" #M!0 &0 'AL+W=O ML+MNVK]G=IV$(*5Y\=YFSIXSZS/CK52/ND0T\%R+1D^\ MTIC-* AT5F+-]:7<8$,GA50U-[14ZT!O%/+<)=4BB!A+@YI7C3<=N[V%FHYE M:T35X$*!;NN:JY*&WW[BOUJ6Q&\%TO.%K7*+YOEDH6@4'E+RJL=&5 M;$!A,?%FX6B>V'@7\*/"K3Z:@U6RDO+1+C[G$X]90B@P,Q:!T_"$URB$!2(: M?W:8WN%*FW@\WZ-_=-I)RXIKO);B9Y6;A8ODT*[ M+VR[V#CV(&NUD?4NF1C45=.-_'E7AZ.$ 7LE(=HE1(YW=Y%C><,-GXZ5W(*R MT81F)TZJRR9R56,?96D4G5:49Z:S+%,MYO"UXJM*5*9"#>\>^$J@?C\.#-U@ MXX)LAS;OT*)7T%*XDXTI-=PV.>;_YP?$[$ OVM.;1VA"F[.L,W.?!-SJ%/EV3"O!4(LH#]4]T^DR,UZE-%@MO<3&JC MX2WTH\0/&:/9(![XZ2"&I9'9XP?K)AM56SW@/B?VI M=PV.+%BC6KM&8PO9-J9SXV'WT,MFG87_A7>-\(ZK==5H$%A0*KOL]SQ077/I M%D9NG*%7TE![<-.2^C$J&T#GA91FO[ 7'#K\]"]02P,$% @ C($.5]U[ M]Z7J! 8 P !D !X;"]W;W)K&ULG5=M;]LV M$/XK!W>X[WPO/%5JH'72(:>*Q$K2][I3&K\\% YR563/MRA35]64A5,4-+ MM1SHE4)6.*5*#*(@2 <5XW5OW:C)A5P;P6N\4:#75<74TPR%W%[VPE[[ MXI8O2V-?#"87*[;$.S2?5S>*5H,.I> 5UIK+&A0N+GO3\'R6VOUNPQ>.6WT@ M@_5D+N6#77PL+GN!)80"(5"6""B\6V'V>M,6L5#N45_[WPG7^9, MXY447WEARLO>J <%+MA:F%NY_0UW_@PM7BZ%=K^PW>T->I"OM9'53ID85+QN MGNQQ=PX_HA#M%"+'NS'D6+YCADTNE-R"LKL)S0K.5:=-Y'AM@W)G%'WEI&@D48;@KF<+^C-PLX(8]T>D;#6?W;"Y0O[D8&+)H]0;Y#GW6H$F2K%ZB4[^:SK71E'J_'W,^08[.8YMR^EGT"=W5)[%6B#(!=P9F3] X\65K*A@-7,Y?_UH93S&_23Z<>Y?DF 5>%F9.CL+ &XX2N"4/ MF,I+!U3@AEK1RH4W'GMI%D(\]()H"%F6>N,T@60<>W&6P+TT9/P_/25+I!>- MG!!YP\!)WCC)O'04.CD+8F\\',&)N ^[N ]_,NY_KAR=J>UOW#P="_9IR&G; MDBVFD2 M=$.4 OZ(*N=T*YPA?7>K,70R&2?IR##(_C X@,S]M M8S#=,E7HY^ ;U"Z3FD\VUTPI*6=LU>7VBY%N#S#S'9'8BX:GB63'B7S9&25K MV$3%WGS?FXC3P$N#E_-M&/CA\)D)XN-,G.@ :=LA,\&HI9(?DL8*V!"AIJ-6LD!A&6/+V.Y>6-:;EO7S_M1DQ[;$ M&I:[0K;JU4K()T3MG[IG&O]7K@<=UE83TENN'_H+>V]Q@E4VTY1EU.[[%6(_ M2NGQCCID@90Q3QS%OH;WU;W+UXT4Y*6PW72/$8:IG]&SVT6F*CBC$+@@U<#/ MZ,)0S3S;+(Q_2+'-A G&;:A[8(Z6SX,^T!+9XN()*HD%2?_ MOD=*5FS$=;L/-GG4W>I](<2Z8&HL:* MGFR$+)DF4VX]54MDF0TJ"R_T_9%7,EXYBYE=NY.+F6ATP2N\DZ":LF3R98F% MV,V=P-DO?.';7)L%;S&KV197J/^N[R197H^2\1(KQ44%$C=SYRJ8+H?&WSK\ MPW&G#N9@,ED+\6B,/[*YXQM"6&"J#0*CX0FOL2@,$-'XVF$Z_98F\'"^1__- MYDZYK)G":U$\\$SGH+F:>)G#CXJ4=T+(%"K\#-()/HM*Y@MLJP^PX MWB-2/;-PSVP9G@7\LZD&$/DNA'X8G<&+^DPCBQ=]!^^6R8I76P5W?;;_7JV5 MEB2,_T[EV\+%I^%,LTQ5S5*<.]0-"N43.HOW[X*1?WF&;-R3C<^A+U;4?%E3 M((@-7(NR;C2S(B9SR11/@549W/"BT9C!9^I=>XY]9J?2.;_A?8ZP$07U*-4( MM%$!*-2*%J7.0=/C])C'NN>1=3PJXE'L]:1LA2G:QM(*%YD"7F4\9>0\A?M< M(AZ)!E;\^7AA>7X/8E02&;O5U.K$_(4'L\]-B9)I(:>V2C;R%_@0Q*X_3MQA M/+ZP9N(F0>"&26+-<.Q&4>+&HTEKCMQ)[+O))+Z &ZP$=6&+^&!;GDBQ)]ID MBT=\%- K4&GB;@H:N1."&?I#,Z.MXDE@9XGK1_W:*'HE^5I"*O4>5XOT\?V[ M21B$EV^K3TRC04=Y. A#.QD/@E$W\>.+,\(<]L(<_K0P_SI(<(5I([GFE/?M MP?7(;7_UE[ZBA)H*MW>C/UJ_UUQU5ZGK^[M M1\DG)K><^!>XH5!_,";IR?:B;PTM:GNYKH6FJ]I.<_HV0FDE85F 6$!-C,JJN/;') MB.Y$C@EZ8H#OB@*R[P\HIX>Q81MO%S[CS5:H"^9D5,(->D;B2_G$Y)G94C)< M(,(Q)8"A]=BXM^]6L8JO O[$Z,"/CH&JY(725W6RRL:&I1J$F'XX$MON.P&D$SIG <=X1N(W M'2KP&H$W5. W G^H(&@$P5!!V C"H8*H$41#!7$CJ/QEUN-7#?X,"C@9,7H M3$5+FCJH'%2IY9ACHKS^+)B\BZ5.3!X@QQS0-7ABB",B8&7!7\!]EF%U"'.P M(O644C<^S9" ..<_CTPALRN&F3:9IG4FYYU,+GBD1&PYF),,91WZ1;\^Z-&; MLNJV=.>M] >G%_@(OP/+O0&.Y;A=Y?2K?]N16^!:M1Q\>9Z!3S]V]CIFZ6>HE;]F!E*/RKJQ#]N.W7$TQUD]3R#)3F>4G&$))I"D6,ZH9WD1R2\,P<%?]R]<,+GD_]U1 MV$/= *^[ >IK\(Z7,$5CHU2YV!X9DY]^L /KURX_ZX3-=,+F.F&)3MA")VRI M$[;2!#MQOM=VF"EI3!;VF^BK?JS#9@!266,"\RU"]@&L-%5SVGV];ZN_,3SJSSG7"$IVP MQ=#^6.K,NM($.W%^N-#7OQ(=1 MZ\/H0Q_FE'=:K5=YK=6BR][PK##VO?!LR>L(=!T_CAW[-'#>$1C'MNW$\6E@ MV77<->X^*@JZ]8ZZZ-I;\YK5PR=L+E.6*(3MM ) M6^J$K33!:G^:1YN)!6*;:B>:2^OMB*@W1]JK[6;W?;7'>W9]:M\E=L?UA7VW MK/>R_\?7.^N/D&TPX2!':YG*N@WE\LSJW>KZ1-"RVLI\H4+0HCK<(I@AI@+D M_36EXNU$)6A_,IC\!U!+ P04 " ",@0Y7/W:N_BH" &!0 &0 'AL M+W=O$ \N.DDL=:Q@^TVR]]C.]FH*](5#[PDGO&M5 ^Z C#H ML>9"I[@RIED2HO,*:JHGL@%A=PJI:FJLJ4JB&P7TX$$U)U$0S$A-FY861GG(%G2T!)V8.Z;K;(6&5@.K :A MF11(09'B5;A!WQCT.JS-7)*]E(^../S(<6!2P@XY,8Q4/L[P1HX=T0V MC5\])QZ.=,#S]1/[1Z_=:ME3#6O)O[.#J5*\P.@ !3URT@6:,=*P0J64V'0*L_E41@F M2K25G.4,-'J'UE17Z&H#AC*NKZWC?K=!5Z^O$V)L*HZ0Y/VQM]VQT85COQS% M!,7!6Q0%43P"7[\,WT!NX:&'1\_AQ!9@J$(T5"'R?/$%OC&Y/U9[;92]9C_' MY'5\-^-\;O26NJ$YI-C.E@9U IR]>17.@@]C8O\3V3/I\2 ]?HD])]L%@,@5UBY.R6NA?B*U4E$QIQ*"PT MF,RG&*ENZCK#R,9?W+TT=@S\LK(/%2@78/<+*/JR/U!+ P04 M" ",@0Y7T/3L+IH" "YCV8)*;Q,.Q@^VT\.]G M.VE:H*TT:2^)KWW/\3G7\4V\$O)!E8@:GBK&U<0KM:[/?5^E)59$G8@:N5G) MA:R(-J$L?%5+))D#5NN)6UJ4VD[X25R3 A>H[^JY-)'?LV2T0JZHX" QGW@7X?ET9/-=P@^**[4U M!NOD7H@'&UQG$R^P@I!AJBT#,:\E3I$Q2V1D/':<7K^E!6Z/U^Q?G'?CY9XH MG KVDV:ZG'AG'F28DX;I6['ZBIT?)S 53+DGK+K1@<99YB>P" \ABB(HAV"IH?AWQINX(&# M#P[(&?1U'SB^P1Z^32GGC'1EW!3UUW>3#M<:*_5[5_%:[N%N;GOQSU5-4IQX MYEP4RB5ZR8=WX3CXO,OX?R)[489A7X;A(?:^#,X_KOT? T>]RW=+-G9DMC\M MD[-P' 6QO]PV]#9K')R>;K)>*!WU2D<'E4Z)E,_V/BP):Q!(]L=<3BM6[1(Z M>B/AMG1JAL>V$;:%&[=G(OM&E.;EB:WP=*FV#61H=& @ 0@4 !D !X;"]W;W)K&ULK51M:]LP$/XKAU=&"UODE[YLG6-H$\8V*(2&;A_&/BCR.1:5)4]2DN[? M3Y(=XX);]F%?;)UTSZ-[[G27'Y1^-#6BA:=&2#./:FO;:T(,J[&A9J9:E.ZD M4KJAUIEZ2TRKD98!U B2QO$E:2B749&'O94N(:[4.[TLXB TO)&Y2&*PD:JWETDUPO,N\?'+YS/)C1 M&KR2C5*/WOA:SJ/8!X0"F?4,U/WVN$ A/)$+XW?/&0U7>N!X?63_'+0[+1MJ M<*'$#U[:>AY]B*#$BNZ$O5>'+]CKN?!\3 D3OG#H?>,(V,Y8U?1@%T'#9?>G M3WT>1H#D_ 5 V@/2?P5D/2!DCG21!5E+:FF1:W4 [;T=FU^$W 2T4\.EK^+: M:G?*'P.MJZB%TR5:RH4Y/H<3EZ(A3^F0IS3P92_P327DY\W&6.T> MXJ\I>1W?^32?;\YKTU*&\\AUGT&]QZAX^R:YC#]-B?U/9,^D9X/T[#7V8J6Q MI;P$/:Y^.:H^4\9.5KCC3>) [.?)ODAF'W.R'TN;<#J?70U.7LNE 8&50\6SJXL(=->QG6%5&Q[]1EG70F%9NR&'VCNX\THI>S1\'PUCL_@+ M4$L#!!0 ( (R!#E<4W,F@\@( %H* 9 >&PO=V]R:W-H965T(R[\WP#3&<[H;Q9Y$"2/229U3TK%3*5<>V19Q" MCL4M6P%5.TO&V6'' "P/*,]MSG-#.,:%6U#5K4QYU62$S0F'*D2CR M'/._ \C8IF>YUG;AD22IU MVU%WA!&8@GU93KF9VS;(@.5!!&$498P%#EOTD"YGVK+:%%K#$128?V>8K5.L MH6'5S]\ZNFG?A8';M=>[&3SI_*T9/,_G^)(^)PT^[QTW;-<^]U0/:M6#DZIO M2S%4I;A)X>#(L^^$X:' QU9>>-?>-QH=&P6A-[@7M -CEYLK?> M5GOG[3T3]0 M2P,$% @ C($.5WH'4^8R @ R@0 !D !X;"]W;W)K&UL?53;CM,P$/T5RT@()*C3] (J2:1V%\0B+:JV AX0#VXR2:SU M)=A.N_P]OJ2A2-V^)!Y[SIDSXQEG1Z4?30M@T9/@TN2XM;9;$6+*%@0U$]6! M=">UTH):9^J&F$X#K0)(<)(FR9((RB0NLK"WU46F>LN9A*U&IA>"ZC\;X.J8 MXRD^;3RPIK5^@Q191QO8@?W6;;6SR,A2,0'2,"61ACK'Z^EJ,_?^P>$[@Z,Y M6R.?R5ZI1V_<53E.O"#@4%K/0-WO #? N2=R,GX/G'@,Z8'GZQ/[IY"[RV5/ M#=PH_H-5MLWQ>XPJJ&G/[8,Z?H8AGX7G*Q4WX8N.T??= J.R-U:) >P4"";C MGSX-=3@#I.DS@'0 I$%W#!14WE)+BTRK(]+>V['Y14@UH)TX)OVE[*QVI\SA M;+&+EX%4C7:LD:QF)946KX;W4C5^KO?&:M=4ORXE'OGFE_G\H*U,1TO( ML9LD _H N'CY8KI,/EQ1.Q_5SJ^Q%U][L0?M;]2-KJ9!]E +:&&3J9U>>&Z*LD@IZHG2BAP9"%D3C5V MY=)5I02:6E#.W<#SSMR.9Q("#HDV#!0?*Q@!YX8(T[AK.)TVI %NMS?L'^W:<2USJF D M^$^6ZFSHG#LDA06MN+X1ZT_0K,\; M';8 ?O@,(&@ P;Z ?@/H[PL(&T"X+R!J ';I;KUV*]R8:AH/I%@3:68CFVE8 M]2T:]6*%V2 M"0F\H-\!'^V&CR%!N&_A00=\O'_T+OAD-_Q;HGO$#PW<#Q_#7;2D]25H?0DL M7_\9OA&G2A&Q:*3^]07'R;6&7/WN4K8F"[O)S%ESH4J:P-#!PT2!7($3OWWC MGWD?NG0^)-GXD&23 Y$]L M:-X>=QFV,]9K#3LDV?B09).:++)DIF2M8C^(//P-W%6'%V'K1?C?7F!15)H6 M*2N6+YD1/LGR/(K._3;'6N6]9HUW)OY:^0Y$]DCCJ-4XVJEQ?? PI2J4EN+> MQFN!PO)K#J7$ZF_O"B](&ST1S?M'UIU9O';SOAAN'M#J29@.,+(?2F8\I[>U^,_P)0 M2P,$% @ C($.5VZ 11F9! MQP !D !X;"]W;W)K&ULK9E=;]LV%(;_"J$-6PMDUH<_D]D"&DO%4K1 T&#KQ; +1J)M M(A*IDK3= OWQ(RE9LAR9MC;>V!+%\QSR/=0QCSG?4_;"-P@)\"W/"%\X&R&* M.]?ER0;ED ]H@8A\LJ(LAT+>LK7+"X9@JHWRS T\;^+F$!,GG.NV1Q;.Z59D MF*!'!O@VSR'[?H\RNE\XOG-H^(S7&Z$:W'!>P#5Z0N+/XI').[>FI#A'A&-* M $.KA?/.OXO]F3+0/?[":,^/KH&:RC.E+^KF(5TXGAH1RE B% +*KQU:HBQ3 M)#F.KQ74J7TJP^/K _V]GKRJ)C16 MO(1F7'^"?=EW.G9 LN6"YI6Q'$&.2?D-OU5"'!D,@S,&06407&LPK R&)P:! M?\9@5!F,KO4PK@STU-UR[EJX" H8SAG= Z9Z2YJZT.IK:ZD7)FJA/ DFGV)I M)\(G09.7#([^ T\(881!TOP*..&&$,IT#W! ^=;2!+Y[$V$ M!,09?SMWA1R(PKE)Y719.@W..)V 3Y2(#0\ 8$GC\#/P,7\ UD4ILID0HD12_ MHEP85DO)8;T>AMK#\(R'908Y!W15A?OOC_(Y>! HY_]T#/>^A(VZ82K)W?$" M)FCAR"S&$=LA)_SE)W_B_=X5$INPR"8LM@1K16141V1DHH?-&UC%.J%DAYB0 M#9@(*F_S7&96_TU#=<)6RL8>KW:!?ZFT/RP?+W7S9>R#-&/WV#-7V=9V:>=Y)J M;'J,.STVR:TE[JP6=V84][!Q4BO^.&7? "++@0MZSEX/R)L%D[8&2^, ^JYJ MF[#8$JPE_&TM_.U_7]4%9& 'LRW2$4AIED'&08%8&8VWX,?1+JLK,J7O22LR MIXMS>4VGR#B+OH)?\-@2TO>:6L'[WPE"%J-<0))BLKZTJLW>^J:)BG8A3UCU M&7?[/),I_*.:S#?O3/0O8I5J(0=0EN1<5KYE[E QT'7Z)7F-3GK+ZU_<[G5T M&9_L]VR-J2ULT @;7+& RS\YH,"T4[82<7LT"V_@S4Y>:;.COLG6*BVV16N+ MW%20OK$<"D__,O@!3#MM,ZSW*K5:0UJEQ;9H[; T9:0_LKG?]JW6BE9ID55: M;(O6CDM3A?KF,M3>KKMR9$C12_-8>L?!:C%JB]:.0U..^L;:*OP"&8-$=.[R MS*:]7P:KY:=56FR+U@Y"4X'Z4ZM)RFJA:9466:7%MFCMN#3%JV^N7@\OQ[69 MZ'7!.AJ-3NM5L\_>>ENM6&W12KW=HP.:'+&U/AE3_^1NB2A/.>K6^O3MG3YS M.FE?^G=1>8;68,HCO4^0K3'A($,KB?0&Z@R,E:=DY8V@A3X&>J9"T%Q?;A!, M$5,=Y/,5I>)PHQS49Y7AOU!+ P04 " ",@0Y7N5WXHDP# #<$ &0 M 'AL+W=OQAVH.;W+863MS93LND_?C929HV$#(Z^:$O;9S<>W+NN2?I=0=K MQI_$ D"BYY@F8F@MI%R>V;8(%Q!C<;] OL^)5,5,L8,3H=Q+)Q=#J62B" M&4ZIO&?K*R@*R@B&C(KL$ZV+6,="82HDBXMDQ2 F2?Z-GPLA=A+$>PI1SDLS1!19$ MH*,Q2$RH.%;Y#Y,Q.OIX/+"EHJEO9H<%I8NJZ;82IU3(*Q7R,CS_GPJ=H',A0(F#D^@=DNBH;RSA+S3Z<:-N M@*XEQ.)GG3@YFU8]&_U4GXDE#F%HJ<=6 %^!%7SZX':<+W52&0*K".>7POE- MZ,&()5*5K>R$0J:>^P@XUH]N7=$Y4B=#TF^>5> YK8[7=P;V:K>>NKB^W^VZ M95R%:JNDVFJDNFW:5/>HCF$CP+YM,016J;5=UMH^*#^W30IG"*PB7*<4KF/, MSSE2>]>G+?7+ZKST)[9?&]@S)XSZ1PAL JPO5+X?K&#-Y_9=R7UFZ*J-!SG>VLXOR7K9%7/V8T MHNW;&5-HU=IWYC3WH%Q=T#$EGB&TJGC;$VPY#9/ M2V]ZVZ_W=B/:WNTQA%:M?3M]N:W#\K;18KZC#&Y6>@-;OF'1O 74$L#!!0 ( (R!#E>QOM/$P@( '@( 9 M>&PO=V]R:W-H965T%)M)A,J2)\E)]_>C9,=+!C=;@3PL#[$NY"'/$2UZN)+J M62\ #'DIN- C;V%,>>;[.EM 075/EB!P9R9500U.U=S7I0*:.Z>"^U$0)'Y! MF?#2H5N[4^E05H8S 7>*Z*HHJ/IY 5RN1E[HK1?NV7QA[(*?#DLZAPFU(Z[@Y7J-?.N[(94HUC"7_RG*S&'DG'LEA1BMN[N7J M"AH^ XN72:[=/UDUMH%'LDH;633.F$'!1/VD+XT.&PY1](I#U#A$_^H0-PZQ M(UIGYFA-J*'I4,D54=8:T>S :>.\D0T3]A0?C,)=AGXFO:1,D2?**R"W0'6E M (_(:')$SO.<6:4I)]>B+A>K^\$$#&5Z9)F,/+P]=2@EN"E']Z%2?"I2[(]@6T)%[?"Q;O04^1^9*ECX9!2 M*EJ^9#,K*1+=X46OZ]0PD19F2Y)ZCAAN%'$02\X&02;O_"/PG^C M4TW1W^@+MB??4C5G0A,.,T0)>L&ULQ5==3]LP%/TK5B9-F\3(1S]A;24H0V,: M$H+!'J8]N,EM8^'$P79:^/>[=D)(4 A"RD0?&MOQ.;[W^#BYF>V$O%4Q@";W M"4_5W(FUS@Y=5X4Q)%3MBPQ2O+,6,J$:NW+CJDP"C2PHX6[@>6,WH2QU%C,[ M=B$7,Y%KSE*XD$3E24+EPS%PL9L[OO,X<,DVL38#[F*6T0U<@;[.+B3VW(HE M8@FDBHF42%C/G2/_<.E;@)UQPV"G:FUB4ED)<6LZ9]'<\4Q$P"'4AH+B90M+ MX-PP81QW):E3K6F ]?8C^ZE-'I-9405+P7^S2,=S9^J0"-8TY_I2[+Y#F=#( M\(6"*_M/=L7 \8O 8E8& 3 M+2*S:9U031##@(7I:CT"![U. XZ&7_DZ3X9>'LD\()! M6T#=\!,($>Y;>- 1SJ#:GH'E&[[ =\Y2EN1)F[*=0'/Z#U5&0Y@[>+P5R"TX MBX\?_+'WM2VKGL@:.0ZK'(>6?? F"Y*S-,O1B#2-[$UJ3_TO"..4W>6@R)^? MR$/.-"3J;YL^PS[UZ8FLH<^HTF?4Z8$+*59TQ3C3#T2L\8$;AJ"4:2:, SXA M4 8:Q@RVQ=EM$Z-8P2]L:Q[MVX6W[Z/!M_4L7YO5"']P\*1/?7HB:^@SK?29_G<+3]O,.7SFX%K]B117VQ-C6H5D]_IAR56 M'"S=&%U"+(Y8!-(*LD?61KVM52^IJ<>,>JVRE+69W["K-QUY]9__S.-O115I MNK4:,0&YL:6S(M;91;E8C5;E^9$M2MVGZ45M?T[EAF%5R&&-4&]_@N\-693+ M14>+S%:<*Z&Q?K7-&#\Q0)H)>'\MA'[LF 6JCY;%/U!+ P04 " ",@0Y7 MA#.;$]4" ">!@ &0 'AL+W=O]O MVC 0_5=.V31U$C1I@&SJ(%*AJ]:IE2JJ=A^F?7"2@UAU[-1VH/WO=W8@91+0 M\8'XQ[WG=\^7RWBM]),I$2V\5$*:25!:6Y^'HE M=0MA.J[9$N_1/M1WFF9AQU+P"J7A2H+&Q22X.#N?)B[>!SQR7)N=,;A,,J6> MW.2ZF 21$X0"<^L8&#U6.$,A'!')>-YP!MV1#K@[WK)?^=PIEXP9G"GQBQ>V MG 1? RAPP1IAYVK] S?YC!Q?KH3Q_[#>Q$8!Y(VQJMJ 24'%9?MD+QL?=@!Q M? 0;P"QU]T>Y%5>,LO2L59KT"Z:V-S I^K1)(Y+=RGW5M,N)YQ-KQC7\,A$ M@W"+S#0:R7%KH \7SB]N7X%N'G;"U )F2EHNEQ3HAH87J)GW^.02+>/"?/;X MYX8;[M;[&@6S6!P&]N'D!EP;OV]^"&LXP+,@S-]BX*(&_>W)@Z-WKP(%5F4*]8)A"N9=U8%Z-D3FAO M9P]F3.2-:+W]/5=" -7PFNGBSSXS6XW#_1I=6S@W-Q3W'(FGM/UG54:#Y.( M?N-PM4?,J!,S.BIF5C*J3N 2%NYB5K[@-7FKJ8S<,C+M!.XMR99ZM*.I/SPL M*>DD)?_K#\KB?6>2/<[$>V2$.SVC0KWTG=% KAIIV_;1K7;-]Z+M.6_A;>>^ M99HNSH# !4&CTR_D@6Z[83NQJO8=*%.6^ID?EO0!0>T":'^AE-U.W '=)RG] M"U!+ P04 " ",@0Y7^9*LUKT^8\^D&K? #YE\W"RI:9D])LP*7 M+",EH'@Y,V[M26Q[M:"YXN\,;]G>,:B'\DC(M[KQ,9T95MTCG..$UP@DOI[P M/<[SFB3Z\;V#&KUG+=P_?J7'S>#%8!X1P_ M60^/S!163E/(7@,H41-^K;".F#;\&I9C4[\%B$8&K$'.4Y>R=:']] M",'5[^^F)A?6-ZR6AS@1>0V_#< M-^;0-5CDJ.3#J03^_20N!Q\Y+MA_LHG3LCTYNRZL$[9!"9X9HG(R3)^P,?_C M-QM:?\JRIA,6ZH1%.F&Q)M@@VUZ?;4]%GW_"C$W ;9)4194CCE-1R(5-DJ%Z MJ9!EN.7!AE>O=$_S]ZX76($W-9_VDZ?T/3=Y)YI&.DUCF:D%QY[?FPY"[O%5XS'*A"^%!S(Y9GNWX!XZQ: SVSIAH4Y8I!,6 M:X(-LCWNLSV^8&&1979\5(9<#\*1?5#YE';GYNPTSTBG9SP^+LH.= -'OJS8 MUNXQRU(72<:SHKE;JAA>5CG(LR4&5UD)7C"B3/Y(I4:ZK53VUU$KS\W#Q?V( MM/8CUD4;IG#O2=E6CC.N:)GQBN+FW[+,GNMCV;#OU*!SZZ!66JB5%FFEQ;IH MPP0[NP0[OW#MZ^"ZDJZ3%FJE15IIL2[:,.F[O0M;^;!\QA+8@?;7(^B(V_^# M)5#M=W;F3C*-M)K&;YH.8[W;.;#56P<7+8)JY$BQ"&K=3[BX'Y'6?L2Z:&T* MS;V=XP+35;/'ST!"JI*W&X#]V?X]PFVS>WYP_LZ>W-N2\Z$]B=JW!#M\^]+B M,Z*KK&0@QTMA9=V,Q$T7;=\#M U.-LV^]2/AG!3-X1JC%-/Z O'[DA#^VJ@- M^K&PO=V]R:W-H M965TS'MA4D.8M6Q,]M ]^UW=B"E-,TF-EX0/]W_[G>.?1ELI'K0.8 ACP47>NCE MQI27OJ_3' JJ+V0) F<64A748%^^1#!9TQP:HTVP0;@W"0X/N*P;1UB!RH%5D#NN& M&IH,E-P095>CFFVXW#AKI&'"[N*=43C+T,XD$X',3# #YQSSF9&),%0LV9P# MN=8:C";G9#*=G="BO+HA[V[ 4,;U*8[>WV'_[>G -QB'5?/3K<]1Y3-\Q6=, M;J4PN28?T7GVW-['^&N(< 9Y)S@B[BA*OO1E,+*1;?9A3W;E[JD*0P]/+P:U!J\Y.1-)PZNFOC_ MD]BS;'3K;'3;U#$;YZ62*6A-K#A5:4ZHR/"LK?$.*?%&,&=D#DLF!!-+/).< MBA2:4E+YB9T?>SNMDZCS(<#?P%_OT[;&<-:@SD2M5^C]MM1BY(R98F( M7#S==$TX_1?OWR%(VXHJ.G_OJBY +5T%TR25*V&J"Z\>K8ODM:L-!^,C+)Y5 MK7N2J2KO+55XF#3AL$#)X**/&Z"J:E9UC"Q=09A+@^7%-7/\ !E%^#\0DJS MZU@']2=%\AM02P,$% @ C($.5]SI%,#C @ )0@ !D !X;"]W;W)K M&ULK99=;],P%(;_BA40VB2V?'^--M+6"@$"4:T: M7" NW.2TL>;$P78_]N^QG39JFZSB@ILV3L[[]GGM^+BC+>//H@20:%?16HRM M4LKFSK9%7D*%Q2UKH%9/EHQ76*HA7]FBX8 +(ZJH[3E.9%>8U%8V,O=F/!NQ MM:2DAAE'8EU5F+\\ &7;L>5:AQN/9%5*?P1SD4S/C:F1W+@6IH!:$ MU8C#31->;@A\$MN+H&NDD"\:>]>!S,;8<#004T^I^4@N/KP_N'TUVE66!!4P8_4D*68ZMQ$(%+/&:RD>V_03[/*'VRQD5 MYA-MV]K L5"^%I)5>[$BJ$C=?N/=?AZ.!&[PBL#;"[Q_%?A[@6^"MF0FUA1+ MG(TXVR*NJY6;OC!S8]0J#:GU*LXE5T^)TLGL/L_Y&@KTE> %H402$.AJ"A(3 M*J[1#7J:3]'5V^N1+=6/:8F=[XT?6F/O%>,OZ_H6^/R"?7)9/(5=R MU\B]4[FM(G8YO2ZG9_S\5_QF^ 4OJ J'ZP*9T)@*].M^(217K]+OH8"M8S#L MJ+?7G6AP#F-+[1\!? -6]NZ-&SD?AN+^)[.3\'X7WK_DKL-S1JG)SH%BJ18\ M9T**H=2M562L= _89+$7N(XSLC?'>?IEB9]$B=^5G9 &'6EPD70N6?Y\H_>E M)JQ4KQ)8;_U0)CGI9G/ C:J%3:J ML<=O:TG4$D'E5R$ M.G1%V.DW<'C6DMX&\%TGB=/@#+!?%\1IFO9VBGW4Q/4!^@WS%:D%HK!42NRBU \D:T]<73*I3PER6ZAP'K@O4\R5C\C#01T7WSR#["U!+ P04 M" ",@0Y7?,43'@\$ !"$0 &0 'AL+W=O^+Y.,%%C> M\ UA<&?%18$5#,7:EQM!<&I 1>Z'03#T"TR9-QV;N2/KI'>RI+S5SUX3"=>H#TB.4F4IL#PLR4/),\U$_CQM2+UZC4U M\/CZP/ZKV3QL9HDE>>#Y%YJJ;.*-/)22%2YS]8GO?B/5A@::+^&Y-/_1KK(- M/)244O&B H,'!67V%[]50AP!>OT3@+ "A.\!@Q. J )$[P&W)P#]"M _UZ5! M!3!;]^W>C7 +K/!T+/@."6T-;/K"J&_0H!=E.E&>E8"[%'!J.DL27C)%V1I! MUJ'G# MR/0?E4_2$]Y 12J)K-$M3JN.*<_3(;';J*%\MB,(TEQ_ Y.5Y@:Y^ M_##V%7BEN?VD\N#!>A">\"!"'SE3F40Q2TG:@E^X\4,'W@\EN4!#]C,*@%[7MYPQX%&AXV 9?_#]X?#X\=(@1U?D1&;[H!)]-B*5)B => M0'V2-O8S(3!;$YTA:+E'QW95XJ#9#HL4_?4'4*)'10KY=\M^YG;]?OOZND[> MRPU.R,2#0BB)V!)O^M,/O6'P2UMHNB1;=$D6=T36"&*_#F+?Q6Z#*!$N5<8% M_0="=$49DF:V[8F=.^DNC8DE&Q@R_=[:3@>!_AO[VV.USS.+.W*MH>.@UG'@ MU/$SD:92;HB@W(JX)UBT:^BFBBRR32\G\-(<[I(L[HBLH?VPUG[H%.P!BKR M8T4)[R!%1/$?ZKO)>L%I^9W(2^7ODBSNB*PA_VTM_ZU3L3^Y N%7F JTQ7E) M$%\AK.N[1%MX*EI?W',GY:5EI$NRA24;'A6;,&RK-M_;]8.F74/-4:WFR*GF M"Q,DX6MF:G%R_%I-N%1P ,\Q2(H41XRS:RLP@K-@\MHFLW.M2V4>?;?C45NU M/L\L[LBUALAWM&IV)KE):[401] M^[LGZ%S#N"O_K,3^4:]8$+$V3;K6"KI VR/5L_6'@)EI?]_-+_0' M.#?J.Q M7Q<^8K&F3**F2*^AOS65&<$J$-H#[*\[58: 7 MJ#^;3/\%4$L#!!0 ( (R!#E>"AL!QGP, .$0 9 >&PO=V]R:W-H M965T?=9F>"+UG.0!'#U59 MLYF1<[Z_,4V6YE!A=DWV4(LG6T(KS,66[DRVIX SI525IF-9@5GAHC;BJ3J[ MI?&4''A9U'!+$3M4%::/"RC):6;8QM/!7;'+N3PPX^D>[V -_//^EHJ=V5&R MHH*:%:1&%+8S8V[?K&Q+*BB)/PHXL=X:25_(Z3=H M'?(E+R4E4W_1J96U#)0>&"=5JRQN4!5U\XD?VD#T% 1'K^"T"LY0P7M!P6T5 MW-=:\%H%[[46_%9!N6XVOJO )9CC>$K)"5$I+6ARH:*OM$6\BEH6RII3\;00 M>CR>IRDYU+RH=TA4'5KGF,+50D0^0[?X450$9^@*K3E)[]OC):E$E3*L\OPF M 8Z+DKT50I_7"7KSX]NIR<6])-U,VSLLFCLX+]S!19](S7.&5G4&F48_N:P? M7- W13RZH#A/05DX%X$?#O4UK.SIW_I_UU7^V?A8,MZL0 M5_'<%WA-26R^S/V<4ESO0-8(VCRBOEQ;.FA^PC1#?WT42/2>0\7^UE5'8]_3 MVY>=\H;M<0HS0[1"!O0(1OS3#W9@_:)+S9BP9$S8:B3861*]+HG>)7K\.^&X M1$Q]C9L4I?U4PH-<@RXY#3=07/FKU_S*\<) M/7?07+X4LX749""6:,1$UPCM<-!<=#C;\B>>OKE,NC!,+H;A3@06TS17W26# MHW@'W\M"U3E^D?2U53DF+!D3MAH)=I:.J$M'])U;2S1F$L>$)6/"5B/!SI)H M6\_CB?6-FDL+[K]$N%$0#EXUECHQWW+\07/1B(5A$ 7>H+EHY+S(=<-AGW3P^5U/HX'QAWRQMS7DBYW)_ 5!+ M P04 " ",@0Y7R.FV_",( "N10 &0 'AL+W=O3'+Y2+?9)^SU:$4/2XCN+LCG9/\'J8",'Q,X)=+?R4_+VFHU+@&[])W:\:(;>HCN:++ZCOS?% MR%_E(Q_2)_3J/:%^&&6OCWLDQ1YYBR]W[]&KGU]?3"E+,N]JNJ@2NBX3PL\D MY*)/24Q7&?H0!R20M+^!VYL8"#!EHW,<(GP8HFL,1OQS&Y\ARWB#L($M64)P M\_=DP9J;17,,I&,=CYA5Q+.>B??7=GU/TE]^,EWCUV19'91,-M!E'%L>)U\? MWF4;?T$N)VP!R$BZ(Y-Y&58&J2E8 ]D^(MM0]/FU'_GQ@B"V#&74CX/\;/4I MHBN"[LE#&,?Y!C86^88-2<,D0*_"&&7YR9Q)S\&R/Z?H+U_I=G/;MCW[_&*Z MJT.#:2E".T=H!X3^/?5C2CI)'('$:$& W2A"N$<(%X2X"OYE:UB^C!3+2U:L M$MDF"FD7ERL>H5D+#.Q:$)W'!^Q($6-VQ)B!&.RK M<$G"'J?93,!X:YJX10+VI4AR?B0Y!TEN\A4BBKI)SB4D5GOB@WTIDI@&_TXV M5-<[$@?#5KJJJ]92Y]ANBUB^7WU);,+4!,.$EX"]GP99G>4-VI$L/^?\\B.V ME0$E&:-[W#"]8Y_0I-A'G=J4T%C8$:C!W%4/-.9C@\&Q^5J- \,CY8+BWT=$ MG1H+U)9KN$;[[(:S4J7F F/"!O.M<&O&?;4C*?NM@ Z+*;I-0W;:WY)*1*6, M6JU&5[3F2'"O,4<1FR")(C_-\DWEZ2 _&\J^9_4YX)ZUUVPX0]41X))C]K>< MGEC=Q@/WJ]<0254G$&L.4,#]*:7WVO1CN!/F[H3UNU-/?BP<5L,L7*"O?K25NA+6ZDJZHC5YN2MAW:XD'9*R$Q?X H+S4.7D1H1A(WK> M'J0\W38$]Z?*PVT(PS94&9XT^6['@8.K)L\=!_=T'&GZW3(#AU=-G\L,[BDS MTO1%:Q'2'T-:,)<6W%-:I.F+=B*D/X:<6%Q.+'UR(JW?BR69-F&UBWPY:Z;- M]PM#J&%!)W?N' 2:A"UJXG#2S'?";Y]=_\;+U) MF&3X"[KU(_0/\==20+V7F<:0#(M+AC5<,BA)UX4]/A'FCE)C[(CJE4V1A];E MI4G30X'_)+MH=],1:E:%,LM0\DA->&X>5H=YC/:[ Q@Y.*5!(S>&YUC<7+FH'KZI"JMJ5)M"KP,;3-XMIFP=K6/.)O4,0"U,[_\@SH_W.\ZJW^ M<]RTSMH7@^&<5&]0X*YGPZ[79EZQ[]270-N2RW&&A=OJ &>E2LU5T89543JW MZ3Z1$FE2N0I\##&TN1C:6-OP\<<[F/.$!\[S.IP)S^YM9;J=$5KDG,QT)C@7,T=?UI_#>%>YIZV M9N:*-3,!&4Y)%9D;F:M0,,O(CL12(*TE,UW1FNCLFLG*X7!6JM3NF;W&([F\DQ;0//'& M>LGDAG-29>:>YIVVAN:)-\#))C>V)&&N2/A0/"LE0\:R+\N$8QZW' MAY%<%8_@F/+=RR>9?/+3AS#.4$26K*EQYK%E*BT?#E*^H+[&?4)ILBY> MKH@?D#3?@7V^3!)Z>)-W<'Q$R_Q_4$L#!!0 ( (R!#E&PO=V]R:W-H965TOV82^))9%_ M_TA*HF<'J1YTCFC@L1"EGGNY,=6E[^LTQX+ID:RPI)6M5 4S-%0[7U<*6>:< M"N&'01#[!>.EE\S'E#FA+P"9G"L^6E)<,UNQ(Y3(:SN";RP9F9XL]*BHN+#25O;*%T'!G MC9>"I0^P27,I4,-7F:& #U=H&!?Z(RELC*1UV;JKM[ M.( 3=36)G%[T4DVH'AD7M=W@L,&T5MQPRNKU8RIJBABV2A:PDD55&^8.@]S" M-5,E55'#&MLRPO>_21AN#!;ZW[XL-Q3G_13V^KC4%4MQ[M']H%'MT4O>OQO' MP5]]*?I-8L\2=MXE['Q(/6DV5Z5XBO"!EY!)(9C24%$JW";[V!=^HQD[37O9 M[9-@YN]/8VHLIB<6XV@T[8R>L5YTK!>#K+=9+[B>YYAF<&1H\C>@!J_CCIH\HQR MTE%.!BFO'ROJ#70\]E+0L1#<'-^ .GD==?+_K(Y'XWC2CSOM<*=OPZ5=4+AM M>T3:M+V0PTI!X]EW*H<=XS[')AC_I*44J':NTVIPS:*Y6+O9KIDO7 _[97Y) M3;[IR?_)-%\(7YG:<6H& K&PO M=V]R:W-H965T]O:8+4A)!M M6JNK7G7][ M.@B[@S#9)^^]G&\*2S"#NAO8E ?.<E9FJ7@B_Y_L!$@1XMCG"/GA#[>GPD_$WO M6+*\1!7-<04(VBVUC^9\&XIX&?!'CL[TZAF(FCQC_")>?LV6FB$20@5*F6" M_.^$UJ@H!!%/X\^64^LD!?#Z^<*>R+KSNCQ#BM:X^)9G[+#4 @UD: ?K@GW! MYU]06Q]7\*6XH/(7G-M80P-I31DN6S#/H,RKYA]^;]OA"L!YU "K!5CW *<' M8+< >RS :0'.6(#; MRQ=?!:@#=6P6\!OC2K:5UI30P9C!8$GP$1T9Q-/$A_ M)9H[DE>B)SXQPK_F',>BWS&EX(@(>#I @L![L,;EL690]A.\ RM(\Q3 *@-Q M7M0,9> S'QX2]=BA'F+$8%[0=QS_]2D&#S^]6^B,9RP-XG;=*US36I6E6UB#A;W4U [;Q,[ ,RU;DLQZ&?X*$ MP\U>>#Q>W5+ -^/55?#DO]5]^Z^3O['"[GJI+?GL'K[/=8D(9)C,5?VJP3IJ MK)C*Y_0(4[34^%Q-$3DA+7K[QO2,#RI3IR2+IR3;3$F63$FVG8CLIFLX7==P MAM@C,1T5?#I2=8P&Z4FD6))/T7O3,?S0=?R%?KIV715I6VX86N9M9*R*#$/3 MM,+P-G*CB/1"*_0"]S8P401:OFV'CA?<1FY5D5[@&&'@=)$WK>AVK>@.#K 8 M59BO+KU#S)URB$U)%D])MIF2+)F2;#L1V4WG\+K.X0T.L6]R/\>7?GCBL_ > M@127)=\>4+'X4\#WMY3Q'4)>[<%#?BE6[@ :'?>J_]J!Y;G&W8A8#^;SVAZB M$C5-)[@;V9LI11.E:&C8=S7=]B3GV>KQ['>6^?^39?Y(RP;S>:UE*E&595.* M)DI1A64]R?59%G26!:,6,KD;EX:(_??%-X;3E[=O LNT/CS++;FP+<-% 8>=< M.(US67N$&N]=.,J[P?1>ZYU"4N'=E)*)0E+AG3+J'][I5V=A?FC8RVL.RMVH M*]8<.+K2[B;EH[Q N"M?F?.-J2A/S/FVN2CYF[ZYMN%GKGU>45"@'9$,P0$0'\^PYC=GD1 MU]5/074$L#!!0 ( M (R!#E?S*QPTV , #82 9 >&PO=V]R:W-H965TG? M[Y"29/.;&+7KN1L(G*=, Y7DJ@\3:G\ M-8=$[*:.[^P7OK#U1IL%=S;)Z!J6H+]E5Q)G;H42LQ2X8H(3":NI<^&?+_S0 M.%B+?QGLU-&8F%!NA+@UDX_QU/$,(T@@T@:"XM\6%I D!@EY_"Q!G6I/XW@\ MWJ-_L,%C,#=4P4(DURS6FZDSF,TC)LT+K7$IPS]].R34(ID(,ER0R60MV2)A1+G"1"Q(O_D6FG* M8\;79 E1+IEFH,C[NRC)8XC)2HJ4+$2:Y9K:I*#/G"H6$70BERS)-5I=6REQ M8+=0-=17EZ I2]1KW%G9QQ-78UB&G!N5(](8$7]!KX+![O'K30Z54IZEF\W@-X%URSV&B)]?[H M-+RGDJ/ BEQ5N?W^"8')1PVI^M&D"]=O09U^%I@F6H&9O*]W40;=7C)>U]KI)A@)[8+'-2W [ M"T/?&V,A;(\#;#0+QL/*K$9]4%$?M%+'+*9B3X\PI7)Z@VJW%_,#XY!^TV-=*CBO2HVT.P>,PA:-WSJ3GM"*PFS[B29_PL#L&X M2\$Z JL)YGN')L?[@\>@!#^N\5%P>@Z:C'I>\T'PC[HSOY7XTE0S$9E)8W-K MU.K_U"QUA5:/-CA$&SR+RBYI="5:1VAUT0[=H=_:2_UN;??NE6V_WQ_TP]/R M;K0;]A]XU?N'7LUO;]:NJ91(7I&7+T:![[\C\#-G^A>)$JH46['3CKZDW0KZ MY QVA%:7X-#S^8/G4?:=]H%=H=5%.W2"?FO?]+ME']XKY\ ?#.YU-_]O5]!W MC[[ 4Y!K>S&AL%O)N2X^/*O5ZO+CPG[RGZS/S:6(_;(_P!0W*I^I7#.N2 (K MA/3.ADA*%I<4Q42+S'[GWPBM16J'&Z Q2&. SU="Z/W$;%!=%,@# #E%@ &0 'AL+W=OXPSMC++<\B=EVZWP)WRM4I;#K2!R MG654/%]"RC=3R[5>&N[8U!?BENA[^R&DK ,S%-9?I)- M'>M8)%Y+Q;-:K'N0L;SZID_U1&P)-*==X-4"[U=!_Q5!KQ;T]LW0KP7]?3,, M:L%@7\&P%@SW%8QJP:A*SWID1N=>R5)F">0 MM.B#;OVP0V_K66FFQGN9FDNO$_AIG9^2GG-"/,?KM?1GMK_<:QO.[V4/?R][ MU"W_'"LM=XWZW@\U&/Y8%C6%JZ9U<@G@$R__KG3MT_FY;<4Q8 M@ D+,6$1)FR.!-OQ3;_Q3;^+[M_I?8W DSZW);29HU+K@]3(S:G]Z#NG[L1^ MW%[T?8*"UB!O-RC<)RCJ'-&ADX\$VYG\03/Y@\[)GW%1<$$5D,^+!8N!W)M4 M;T5%O"+7],&<0EP\MUFCDW>H-3!A 28LQ(1% MF+ Y$FS'+N>-7<[_U-%SCND;3%B "0LQ81$F;(X$V_&-Z_RLFCB=&\T_;Q\Z MW81#+8)*"U!I(2HM>F/F>VV'164)K'Y4GK"WBFH9B&59+Y4DYNM<596+IK6I MR5Z4E%9>KH F($R ?K[@7+W6QE+M[_G!?Z M]EW@[FWN_$+"UR2T"MZY%M[)O=-=DTC:&ZZ61E5.BPSWW#E!S_]VG:=,,D7%IFE3^\>\RJ]V''7?RK+] M5MDU[/58O[F/W>3-*9B,C]]DE!R_Q_KT=.PF>Z=@\A2VN_MFW^Q[38;U26CC MN+5UV&JB 1QJ!^0[')'%.FDPGG.AN:Q[,YZF3+XX/F1&UR<9FR!4M'=5=-Q[89F(;) M6E] V$7N[.5',([#_ A@6![, <9Q+"S/_S2?'CH?AV'>>EZDAW)Z*,>Q?,C( M?K \?DYB+O],DR2*XAA;T='(ZV"$K5LF^"L%FBE8&"[@-4.Y/?G@9KRRI<_P]S^ =02P,$% @ C($.5Y>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_';8EQ6F#ND#JM%N M;#'F(:\#+9UM(A3IDE2R]*_?29ZQ4^<<]G+UDRWJAS^=S/ONJ'?//CRNO7]4 M?S76Q7FV2VE_-1[':@>-CC_Y/3C("03/6?X54'^8=>QWXDZ?7O&D'F MV6R"%]R8$%-_1']]C8Q/@ 0G=3^"NW M]>$&$Y*1<(4K@SO";=TS2O*X&ER$6N&WZ*VID:-6'[35K@)%(',&,C\CY)\Y M@2P8R.(LD*L.!T\ED"4#69X1<)L-@O1'&TM%$Y3=J&2#BH?T1!.TM@_96%FW5-HT.+QW< MRFR=P=.T2^JZJGSKDJ%)>\)E[8DP9O+5X\[;&D+\3GW\W*)L*1MK%&&E?-(F MJ =M6U"_@HYMZ-)?BA2/<\E46"98PNRQP'A1VM5]Y/;="3\J!XDB- M2?VD[2<)"JZ+)+CJJR?,*60J[)!5NX[PN<6#U,>GK_,+)Y#I.0TR*+%RSB"Y ML$%>R=+J>VR:[. QYYQ,67%@L)S+V\8'_ M0!DYJ^3R5GD]=0]#R1DF%S;,,'6?C")GEES8+"=+;#52UW6-C]U33$XUN;!J M^&1)6[V>_*SJN:#K))QZ"NGFA<6<44Q./86P>GC,2XK) MJ:<05L^I5A G^@I"E]VO*2:[.B:L'AYS03$Y^Q3"]GFM+$)2O'I-,3G[%,+V M>1VS3_ 4D[-0(6PA!C/&EK9A!6>A0MA"#&;W'H%BLE9J!2VT,E:^ :2-G90QI6<@TIA!_'%\""6G(-*80?QF+0^*CD' ME?+M#X-)ZZ.2?4=SU@Z(UD_'C._WW?P-02P,$% @ C($.5Y(LH):X 0 MYQP !H !X;"]?[0YI6ZYS;MQ#2?!WW=>HW;3R<[RR;;E_G\[);A;:>;^M5##H8 MC$)W/Z-ZG]S/[,U.;?S/Q&:YW,SC1S/_WL=#_F-P^&FZ;5K'F*O>K.Y6,4^K M<-S=ME.X7*1_GESU/A?3JOM<2!5*!RD$:?D@@R K'^00Y.6#AA T+!\T@J!1 M^: 7"'HI'_0*0:_E@\80-"X?) .4<4"0]( U@=:"7 N!UX)@"X'8@F0+@=F" M: N!VH)L"X';@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!WOKPL4V@MZ+>2J"W MHMY*H+>BWDJ@MZ+>2J"WHMY*H+>BWDJ@MZ+>2J"WH=Y&H+>AWD:@MZ'>1J"W M/1R6$.AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>CMJ+<3Z.VHMQ/H M[:BW$^CMJ+<3Z.T/A]T$>COJ[01Z.^KM!'H[ZNT$>COJ[<_4.^73+J9;SW6- M[W\FU?G\;+R]_K*\;J*$PPO. ?YKOO\"4$L#!!0 ( (R!#E>,3^J/N@$ M .X< 3 6T-O;G1E;G1?5'EP97-=+GAM;,W9R6[",!0%T%]!V2)B/)0. M C9MMRV+_H";/$A$$ENVH?#W=<(@M:*HB$J]FT2)[7=?;.EL,G[;6O*]35TU M?I(4(=@'QGQ64*U]:BPU<61N7*U#?'0+9G6VU MB8C@5:'WO(FO?6F:2>*H\DGO<3>QS9HDVMJJS'2(XVS=Y-]2!ON$-*[LYOBB MM+X?)R3L9$([\G/ ?MWKFIPK<^K-M LONHZSV*9B/FPK\NGY$B=Z-/-YF5%N MLE4=EZ3>.M*Y+XA"7:6[HOWSR2'N,.VN_.K\KLRYP#ASYHSU\<0<71YW.))V M]<#&0N1">?X3CXFQ]-7?1^UIYY3_,CMN[X=QR^X\/.MNU^_QUS,^UK^P#P'2 MAP3I0X'T<0/2QPBDCUN0/NY ^K@'Z8,/41I!$96CD,I13.4HJ'(453D*JQS% M58X"*T>15:#(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&25*+)*%%DEBJP2 M15:)(JM$D56BR"I19)4HLDH4616*K I%5H4BJT*15:'(JE!D52BR*A19U7_* M^F[,\J__P+7WM-9E<\AGW6_.Z2=02P$"% ,4 " ",@0Y7!T%-8H$ "Q M $ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 M ( (R!#E>/_K$*[@ "L" 1 " :\ !D;V-097)PC$ 8 )PG 3 M " &UL4$L! A0#% @ C($. M5PTX85'Q!0 QA\ !@ ("!#0@ 'AL+W=OPSA\/: 8 -<; 8 M " @30. !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ C($.5U"SE(O+!0 XQL !@ M ("!-!@ 'AL+W=O3,?Q%6P, ',, 8 " @34> !X;"]W M;W)KP & @('&(0 >&PO=V]R:W-H965T&UL M4$L! A0#% @ C($.5]8S,P.C!@ P1L !@ ("!8"X M 'AL+W=OH!8U^ MUP8 %D. 8 " @3DU !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ C($. M5XL@O.FW% B3L !D ("!9T4 'AL+W=O&PO=V]R:W-H965T$5!O"U00 <, 9 " @:]? !X;"]W;W)K M&UL4$L! A0#% @ C($.5V?-8JC# @ * 8 M !D ("!NV0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C($.5UP"WR[1"0 OA@ !D M ("!DFT 'AL+W=O&PO=V]R:W-H965T MUP8 .40 9 M " @>%[ !X;"]W;W)K&UL4$L! A0# M% @ C($.5PS=/5/X 0 H00 !D ("![X( 'AL+W=O MT4 > M0 &0 @($>A0 >&PO=V]R:W-H965T&UL4$L! A0#% @ C($.5U.7 MA,C2 @ (P8 !D ("!D9X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C($.5]U[]Z7J! 8 P !D M ("!=:< 'AL+W=O&PO M=V]R:W-H965T'M/8E9 0 M #X8 9 " @:VP !X;"]W;W)K&UL4$L! A0#% @ C($.5S]VKOXJ @ !@4 !D ("! M2+4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ C($.5Q3&PO=V]R:W-H965TQOM/$P@( '@( 9 " @>;- !X;"]W;W)K&UL4$L! A0#% @ C($.5Q2)Z@ T P P P !D M ("!W] 'AL+W=O!@ &0 @(%*U >&PO=V]R M:W-H965T&UL M4$L! A0#% @ C($.5]#D]_7( @ 7@@ !D ("!P-L M 'AL+W=O&PO=V]R:W-H965T#P0 $(1 9 M " @=GA !X;"]W;W)K&UL4$L! A0#% @ MC($.5X*&P'&? P X1 !D ("!'^8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ C($.5QE^:=WL P MFQ( !D ("!RO4 'AL+W=O&PO=V]R:W-H965T; M:7YXR , .46 9 " @?S] !X;"]W;W)K&UL4$L! A0#% @ C($.5]F"DR9( P T!0 T M ( !^P$! 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ C($.5Y(LH):X 0 YQP !H M ( !DPH! 'AL+U]R96QS+W=O<&5S72YX;6Q02P4& #@ . _#P ;@X! end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 134 215 1 false 36 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.hepion.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.hepion.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity Sheet http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders??? Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - Business Overview Sheet http://www.hepion.com/role/BusinessOverview Business Overview Notes 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation Sheet http://www.hepion.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Stockholders' Equity Sheet http://www.hepion.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 0000012 - Disclosure - Fair Value Measurements Sheet http://www.hepion.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 0000013 - Disclosure - Property and Equipment, net Sheet http://www.hepion.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 13 false false R14.htm 0000014 - Disclosure - Indefinite-lived Intangible Assets Sheet http://www.hepion.com/role/IndefinitelivedIntangibleAssets Indefinite-lived Intangible Assets Notes 14 false false R15.htm 0000015 - Disclosure - Accrued Liabilities Sheet http://www.hepion.com/role/AccruedLiabilities Accrued Liabilities Notes 15 false false R16.htm 0000016 - Disclosure - Accounting for Share-Based Payments Sheet http://www.hepion.com/role/AccountingforShareBasedPayments Accounting for Share-Based Payments Notes 16 false false R17.htm 0000017 - Disclosure - Loss per Share Sheet http://www.hepion.com/role/LossperShare Loss per Share Notes 17 false false R18.htm 0000018 - Disclosure - Commitments and Contingencies Sheet http://www.hepion.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 0000019 - Disclosure - Subsequent Events Sheet http://www.hepion.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 9954701 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.hepion.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 9954702 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.hepion.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.hepion.com/role/FairValueMeasurements 21 false false R22.htm 9954703 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.hepion.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.hepion.com/role/PropertyandEquipmentnet 22 false false R23.htm 9954704 - Disclosure - Indefinite-lived Intangible Assets (Tables) Sheet http://www.hepion.com/role/IndefinitelivedIntangibleAssetsTables Indefinite-lived Intangible Assets (Tables) Tables http://www.hepion.com/role/IndefinitelivedIntangibleAssets 23 false false R24.htm 9954705 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.hepion.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.hepion.com/role/AccruedLiabilities 24 false false R25.htm 9954706 - Disclosure - Accounting for Share-Based Payments (Tables) Sheet http://www.hepion.com/role/AccountingforShareBasedPaymentsTables Accounting for Share-Based Payments (Tables) Tables http://www.hepion.com/role/AccountingforShareBasedPayments 25 false false R26.htm 9954707 - Disclosure - Loss per Share (Tables) Sheet http://www.hepion.com/role/LossperShareTables Loss per Share (Tables) Tables http://www.hepion.com/role/LossperShare 26 false false R27.htm 9954708 - Disclosure - Basis of Presentation - Additional Information (Details) Sheet http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails Basis of Presentation - Additional Information (Details) Details 27 false false R28.htm 9954709 - Disclosure - Summary of Significant Accounting Policies - Cash (Details) Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesCashDetails Summary of Significant Accounting Policies - Cash (Details) Details http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies 28 false false R29.htm 9954710 - Disclosure - Summary of Significant Accounting Policies - Property, Equipment and Depreciation (Details) Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails Summary of Significant Accounting Policies - Property, Equipment and Depreciation (Details) Details 29 false false R30.htm 9954711 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details) Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails Summary of Significant Accounting Policies - Research and Development (Details) Details 30 false false R31.htm 9954712 - Disclosure - Summary of Significant Accounting Policies - Foreign Exchange (Details) Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesForeignExchangeDetails Summary of Significant Accounting Policies - Foreign Exchange (Details) Details 31 false false R32.htm 9954713 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details) Sheet http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails Summary of Significant Accounting Policies - Segment Information (Details) Details 32 false false R33.htm 9954714 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details) Sheet http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails Stockholders' Equity - Series A Convertible Preferred Stock (Details) Details 33 false false R34.htm 9954715 - Disclosure - Stockholders' Equity - Series C Preferred Stock Issuances (Details) Sheet http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails Stockholders' Equity - Series C Preferred Stock Issuances (Details) Details 34 false false R35.htm 9954716 - Disclosure - Fair Value Measurements - Schedule of Liabilities Measured on Recurring Basis (Details) Sheet http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurements - Schedule of Liabilities Measured on Recurring Basis (Details) Details 35 false false R36.htm 9954717 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 36 false false R37.htm 9954718 - Disclosure - Fair Value Measurements - Assumptions Used to Calculate Fair Value (Details) Sheet http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails Fair Value Measurements - Assumptions Used to Calculate Fair Value (Details) Details 37 false false R38.htm 9954719 - Disclosure - Fair Value Measurements - Activity for Fair Value of Contingent Consideration (Details) Sheet http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails Fair Value Measurements - Activity for Fair Value of Contingent Consideration (Details) Details 38 false false R39.htm 9954720 - Disclosure - Property and Equipment, net - PPE (Details) Sheet http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails Property and Equipment, net - PPE (Details) Details http://www.hepion.com/role/PropertyandEquipmentnetTables 39 false false R40.htm 9954721 - Disclosure - Indefinite-lived Intangible Assets - IPR&D (Details) Sheet http://www.hepion.com/role/IndefinitelivedIntangibleAssetsIPRDDetails Indefinite-lived Intangible Assets - IPR&D (Details) Details http://www.hepion.com/role/IndefinitelivedIntangibleAssetsTables 40 false false R41.htm 9954722 - Disclosure - Accrued Liabilities (Details) Sheet http://www.hepion.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.hepion.com/role/AccruedLiabilitiesTables 41 false false R42.htm 9954723 - Disclosure - Accounting for Share-Based Payments - Additional Information (Details) Sheet http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails Accounting for Share-Based Payments - Additional Information (Details) Details 42 false false R43.htm 9954724 - Disclosure - Accounting for Share-Based Payments - Stock-Based Compensation (Details) Sheet http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails Accounting for Share-Based Payments - Stock-Based Compensation (Details) Details 43 false false R44.htm 9954725 - Disclosure - Accounting for Share-Based Payments - Stock Option Activity (Details) Sheet http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails Accounting for Share-Based Payments - Stock Option Activity (Details) Details 44 false false R45.htm 9954726 - Disclosure - Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) Sheet http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details) Details 45 false false R46.htm 9954727 - Disclosure - Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 46 false false R47.htm 9954728 - Disclosure - Loss per Share - Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding (Details) Sheet http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails Loss per Share - Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding (Details) Details 47 false false R48.htm 9954729 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 48 false false All Reports Book All Reports hepa-20230630.htm hepa-20230630.xsd hepa-20230630_cal.xml hepa-20230630_def.xml hepa-20230630_lab.xml hepa-20230630_pre.xml hepa-q2202310xqxexx311.htm hepa-q2202310xqxexx312.htm hepa-q2202310xqxexx321.htm hepa-q2202310xqxexx322.htm hepa-20230630_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hepa-20230630.htm": { "axisCustom": 0, "axisStandard": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 509, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 134, "dts": { "calculationLink": { "local": [ "hepa-20230630_cal.xml" ] }, "definitionLink": { "local": [ "hepa-20230630_def.xml" ] }, "inline": { "local": [ "hepa-20230630.htm" ] }, "labelLink": { "local": [ "hepa-20230630_lab.xml" ] }, "presentationLink": { "local": [ "hepa-20230630_pre.xml" ] }, "schema": { "local": [ "hepa-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 331, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 1, "http://xbrl.sec.gov/dei/2023": 5, "total": 6 }, "keyCustom": 15, "keyStandard": 200, "memberCustom": 12, "memberStandard": 20, "nsprefix": "hepa", "nsuri": "http://www.hepion.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.hepion.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "11", "role": "http://www.hepion.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "12", "role": "http://www.hepion.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Property and Equipment, net", "menuCat": "Notes", "order": "13", "role": "http://www.hepion.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Indefinite-lived Intangible Assets", "menuCat": "Notes", "order": "14", "role": "http://www.hepion.com/role/IndefinitelivedIntangibleAssets", "shortName": "Indefinite-lived Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Accrued Liabilities", "menuCat": "Notes", "order": "15", "role": "http://www.hepion.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Accounting for Share-Based Payments", "menuCat": "Notes", "order": "16", "role": "http://www.hepion.com/role/AccountingforShareBasedPayments", "shortName": "Accounting for Share-Based Payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Loss per Share", "menuCat": "Notes", "order": "17", "role": "http://www.hepion.com/role/LossperShare", "shortName": "Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "18", "role": "http://www.hepion.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "19", "role": "http://www.hepion.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "lang": "en-US", "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "20", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.hepion.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Property and Equipment, net (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.hepion.com/role/PropertyandEquipmentnetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Indefinite-lived Intangible Assets (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsTables", "shortName": "Indefinite-lived Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Accrued Liabilities (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.hepion.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Accounting for Share-Based Payments (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.hepion.com/role/AccountingforShareBasedPaymentsTables", "shortName": "Accounting for Share-Based Payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Loss per Share (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.hepion.com/role/LossperShareTables", "shortName": "Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Basis of Presentation - Additional Information (Details)", "menuCat": "Details", "order": "27", "role": "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails", "shortName": "Basis of Presentation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Summary of Significant Accounting Policies - Cash (Details)", "menuCat": "Details", "order": "28", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesCashDetails", "shortName": "Summary of Significant Accounting Policies - Cash (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-4", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Summary of Significant Accounting Policies - Property, Equipment and Depreciation (Details)", "menuCat": "Details", "order": "29", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails", "shortName": "Summary of Significant Accounting Policies - Property, Equipment and Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-72", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Summary of Significant Accounting Policies - Research and Development (Details)", "menuCat": "Details", "order": "30", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails", "shortName": "Summary of Significant Accounting Policies - Research and Development (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Summary of Significant Accounting Policies - Foreign Exchange (Details)", "menuCat": "Details", "order": "31", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesForeignExchangeDetails", "shortName": "Summary of Significant Accounting Policies - Foreign Exchange (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)", "menuCat": "Details", "order": "32", "role": "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails", "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-73", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "33", "role": "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "shortName": "Stockholders' Equity - Series A Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-73", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Stockholders' Equity - Series C Preferred Stock Issuances (Details)", "menuCat": "Details", "order": "34", "role": "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails", "shortName": "Stockholders' Equity - Series C Preferred Stock Issuances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Fair Value Measurements - Schedule of Liabilities Measured on Recurring Basis (Details)", "menuCat": "Details", "order": "35", "role": "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-80", "decimals": "0", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Fair Value Measurements - Additional Information (Details)", "menuCat": "Details", "order": "36", "role": "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-90", "decimals": "2", "first": true, "lang": "en-US", "name": "hepa:ProbabilityOfMilestoneAchievements", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Fair Value Measurements - Assumptions Used to Calculate Fair Value (Details)", "menuCat": "Details", "order": "37", "role": "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails", "shortName": "Fair Value Measurements - Assumptions Used to Calculate Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-90", "decimals": "2", "first": true, "lang": "en-US", "name": "hepa:ProbabilityOfMilestoneAchievements", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hepa:ScheduleOfFairValueForContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-94", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Fair Value Measurements - Activity for Fair Value of Contingent Consideration (Details)", "menuCat": "Details", "order": "38", "role": "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "shortName": "Fair Value Measurements - Activity for Fair Value of Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hepa:ScheduleOfFairValueForContingentConsiderationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-94", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Property and Equipment, net - PPE (Details)", "menuCat": "Details", "order": "39", "role": "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails", "shortName": "Property and Equipment, net - PPE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-4", "decimals": "0", "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-4", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Indefinite-lived Intangible Assets - IPR&D (Details)", "menuCat": "Details", "order": "40", "role": "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsIPRDDetails", "shortName": "Indefinite-lived Intangible Assets - IPR&D (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "0", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Accrued Liabilities (Details)", "menuCat": "Details", "order": "41", "role": "http://www.hepion.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - Accounting for Share-Based Payments - Additional Information (Details)", "menuCat": "Details", "order": "42", "role": "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "shortName": "Accounting for Share-Based Payments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-101", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - Accounting for Share-Based Payments - Stock-Based Compensation (Details)", "menuCat": "Details", "order": "43", "role": "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails", "shortName": "Accounting for Share-Based Payments - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-110", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - Accounting for Share-Based Payments - Stock Option Activity (Details)", "menuCat": "Details", "order": "44", "role": "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails", "shortName": "Accounting for Share-Based Payments - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-113", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-119", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details)", "menuCat": "Details", "order": "45", "role": "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails", "shortName": "Accounting for Share-Based Payments - Weighted-Average Assumptions Used Black Scholes Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-119", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "menuCat": "Details", "order": "46", "role": "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails", "shortName": "Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954728 - Disclosure - Loss per Share - Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding (Details)", "menuCat": "Details", "order": "47", "role": "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails", "shortName": "Loss per Share - Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954729 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "48", "role": "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-9", "decimals": "0", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-41", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity", "menuCat": "Statements", "order": "6", "role": "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-48", "decimals": "0", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "hepa:BusinessOverviewTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Business Overview", "menuCat": "Notes", "order": "8", "role": "http://www.hepion.com/role/BusinessOverview", "shortName": "Business Overview", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "hepa:BusinessOverviewTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://www.hepion.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hepa-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.hepion.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hepa_AdjustmentToAdditionalPaidInCapitalStockBasedLiabilityAwardsConverted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment To Additional Paid In Capital, Stock-Based Liability Awards Converted", "label": "Adjustment To Additional Paid In Capital, Stock-Based Liability Awards Converted", "terseLabel": "Stock-based liability awards converted to equity" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalStockBasedLiabilityAwardsConverted", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "hepa_BusinessOverviewTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for Business Overview Footnote.", "label": "Business Overview [Text Block]", "terseLabel": "Business Overview" } } }, "localname": "BusinessOverviewTextBlock", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/BusinessOverview" ], "xbrltype": "textBlockItemType" }, "hepa_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Acquisition related contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Acquisition-related Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Eight", "label": "Exercise Price Range Eight [Member]", "terseLabel": "Exercise price range eight" } } }, "localname": "ExercisePriceRangeEightMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Five", "label": "Exercise Price Range Five [Member]", "terseLabel": "Exercise price range five" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Four", "label": "Exercise Price Range Four [Member]", "terseLabel": "Exercise price range four" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Nine", "label": "Exercise Price Range Nine [Member]", "terseLabel": "Exercise price range nine" } } }, "localname": "ExercisePriceRangeNineMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range one.", "label": "Exercise Price Range One [Member]", "terseLabel": "Exercise price range one" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Seven", "label": "Exercise Price Range Seven [Member]", "terseLabel": "Exercise price range seven" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Six", "label": "Exercise Price Range Six [Member]", "terseLabel": "Exercise price range six" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Exercise Price Range Three.", "label": "Exercise Price Range Three [Member]", "terseLabel": "Exercise price range three" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents exercise price range two.", "label": "Exercise Price Range Two [Member]", "terseLabel": "Exercise price range two" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "hepa_IncreaseDecreaseInRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Right Of Use Asset", "label": "Increase (Decrease) in Right Of Use Asset", "negatedTerseLabel": "Right of use asset" } } }, "localname": "IncreaseDecreaseInRightOfUseAsset", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "hepa_OfficeAndResearchLaboratoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stans for office and research laboratory member", "label": "Office And Research Laboratory [Member]", "terseLabel": "Office and Research Laboratory" } } }, "localname": "OfficeAndResearchLaboratoryMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hepa_OfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing information pertaining to office space .", "label": "Office Space [Member]", "terseLabel": "Corporate Office Space" } } }, "localname": "OfficeSpaceMember", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hepa_ProbabilityOfMilestoneAchievements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the probability of a milestone achievement occurring.", "label": "Probability Of Milestone Achievements", "terseLabel": "Probability of success of milestone achievements" } } }, "localname": "ProbabilityOfMilestoneAchievements", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "percentItemType" }, "hepa_ResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.hepion.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Research and Development Expenses Current", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpensesCurrent", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hepa_ScheduleOfFairValueForContingentConsiderationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents tabular information of changes in fair value of contingent consideration.", "label": "Schedule Of Fair Value For Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Contingent Consideration" } } }, "localname": "ScheduleOfFairValueForContingentConsiderationTableTextBlock", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForStockSplit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustment for Stock Splits, Shares", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Adjustment For Stock Split", "terseLabel": "Adjustment for stock split (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForStockSplit", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForStockSplitIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Adjustment for Stock Split, Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Adjustment for Stock Split, Intrinsic Value", "terseLabel": "Adjustment for stock split" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdjustmentForStockSplitIntrinsicValue", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Exercise Price [Abstract]", "terseLabel": "Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAbstract", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations, Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations, Intrinsic Value", "terseLabel": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsIntrinsicValue", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures, Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures, Intrinsic Value", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the intrinsic value of stock options granted during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "hepa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Abstract]", "terseLabel": "Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "hepa_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentForStockSplitWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Adjustment for Stock Split, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Adjustment for Stock Split, Weighted Average Exercise Price", "terseLabel": "Adjustment for stock split (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAdjustmentForStockSplitWeightedAverageExercisePrice", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "hepa_StockBasedLiabilityAwardsReversedToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock-Based Liability Awards Reversed To Additional Paid-In Capital", "label": "Stock-Based Liability Awards Reversed To Additional Paid-In Capital", "terseLabel": "Stock-based liability awards reversed to additional paid-in capital" } } }, "localname": "StockBasedLiabilityAwardsReversedToAdditionalPaidInCapital", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "hepa_WarrantsNumberIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the number of warrants issued.", "label": "Warrants Number Issued", "terseLabel": "Warrants issued (in shares)" } } }, "localname": "WarrantsNumberIssued", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "sharesItemType" }, "hepa_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Refers to capital comprising of short-term assets and liabilities which is used to perform day to day business operations.", "label": "Working Capital", "terseLabel": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://www.hepion.com/20230630", "presentation": [ "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r264", "r363", "r387", "r414", "r415", "r470", "r471", "r472", "r473", "r474", "r483", "r484", "r491", "r495", "r499", "r504", "r547", "r557", "r558", "r559", "r560", "r561", "r562" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r264", "r363", "r387", "r414", "r415", "r470", "r471", "r472", "r473", "r474", "r483", "r484", "r491", "r495", "r499", "r504", "r547", "r557", "r558", "r559", "r560", "r561", "r562" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r218", "r219", "r220", "r221", "r257", "r264", "r292", "r293", "r294", "r362", "r363", "r387", "r414", "r415", "r470", "r471", "r472", "r473", "r474", "r483", "r484", "r491", "r495", "r499", "r504", "r507", "r543", "r547", "r558", "r559", "r560", "r561", "r562" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r218", "r219", "r220", "r221", "r257", "r264", "r292", "r293", "r294", "r362", "r363", "r387", "r414", "r415", "r470", "r471", "r472", "r473", "r474", "r483", "r484", "r491", "r495", "r499", "r504", "r507", "r543", "r547", "r558", "r559", "r560", "r561", "r562" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r22", "r503" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.hepion.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesDetails", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.hepion.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r45", "r125", "r380" ], "calculation": { "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r31", "r74", "r131", "r376", "r392", "r393" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesForeignExchangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r3", "r12", "r31", "r325", "r328", "r356", "r388", "r389", "r527", "r528", "r529", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r69" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r301", "r302", "r303", "r401", "r534", "r535", "r536", "r550", "r566" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r59", "r60", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "auth_ref": [ "r13", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.", "label": "Adjustments to Additional Paid in Capital, Stock Split", "negatedTerseLabel": "Issuance of common stock in connection with stock split" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r296", "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total anti-dilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails", "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r104", "r127", "r153", "r183", "r197", "r201", "r206", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r320", "r322", "r343", "r370", "r437", "r503", "r515", "r545", "r546", "r555" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r122", "r133", "r153", "r206", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r320", "r322", "r343", "r503", "r545", "r546", "r555" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r319", "r530" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Change in fair value of contingent consideration", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r1", "r61" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Short-term portion of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, fair value measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r1", "r61" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration", "verboseLabel": "Non-current portion of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r110", "r373", "r412", "r432", "r503", "r515", "r524" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r33", "r81", "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r81" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "verboseLabel": "Supplementary disclosure of non-cash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r119", "r128", "r129", "r130", "r153", "r170", "r171", "r173", "r175", "r181", "r182", "r206", "r222", "r224", "r225", "r226", "r229", "r230", "r234", "r235", "r239", "r242", "r250", "r343", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r424", "r446", "r465", "r475", "r476", "r477", "r478", "r479", "r522", "r532", "r537" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r128", "r129", "r130", "r181", "r234", "r235", "r237", "r239", "r242", "r248", "r250", "r396", "r397", "r398", "r399", "r495", "r522", "r532" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r27", "r65", "r372", "r423" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r92", "r216", "r217", "r481", "r544" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r46", "r482" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r505", "r506", "r507", "r509", "r510", "r511", "r512", "r534", "r535", "r550", "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r68", "r424" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r68", "r424", "r443", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r68", "r375", "r503" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock\u2014$0.0001 par value per share; 120,000,000 shares authorized, 3,838,289 and 3,811,481 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r32", "r136", "r138", "r144", "r365", "r384" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r62", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r252", "r253", "r256" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "terseLabel": "Prepaid research and development costs" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesResearchandDevelopmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "verboseLabel": "Conversion of Series C convertible preferred stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Preferred shares converted into common stock (in shares)" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r20", "r50", "r67", "r95", "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "verboseLabel": "Stock issued as a result of conversion (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Cost and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.hepion.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).", "label": "Deferred Compensation Share-Based Arrangements, Liability, Current", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r309", "r310", "r371" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r7", "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r7", "r187" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r265", "r269", "r297", "r298", "r300", "r500" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Accounting for Share-Based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r145", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r173", "r174", "r175", "r179", "r332", "r333", "r366", "r385", "r487" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net loss per share of common stock\u2014basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations", "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net loss per common share: (see Note 10)" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r145", "r159", "r160", "r161", "r162", "r163", "r170", "r173", "r174", "r175", "r179", "r332", "r333", "r366", "r385", "r487" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net loss per share of common stock\u2014diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations", "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r38", "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r167", "r176", "r177", "r178" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r345" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.hepion.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining vesting period over which unrecognized compensation is expected to be recognized (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to non-vested stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails", "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r13", "r120", "r140", "r141", "r142", "r154", "r155", "r156", "r158", "r164", "r166", "r180", "r207", "r208", "r251", "r301", "r302", "r303", "r316", "r317", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r346", "r347", "r348", "r349", "r350", "r351", "r356", "r388", "r389", "r390", "r401", "r465" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [ "r335", "r336", "r341" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "verboseLabel": "Schedule of Assumptions Used to Calculate Fair Value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r231", "r258", "r259", "r260", "r261", "r262", "r263", "r336", "r359", "r360", "r361", "r493", "r494", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r63", "r102" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r335", "r336", "r338", "r339", "r342" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r231", "r258", "r263", "r336", "r359", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "(Level\u00a01)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r231", "r258", "r263", "r336", "r360", "r493", "r494", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "(Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r231", "r258", "r259", "r260", "r261", "r262", "r263", "r336", "r361", "r493", "r494", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "(Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r15", "r63" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value recorded in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at end of the period", "periodStartLabel": "Balance at beginning of the period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r231", "r258", "r259", "r260", "r261", "r262", "r263", "r359", "r360", "r361", "r493", "r494", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r334", "r342" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsActivityforFairValueofContingentConsiderationDetails", "http://www.hepion.com/role/FairValueMeasurementsScheduleofLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r9", "r19" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation": { "auth_ref": [ "r541" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) allowance for credit loss on financing receivable. Excludes net investment in lease.", "label": "Financing Receivable, Allowance for Credit Loss, Foreign Currency Translation", "terseLabel": "Foreign exchange" } } }, "localname": "FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesForeignExchangeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Exchange" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r78", "r448" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Indefinite-lived Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/IndefinitelivedIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r10", "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "In-Process Research & Development" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r7", "r211", "r212", "r213", "r492" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Impairment of goodwill" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r531", "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment of IPR&D" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsIPRDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r75", "r106", "r183", "r196", "r200", "r202", "r367", "r382", "r489" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r214", "r215", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r215", "r449" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r118", "r165", "r166", "r188", "r311", "r318", "r386" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax benefit (expense)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r139", "r307", "r308", "r312", "r313", "r314", "r315", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r6" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r523", "r530" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r6" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r89" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "In-process research and development, ending balance", "periodStartLabel": "In-process research and development, beginning balance", "terseLabel": "In-process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsIPRDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Change during period" } } }, "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsIPRDDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Indefinite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Indefinite-lived Intangible Assets [Roll Forward]" } } }, "localname": "IndefiniteLivedIntangibleAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsIPRDDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r64", "r108", "r143", "r186", "r352", "r450", "r513", "r565" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r146", "r148", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term (in years)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r153", "r206", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r321", "r322", "r323", "r343", "r422", "r488", "r515", "r545", "r555", "r556" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r73", "r105", "r378", "r503", "r533", "r540", "r552" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r123", "r153", "r206", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r321", "r322", "r323", "r343", "r503", "r545", "r555", "r556" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.hepion.com/role/FairValueMeasurementsAssumptionsUsedtoCalculateFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r81", "r82", "r83" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails", "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r76", "r83", "r107", "r121", "r134", "r137", "r142", "r153", "r157", "r159", "r160", "r161", "r162", "r165", "r166", "r172", "r183", "r196", "r200", "r202", "r206", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r333", "r343", "r383", "r445", "r463", "r464", "r489", "r513", "r545" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails", "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations", "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r183", "r196", "r200", "r202", "r489" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r553" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r354" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r353" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r84", "r85", "r86", "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.hepion.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r103", "r126", "r369", "r515" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r5", "r11", "r101" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r5", "r11", "r101", "r135", "r138" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r4" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Contingent consideration milestone payment" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionRatio": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.", "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "PreferredStockConvertibleConversionRatio", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r505", "r506", "r509", "r510", "r511", "r512", "r564", "r566" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r67", "r234" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r67", "r424" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Convertible preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r67", "r234" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Convertible preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r67", "r424", "r443", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Convertible preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r67", "r374", "r503" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Convertible preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r132", "r209", "r210", "r485" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from disposal of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r90", "r113", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r91", "r124", "r381" ], "calculation": { "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Gross, Period Increase (Decrease)", "terseLabel": "Carrying value adjustments" } } }, "localname": "PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r368", "r381", "r503" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r8", "r113", "r116", "r379" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, equipment and depreciation" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CommitmentsandContingenciesAdditionalInformationDetails", "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r66", "r306", "r563" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r70", "r97", "r377", "r391", "r393", "r400", "r425", "r503" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r120", "r154", "r155", "r156", "r158", "r164", "r166", "r207", "r208", "r301", "r302", "r303", "r316", "r317", "r324", "r326", "r327", "r329", "r331", "r388", "r390", "r401", "r566" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r184", "r185", "r195", "r198", "r199", "r203", "r204", "r205", "r254", "r255", "r364" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails", "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Outstanding Securities Excluded from the Computation of Basic and Diluted Weighted Shares Outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r18", "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/IndefinitelivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/PropertyandEquipmentnetPPEDetails", "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPropertyEquipmentandDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r266", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r16", "r17", "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r47", "r48", "r49", "r50", "r51", "r52", "r53", "r94", "r96", "r97", "r128", "r129", "r130", "r181", "r234", "r235", "r237", "r239", "r242", "r248", "r250", "r396", "r397", "r398", "r399", "r495", "r522", "r532" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r204", "r490" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r525", "r526", "r548" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Common shares issuable upon conversion of Series A preferred stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails", "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r525", "r526", "r548" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C", "verboseLabel": "Common shares issuable upon conversion of Series C preferred stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r6" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk free interest rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r266", "r268", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockBasedCompensationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Team" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Vested and exercisable at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested and exercisable at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Balance outstanding at the end of the period", "periodStartLabel": "Balance outstanding at the beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance outstanding at the end of the period (in shares)", "periodStartLabel": "Balance outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Balance outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and exercisable at the end of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Awards outstanding, vested awards and those expected to vest at the end of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Awards outstanding, vested awards and those expected to vest at the end of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Awards outstanding, vested awards and those expected to vest at the end of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails", "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, low end of the range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, high end of the range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsWeightedAverageAssumptionsUsedBlackScholesModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and exercisable at the end of the period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Balance outstanding term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Awards outstanding, vested awards and those expected to vest at the end of the period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of awards vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r84", "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r119", "r128", "r129", "r130", "r153", "r170", "r171", "r173", "r175", "r181", "r182", "r206", "r222", "r224", "r225", "r226", "r229", "r230", "r234", "r235", "r239", "r242", "r250", "r343", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r424", "r446", "r465", "r475", "r476", "r477", "r478", "r479", "r522", "r532", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r13", "r29", "r120", "r140", "r141", "r142", "r154", "r155", "r156", "r158", "r164", "r166", "r180", "r207", "r208", "r251", "r301", "r302", "r303", "r316", "r317", "r324", "r325", "r326", "r327", "r328", "r329", "r331", "r346", "r347", "r348", "r349", "r350", "r351", "r356", "r388", "r389", "r390", "r401", "r465" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r154", "r155", "r156", "r180", "r364", "r394", "r413", "r416", "r417", "r418", "r419", "r420", "r421", "r424", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r444", "r447", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r508" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Changes in Stockholders' Equity" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r154", "r155", "r156", "r180", "r364", "r394", "r413", "r416", "r417", "r418", "r419", "r420", "r421", "r424", "r427", "r428", "r429", "r430", "r431", "r433", "r434", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r444", "r447", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r508" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r35", "r36", "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of common stock in conjunction with milestone payment" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r13", "r28", "r50", "r97", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Series C to common (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r67", "r68", "r97", "r396", "r465", "r476" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Issuance of common stock in connection with stock split (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r67", "r68", "r97", "r278" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/AccountingforShareBasedPaymentsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r13", "r29", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of Series C to common" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r67", "r68", "r97", "r401", "r465", "r476", "r514" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r68", "r71", "r72", "r87", "r426", "r443", "r466", "r467", "r503", "r515", "r533", "r540", "r552", "r566" ], "calculation": { "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets", "http://www.hepion.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r93", "r152", "r233", "r235", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r249", "r251", "r330", "r468", "r469", "r480" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split, conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/BasisofPresentationAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplementary disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r40", "r41", "r42", "r111", "r112", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r505", "r506", "r509", "r510", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants", "verboseLabel": "Warrants \u2013 equity classified" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareScheduleofOutstandingSecuritiesExcludedfromComputationofBasicandDilutedWeightedSharesOutstandingDetails", "http://www.hepion.com/role/StockholdersEquitySeriesCPreferredStockIssuancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r169", "r175" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations", "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r168", "r175" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/CondensedConsolidatedStatementsofOperations", "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.hepion.com/role/LossperShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org//830/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r517": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 68 0001583771-23-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001583771-23-000010-xbrl.zip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end

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